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Chapter one includes the literature overview of research relevance to this project, 
consisting of three distinct parts: design and application of fluorescence sensors, 
purification, functionalisation and application of Single Walled carbon Nanotubes 
(SWNTs), and applications of functionalised SWNTs in cancer research.  
 
Chapter two reveals the synthesis of different fluorescence sensors. This chapter also 
explains how different parts of the functional groups may be assembled together and 
the optimisations on the synthesis of fluorophores. Binding constant determination and 
quantum yield calculation for each fluorescence sensors are being discussed. 
 
Chapter three presents the preparation of SWNTs used were for the synthesis of new 
SWNTs based hybrids. SWNTs are purified via a solvent oxidation method, which was 
adapted here from literature reports. SWNTs were then functionalised either on their 
external surface by -D-glucan wrapping to form a scaffold structure for further 
SWNTs hybrids assembly, or inside their cavities, by filling with small molecules or 
metals, in order to establish a protocol to filling radiolabelled metals in the future. 
Finally, all SWNTs were characterised via TEM, SEM and Raman prior to further 
applications.  
  
Chapter four describes in vitro cell cytotoxicity studies of fluorescence sensors 
synthesised from the chapter 2 and SWNTs prepared from the chapter 3. Several 
different cell lines (HeLa, PC-3and CHO) were incubated with each of compounds, 
which were available as synthesised from chapter 2 and SWNTs (SWNTs hybrids) 
assembled in chapter at concentrations for 48 hours. Finally MTT assays were carried 
out to understand the cytotoxicity effects in functionalised and non-functionalised 
system.  
 
Chapter five examines the applications of fluorescent sensors built as discribed in 
chapter 2 and SWNTs hybrids (Fluorescent sensors@-D-glucan@SWNTs) from 







chapter 3 under the confocal microscopy and FLIM with  different environment 
conditions,  including consideration of concentration, temperature, laser power, time as 
well as a variety of cell lines (HeLa, PC-3 and CHO).  
 
Chapter six contains all experimental details of the work described in this thesis. 
 
Chapter seven summaries current and future work emerging from this project. 
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Chapter 1. Introduction 
 
1.1. Aims of the project and context 
Cancer is one of the top ten leading causes of death in the world. According to a recent 
cancer statistics report from the World Health Organisation (WHO), 14.1 million adults 
in the world were diagnosed as cancer and 8.2 million (58.16%) deaths occurred as a 
result of  cancer, in the world in 2012.1 In the UK, cancer remains in the top three 
common causes of death. In 2011, there were 331,487 people diagnosed with cancer 
and 159,178 deaths (48.02%) from cancer in the UK (Cancer Research UK). Another 
statistic showed that 70% of cancer patients had survived in the first year after diagnosis. 
Then this number reduced to 54.3% in the period of five years after diagnosis. Finally, 
amongst these only 49.8% of cancer patients had survived in ten years time.2  
 
Table 1. 1. Five year survival rates in colorectal cancer by stage at diagnosis (1995-2005)3 
 
Stage at diagnosis  5-year survival rate (%) 
In early stage (local)  90 
Spread to adjacent organ / lymph node  67 
Spread to distant sites  10 
 
 
This survival rate was improved by an early diagnosis: 90% of patients had 
survived in five years when cancer was detected at the early stage (Table 1.1). Once 
tumour cells spread to adjacent tissue, i.e. middle stage, this rate dropped to 67%. 
Finally, only 10% of cancer patients survived when diagnosed at the metastatic stages. 
This was particularly the case with the cancer of lung, and another report from SEER 
cancer statistics review showed that the earlier stage tumour was diagnosed, the higher 
survival rate for this it would be.4 As it can be seen in Figure 1.1, only 15% of lung 
cancer could be diagnosed at localised stage, but 54% of patients survived. When the 
incidence of cancer was discovered at the spreading stage (22%), the survival rate 
dropped to 26%. However, the majority of patients were diagnosed at late stages, hence, 







only 4% survived at the five years’ milestone. Thus, it can be concluded that early 
cancer diagnosis as equally important as rapid, effected and targeted cancer treatment. 









Figure 1. 2. Stages of cancer development and range of techniques can be used (SPECT = 
Single-photon emission computed tomography, PET-CT= Positron emission tomography–
computed tomography, CT= computed tomography, MRI= Magnetic resonance imaging) 
 







 However, unlike other common diseases, the early-stage cancer normally 
appears with initial lack of symptoms, which makes early diagnosis of cancer extremely 
challenging. In fact, the majority of cancer patients are diagnosed at the middle or late 
stages, when a tumour mass is already grown as a result of tumour angiogenesis. There 
are currently four methods which can identify cancer, namely medical imaging 5, 
endoscopy 6, biopsy 7 and blood (other) sample tests 8, 9.  
Medical imaging techniques include X-ray imaging 10, X-ray computed 
tomography (CT scans) 10, 11, Magnetic Resonance Imaging (MRI scans) 12 Positron 
Emission Tomography (PET scans)11 and Single-photon emission computed 
tomography (SPECT)13. All techniques use one source of energy (X-ray, magnetism or 
positron) to create a detailed view of the body to locate a tumour mass. The medical 
imaging techniques are matured techniques, which can be generally used to scan and 
diagnose all types of cancer. The quality of medical imaging methods rely heavily on 
radioisotopes applied as contrast agents. For example, positron emission tomography 
is a modern nuclear imaging method that uses positron (β+) – emitting radioisotopes of 
elements, including 11C, 15O, 13N and 18F, as well as some unconventional metallic 
radioisotopes of 64Cu, 63Zn, 38K, 82Rb, 32P, 59Fe, 68Ga  and the halogen series. Some 
radiotracers including these radio-metals are at the clinical research stage. In PET two 
gamma rays signals are emitted and detected, as they arrive in pairs (occurring at 180 
degree angle). They are produced by a positron annihilation event by collision with an 
electron at the site of interest, with a well-defined image subsequently produced and 
interpreted computationally.  Some radioisotopes and their half-lifes are listed in Table 
1.2, recently, it was found that radioisotopes with a longer half-life are more appreciated 
for future diagnostic imaging, because of their potential to emit during prolonged 
circulation of tracer in vivo which can improve tumour/background ratio significantly.14, 
15 Therefore, those radioisotopes with only minutes of half-life available will not be 
preferred  for most targeted delivery in vivo imaging experiment. However, a long 
lasting radioactivity can also damage living cells. Thus, those radioisotopes with greater 
than 10 days half-life will be considered as toxic to living organisms. Therefore, yttrium 
and gallium become popular radioisotopes in clinical research and recent work showed 
that, when 68Ga was anchored onto a suitable in vivo delivering vehicle able to target 







tumours in precancerous stages, it is selectively accumulated around infected sites and 
areas of inflammation to report the site of rapid cell division.16 By contrast, 90Y and 86Y 
are found recently in many multimodal early diagnosis and treatment approaches17.  
 
 Table 1. 2. Lists of radioisotopes used in modern PET and their corresponding half-life 
 
Radio isotope Decay 
type 
Half-life Radio isotope Decay 
type 
Half-life 
14O  1 min 
62Zn  9.2 h 
15O  2.1 min 
65Zn  243.7 d 
13N  10.0 min 
38K  7.6 min 
11C  20.3 min 
82Rb  1.3 m 
18F  109.7 min 
59Fe  44.5 d 
32P  14.3 d 
64Ga  2.6 min 
61Cu  3.35 h 
67Ga EC 3.26 d 
62Cu  4.7 h 
68Ga  68.1 min 
64Cu  12.7 h 
86Y  14.7 h 
67Cu  61.9 h 
90Y  64 h 
 
Blood sample tests are also common methods that are applied to reveal cancer, 
as characteristic makers such as overexpressed molecules, including sugars, fats, 
proteins, RNA and DNA can be identified by the in vitro assays.18 However, there 
remains selectivity or sensitivity problems in the current testing reagents.19, 20  Biopsy 
continues to be the most certain way to diagnose cancer; whereby a tissue sample is 
collected from the site of interest. Subsequently the morphology and gene status is 
examined. However, it is still the case that it is usually difficult to locate a site of a 
tumour. In this sense, molecular imaging has the potential to speed up the diagnosis in 
combination with blood sample testing to allow location of a tumour or early cancer 
detection,21, 22 including more recently near IR imaging investigations using advanced 
endoscopy for colorectal cancer and breast imaging. Other methods, more commonly 
used in the diagnosis of tumours which are difficult to access, involve optical 
fluorescence imaging. These involve the use of fluorophores and, for enhanced 
imaging,23 quantum dots (QDs) which have recently been used as parts of endoscopes.24, 
25 Endoscopy involves a long, thin flexible tube equipped with a camera and a light 
source on the end, which can be guided to the interior of a hollow organ or cavity of 







the body allowing detailed visualisation of the probe’s environment. In general, 
endoscopy is applied at the middle or late stages of cancer diagnosis and is combined 
with other imaging tools to confirm a cancer diagnosis, or with biopsy to collect a tissue 
sample for further investigations. 22 
 In conclusion, medical imaging techniques are not suitable in early cancer 
diagnosis unless the sensitivity of tools can be further improved and radio-toxicity of 
the tracers in medical use is considerably reduced. Biopsy is a method applicable in 
early cancer research; but due to lack of precision, it could perhaps be more effective if 
used together with more sensitive techniques as a confirmation of a diagnosis. Hence, 
blood sample tests would be ideal for the early cancer diagnosis, and one long term aim 
of this project would be to assemble fluorescent probes that can target cancer cells 
selectively and which would induce minimum harm to normal cells. 
 
The other interest of this project is how to deliver the diagnostic or therapeutic reagent 
precisely to a desired location in living cells and tissues. The design of a successful 
drug delivery system is determined by many factors, including the choice of the types 
of vehicle improved in the drug containment and delivery, size and shape, methods of 
functionalisation, ease of incorporation of the contrast agent (where this may be 
radioactive or fluorescent), issues of cellular and tumour microenvironment uptake as 
well as general side effects induced if the body identities as a “foreign objective”. A 
biocompatible nanoparticulate drug delivery agent would need careful selection as the 
first step, and this could play a crucial role in establishing a drug delivery system. It 
would directly, as well as indirectly, affect the subsequent steps in design, synthesis 
and imaging in vivo for a diagnostic nanomedicine. As vectors for drug delivery, 
nanoparticles offer a range of unique advantages, including their ability to modify drug 
pharmacokinetics in vivo and their capacity to be loaded with high concentrations of 
different drugs, for advanced combination of diagnostic and therapeutic (denoted 
“nano-theranostics”). A nanoparticles properties can also be modified to control drug 
release, alter blood circulation half-lives and improve bio-distribution profiles, increase 
tissue permeability and target specificity, as well as provide enhanced metabolic 
stability.26  







Currently, there are at least nine different types of nanocarriers which are most 
widely used in biomedical research and have applications with relevance to tumour 
diagnosis and treatment (Figure 1.3).27 
 
 
Figure 1. 3. General categories of nanocarriers and current development stages for molecular 
imaging of cancer 
 
As it was shown in the figure above, most of the nanocarriers studied to date 
could be categorised into four groups: (a) lipid-based systems, (b) surfactant-based 
systems, (c) polymer-based systems and (d) inorganic-materials based systems. 
Liposomes were the first types of vesicle which were discovered in 1965.28 
Phospholipids were one of the few solubilisers that could be well tolerated, and an 







increase in the solubility of any drug trapped within was found to be hundred to ten 
thousand folds. Followed by nearly 50 years of intensive experiment and studies, the 
application of liposomes in the biomedical field was approved.29 Both micelle and 
polymeric vesicles were less widely studied than the lipid-based systems, hence, the 
development and in vivo testing of these two types of carriers proceeded slower than 
that of liposomes.  
In recent years, inorganic nanocarriers have become intensely studied due to 
their sizes, shapes and ability to act as nanomedicines scaffolds, as well as their unique 
physicochemical properties, e.g. magnetism, emission/absorption spectroscopies, etc. 
Most inorganic carriers are currently at a preclinical and clinical trial stage. The most 
common of these, Quantum Dots, are intensely fluorescent and it was already 
demonstrated that these may be further bound to anticancer agents to make the resulting 
dual functional (imaging and therapeutic) composition, which is traceable in tissues. At 
the other end of the spectrum in terms of proximity to clinical use, single-walled carbon 
nanotubes (SWNTs) have a rigid framework and can absorb near infrared (NIR) light 
to generate heat, which could be used for photo-thermal therapy cancer treatment. There 
have been several other reviews with a focus on the development of single-walled 
nanotubes and their biocompatibility, which raise awareness of their inherent toxicity.30, 
31 Furthermore, iron oxides are probably the most popular nanomaterials in clinical use: 
they are magnetic, can be rapidly derivatised and combined with fluorescent probes to 
generate a dual modality imaging and/or sensing complex or nanohybrid. For these, a 
core shell design in nano-theranostics (a nanoscale amalgamation of diagnostics and 
therapeutics) is a relatively new but promising field with multidisplinary applications, 
potentially revolutionising the efficacy of diagnostic nanomedicines and in the long-
term their use as combined therapeutics, for patient benefit. This offers a targeted 
approach on a cellular level with future applications on a molecular scale which still 
currently represents an unmet clinical need for improved diagnostic contrast agent 
design32, 33.  
Small molecule-based, contrast agents can be incorporated in in vivo nano-
diagnostics, thus greatly increasing the sensitivity and selectivity of otherwise 
undetectable pathologies.34 Nano-medicines advance further increase this diagnostic 







potential by opening up new possibilities of imaging technologies and applications, 
such as those using fluorescence imaging techniques. There are many different types of 
nanomaterials currently under development – with some even at the clinical phase, such 
as gadolinium chelates and salts (Magnevist®), and iron oxide nanoparticles.35 
Nanomedicine offers use of current imaging technologies, including new opportunities 
in fluorescent tagging, which until now has not been widely used due to poor signal 
strength, wide emission bands in vivo, and poor tissue penetration.34 It offers even more 
insight into disease progression and can give information on tumour uptake 
mechanisms.36 This level of depth is required in order to probe diseased tissue on a 
molecular level and to gain a full understanding of the mechanisms involved. Hence, 
longer term, more precise patient diagnosis of treatment may become available through 
nanomedicine.  
 
1.2. Introduction to SWNTs: from synthesis and characterisation 
techniques 
1.2.1. Carbon allotropes 
Carbon is one of the most abundant elements on earth; it widely exists in the atmosphere, 
as component of living organisms and in minerals. The majority of carbon occurring 
naturally forms a compound by combining with other elements. For example carbon 
and oxygen form carbon dioxide in the atmosphere; carbon and hydrogen form a 
hydrocarbon, such as alkanes, alkenes or aromatic rings, which represent the 
fundamentals of organic chemistry. However, elemental carbon is found as carbon 
allotropes, some of which have only recently been identified, e.g. fullerenes, nanotubes 
and graphene, and their discovery led to two Nobel prices so far (The Nobel Prize in 
Chemistry, 1996 Robert F. Curl Jr., Sir Harold W. Kroto and Richard E. Smalley, for their 
discovery of fullerenes.  The Nobel Prize in Physics, 2010, Andre Geim and Konstantin 
Novoselov, for ground-breaking experiments regarding the two-dimensional material 
graphene.) 
   There are some well-known allotropes of carbon existing in the nature, namely 
graphite, diamond and amorphous carbon.37  The arrangement of carbon atoms in 







amorphous carbon is a non-crystalline, irregular, giving a glassy state. The structure is 
similar to that of graphite but the atoms are not held in a crystalline macrostructure. As 
a result, amorphous carbon presents as a powder.38 Graphite is the most common carbon 
allotropes, formed at normal pressure. Each carbon atom is sp2 hybridised and 
connected to three atoms to form a single layer sheet with a repetitive flat six-member 
ring structure, known as a hexagonal framework. A single layer of graphite can be 
isolated and the resulting material is known as graphene. Layers of graphene therefore 
stack together and constitute the 3-D structure of graphite. Delocalised 𝜋-electrons in 
the hexagonal framework give rise to strong light absorption abilities and electrical 
conductivity for this material. As a result, graphite has very good physical - chemical 
properties.39 Diamond is formed of sp3 hybridised carbon and emerges as a result of 
extremely high pressure. Each of the carbon atoms is attached to four other carbon 
atoms in a tetrahedral arrangement. Then, three other tetrahedral structures are joined 
to form 3-D six membered rings to give the extended structure. The repetition of these 
building blocks forms a network of covalent structures, which make diamond highly 
transparent, heat conductive and as such, one of the hardest natural materials in the 
world.37 (Figure 1.4) 
 
 
Figure 1. 4. Schematic representing fullerene and SWNTs from graphite 
 
There are intermolecular and intramolecular forces in graphite. Each carbon 
atom in the hexagonal framework is connected by covalent intramolecular forces; and 
each graphite sheet is stacked via van der Waals intermolecular forces (non-covalent 
interacts). Therefore, it is possible to separate the graphite into individual sheets, 







forming graphene without damaging the hexagonal framework.40 After the first 
exploration of the theory of graphene by P. R. Wallace in 1947,41 another allotrope of 
carbon, fullerene was revealed in 1985.42 Similar to graphene, fullerenes consist of 
carbon atoms also sp2 hybridised. However, fullerenes (C60 and higher fullerenes) 
contain not only hexagonal ring structures, but also pentagons, even heptagons of 
carbon atoms, which cause the closing of the sheet into spherical structures.43 The 
properties of fullerenes have not yet been fully analysed and represented an intense area 
of research in nanomaterials. As a result of a thorough investigation into fullerene, a 
tubular structure was discovered by a Japanese scientist Sumio Iijima in 1991,44 when 
he wanted to synthesise C60 fullerene via the arc discharge method. However, multi-
layer tubes of sp2 hybridised carbons, which had 3 nm to 30 nm diameters and were 
formed to be closed at both ends, had been observed in the carbon soot of 
graphite electrodes. After two years of further studies of these structures, Sumio Iijima 
and Bethune discovered single-walled carbon nanotubes (SWNTs).45-47 
1.2.2. Structure of SWNTs 
 The shape of SWNTs, seen as a single layer of hexagonal carbon atom ring frameworks 
(or a graphene sheet), can be rolled into a seamless cylindrical structure which normally 
has spherical ends (analogous to hemi-fullerenes).  Many studies had indicated that the 
properties of SWNTs were correlated to their structure (Figure 1.5)48, 49 
The structure of the SWNTs is determined by how the graphene sheet is rolled 
into a tubular structure. A chiral vector C is used to represent the overall chirality of the 
nanotube. This arrangement may be described from unit vectors a1 and a2 in the 




Where n and m are one pair of integers used to define the unit chiral vector. This 
pair of integers can be used to identify three different structures of nanotubes, namely 
zigzag, chiral and armchair. As it could be seen in the Figure 1.5, when the integer 
appeared as (n, 0), the structure is classified as zigzag. If the integer is (n, n), it is 







armchair structure. Finally, once the integer is any number between 0 and n, i.e. (n, m), 




Figure 1. 5. Possible vectors arranged by pairs of integers (n, m) for a general structure of 
SWNTs (the alternating double bonds in the sp2 graphene layer have been omitted for clarity)52 
 
In the same way, the structure of the nanotube can also be defined using a chiral 













In zigzag structure, m = 0, the equation describing the structure is: 
θ=tan-1[0]=0° 
Where in the chiral SWNT structure, 0 < m < n, for example, 0º < <30º, Chirality of 
the tube structure affects many properties of the SWNTs, such as the electrical, optical, 
thermal, magnetic and mechanical properties of carbon nanotubes, particularly in 







electrical properties. The general rules for the metallic character of SWNTs are given 
as follows: 
(1) Once n – m = 3q, where q is an integer, the structure of SWNTs is metallic. 
Otherwise it would be semi-conductive.  
(2) In case of an armchair structure, because m = n, n – m = n – n = q = 0, all 
armchair structured SWNTs are metallic.  
(3) In chiral and zigzag SWNTs, where q = (n – m) / 3 and q = n / 3 respectively, 
the majority of those SWNTs is semi-conductive in nature.53 
In practise, the separation of the three types of SWNTs remains extremely challenging, 
and most samples of SWNTs available commercially or synthesised in house constitute 
of  a statistic mix of the tube (1) – (3). 
 
1.2.3. Synthesis of SWNTs 
There are many different ways to generate SWNTs, including (a) electric arc discharge, 
(b) laser ablation and (c) chemical vapour deposition (CVD).  
The electric arc discharge was the first method developed for the carbon 
nanotube production.  This method could be traced back to the early sixties, used by R. 
Bacon for the synthesis of carbon fibres.54 The same technique was applied to create 
fullerenes in good yields by Krätschmer and Huffman in 1990.55 This method was soon 
modified and improved for the synthesis of multi-walled (MWNT) and single-walled 
(SWNT) carbon nanotubes. At the same time, other methods such as the laser ablation 
and chemical vapour deposition (CVD) were developed and successfully adopted in the 
synthesis of single walled carbon nanotubes. The laser ablation is a synthetic technique 
similar to the arc discharge method. The difference between these two methods is 
mainly due to the fact that laser ablation gives a higher purity, but lower quality of the 
desired product. However, the arc discharge and the different types of CVD methods 
are the most promising and leading techniques in the large scale production of single 
walled carbon nanotubes.56, 57 
 
 








(a)  Electric arc discharge method 
For the electronic arc discharge methods, a high electric current (50-150 A) passes 
through both the carbon anode and cathode; as a result, a high temperature is generated 
at the carbon anode. The carbon sources on the carbon anode are evaporated. A constant 
gap between anode and cathode is maintained by adjusting the position of the anode. 
During the arc discharge, a plasma is formed between the electrodes. The plasma can 
be stabilised for a long reaction time (30 sec – 10 min) by controlling the distance 
between the electrodes by means of the voltage (25 – 40 V) control. The container is 
also filled with inert gas at low pressure, such as helium or argon. This avoids the risk 
that the vaporised carbon reacts with oxygen to form carbon dioxide. This also ensures 
the pressure at the inert - electrode zone remains low. When the reaction finishes, all 
vaporised carbon will be deposited on the cathode. Figure 1.6. shows the schematic 
representation of this process 
 
  











Table 1. 3. Synthesis of different types of SWNTs via arc discharge under different 
conditions 
 
Product Conditions Comments 
SWNTs, CNT  
Ribbons 
Ho/Ni catalyst High yield  
SWNTs Fibre Y/Ni catalyst, S High purity 
SWNTs, Nanohorns Ni, Liquid N2  
SWNTs, Fullerenes,  
Metallofullerenes 
Y/Ni and CaC2 /Ni catalyst, He d = 0.9–1.4 nm 
MWNTs, SWNTs,  
Carbon anocapsules 
NaCl solution  
 
Arc discharge can be used to synthesise both SWNTs and multi-walled carbon 
nanotubes (MCNTs) in the presence or absence of a metal catalyst, such as Ni, Y, Fe 
or Co etc. The quantity and quality of the nanotubes obtained this way depend mainly 
on the metal / carbon ratio, reaction environments and pressure of the container.  
Various conditions are listed in the Table 1.3. It was clearly shown that metal catalyst 
nickel (Ni) has a strong influence on the formation of the SWNTs.58 For instance, Eu / 
Ni catalysed synthesis produces very few SWNTs with nanoparticles; but replacing Eu 
with Y would improve the yield up to 60%.59 Additionally, Y / Ni catalyst with small 
amount of sulphur can produce a high purity SWNTs fibre. 60 On the other hand, 
catalysts also affect the diameter of the SWNTs. For example, the use of CaC2 / Ni 
leads to production of SWNTs with 0.9 – 1.1 nm diameters,61 whilst SWNTs created 
by Y / Ni have a diameter range between 1.3 – 1.4 nm. Liquid N2, deionised water and 
NaCl can be used as a medium. Only a few SWNTs, with different unpurified by-
products, have been find to form in the end.62, 63 Finally, pressure is another factor that 
determines the difference in diameter. An arc discharge reaction in He at 700 Torr have 
been shown to result in high density SWNT bundles (d = 20 -30 nm), whilst at 300 Torr, 
the main products are a mixture of fullerenes and metallofullerenes.61 
  







(b) Laser ablation method 
There are two types of laser ablation methods: (i) pulsed laser vaporisation and (ii) 
continuous laser vaporisation. The major difference between the two protocols is that 
the former method uses a pulsed laser, whilst the later method adopts a continuous laser 
to heat the carbon sources. Because the pulsed laser can provide a much higher power 
density, pulsed laser vaporisation is more commonly used in carbon nanotubes 
synthesis than continuous laser vaporisation. Laser ablation utilises an intense laser 
pulsed at a carbon sources with 0.5% of catalyst (nickel or cobalt). A flow of inert gas 
is blown through the tube, carrying the vaporised carbon downstream to the water-
cooled copper collector.  Carbon nanotubes assemble and can be gathered from the 
collector at room temperature, as it is shown in figure 1.7. This method can produce 
higher yields SWNTs than standard arc discharge methods. However, the production 
yield is low and the pulsed laser vaporisation or laser ablation method is both 















Figure 1. 7. Schematic representation of the synthesis of SWNTs: pulsed laser ablation 
 
The pulsed laser-ablation designed for the synthesis of single walled carbon 
nanotubes was originally established by Guo et al. at Rice University.56 Then, the 
method was further developed by Smalley et al. in 1996, in order to produce SWNTs 
on a large scale.64 Simultaneously, a double beam laser method was applied by both 
Thess et al. and Rao et al. to improve the purity of SWNTs up to 90% with a better 







tubular structure than those produced in the arc discharge method.65, 66 However, the 
amount of carbon deposit found at the end of process was found to be significantly 
decreased. The laser ablation technique was normally adopted to synthesise SWNTs. 
Whereas, MWNTs are only formed under special reaction conditions.  
The work of Maser et al. investigated the effect of metal concentration in the 
catalyst, gas flow and pressure on the synthesis of SWNTs.67-69 There were two types 
of catalyst were applied in the synthesis, one was mono-catalyst (Co or Ni) and the 
other one was catalyst mixture with two metals at equal (Ni/Co) or different 
concentration (Ni/Y). Individual SWNTs were produced in the mono-catalyst system, 
whereas in the mixed catalyst system, majority of SWNTs formed were SWNT 
bundles.69  
Varieties of gases were chosen as carrier gas, including Ar, N2, He, but a high 
yield of SWNTs could be achieved under Ar or N2 environment and the pressure of 
200-400 Torr.69 it has been shown that there were no SWNTs formed once the pressure 
was dropped below 100 Torr. Muñoz et al. reported studies that revealed the synthesis 
on C/Ni/Y target in Ar and N2 at 50–500 Torr of pressure.70 A high yield of filamentous 
soot with web-like structures were observed under 200 – 500 Torr pressure. SWNT 
bundles formed in this soot were about 10–20 nm in diameter and more than 1 μm in 
length.71 Gas flow rates (Ar and N2) have been found to be a less important parameter 
in the system: modifying this parameter has been found not to lead to remarkable 
changes in the quantity and quality of the final product.  
There have also been observations regarding the effects varieties of laser 
conditions, including mode and type of laser, could be modified to change the quantities 
and qualities of the SWNTs formed in the end of the process. The choice of the laser 
mode would dramatically influence the final result. There were basically two laser 
modes: continuous- and pulsed- mode. In the continuous laser mode, the carbon source 
is evaporated at a rate of 200 mg/h and this leads to formation of high quality SWNTs 
at the end of the process. In the pulsed laser mode, the evaporation rate is ca. 4 mg/h 
and the majority of the product emerging has been found to be amorphous carbon. A 
gas- powder suspension method was developed by Bolshakov et al. in order to optimise 
the absorption of the laser radiation for carbon source evaporation.72 In the end, 20% - 







40% of the product find in the carbonaceous deposit was formed of SWNTs of 1.2-1.3 
nm diameter. CO2 laser and Nd:YAG laser are the two most common types of laser 
used in this research field.67, 73, 74 Both continuous and pulsed CO2 lasers can produce 
SWNTs at room temperature, but many studies have reported that the continuous laser 
mode is more effective to produce a higher yield SWNTs than in the pulsed mode.75 A 
continuous mode CO2 laser has been applied to vaporise a carbon source in an Ar 
atmosphere with laser power of 400 – 900 W. This resulted in the formation of bamboo-
like strands of SWNTs with a wide diameter distribution in a range of 6 – 20 nm.76 
When a pulsed CO2 laser vaporisation was used, the majority of SWNTs formed have 
been found to have a uniform diameter, at around 1.3 nm.77 As for the Nd:YAG laser, 
two pulsed Nd:YAG laser mode were tested, one was Nd:YAG laser pulsed with 
intensity of 0.5 – 4.6 × 109 W/m2, the other one was Nd:YAG laser double pulsed with 
intensity of 0.6 – 5.6 × 109 W/m2. The reported furnace temperature has been in between 
800 and 1150 ºC, under an Ar atmosphere.78 Both single- and double-pulsed lasers 
produced high quality SWNTs, but structure and diameter of SWNTs varied slightly 
depend on the choice of the conditions.73 The results reported have demonstrated that a 
larger SWNTs with a diameter around about 1.4 nm has been formed with a high 
intensity laser and furnace temperature. In a single-pulsed laser with a high furnace 
temperature 750 – 1150 ºC, the diameter of SWNTs was reported to fluctuate between 
2 nm and 13 nm. In addition to CO2 laser and Nd:YAG laser, XeCl excimer laser and 
UV laser KrF excimer have been also adopted to synthesise SWNTs. A web-like 
deposit has been observed in XeCl excimer laser ablation technique at 1000 ºC, and the 
soot contained SWNTs bundles with 20 nm in diameter and composed of individual 
SWNTs with a diameter in the range of 1.2 – 1.7 nm.71 When the UV laser KrF excimer 
has been used, a thicker SWNTs bundles with an average diameter of 70 nm have been 
reported to formed at 1150 ºC.79  
 The quantity and quality of the nanotubes depend on the laser type, carrier gas 
parameter and temperature. All the conditions were listed in table 1.4. 







Table 1. 4. A summary of the conditions reported for the synthesis of SWNTs via laser 
ablation in different conditions 
 
 Method Product Conditions Commonts Reference 
XeCl excimer SWNT 
bundles, 
fullerenes 




d = 20 nm 









Laser power: 400–900 W; C/Ni/Co, 
room T Ar: 200–400 Torr; 
d = 6 – 20 nm 76 
Pulsed double Nd:YAG SWNT 
bundles 
Laser intensity: 532 nm, 1064 nm, 
double beam 532 and 1064 nm; 
C/Ni/Co; Ar; Furnace T: 800–1150 °C 
Larger SWNTs with 
diameter at ca. 1.4 nm 
78
 
CO2 continuous wave SWNT 
bundles 
Gas-powder suspension catalyst; Ar, 
N2; 1100 °C 
Gas nature Ar, He, N2 50–500 Torr; 
C/Ni/Y 
d = 10 – 20 nm, 
their length was more than 
1 μm in Ar and N2 
71
 
CO2 continuous and 
pulsed wave 
SWNTs Catalyst composition, gas conditions: 
Ar, He, N2 50–500 Torr, laser power 
density: 9 – 12 kW/cm2 
Configuration of laser wave 
d =  5 – 25 nm  
Diameter of SWNTs 
was 1.3 – 1.4 nm 
70
 
Pulsed Nd:YAG laser Thin SWNTs Target composition, reaction T and gas 
flow velocity 
d = 2 – 13 nm 70 
CO2 pulsed laser SWNTs Target composition 
Gas nature and its pressure 
Diameter of SWNTs was 
0.86 – 1.46 nm 
68 
Pulsed double beam 
Nd:YAG 
SWNTs Effect of the laser intensity Purity > 70% 65 
Pulsed Nd:YAG SWNTs Effect of the laser intensity Purity > 70% 66 
KrF excimer SWNTs Furnace T = 550 °C Purity > 70% 73 
Pulsed Nd:YAG SWNTs Laser parameters 
Target composition 
d = 1.0 – 1.2 nm 80 
Pulsed double beam 
Nd:YAG 
SWNTs Gas pressure, flow d ~ 1.0 nm 79 
KrF excimer UV laser SWNT 
bundles 
Furnace temperature 25–1150 °C; Ar, 
C/Ni/Co 
Bundles of SWNTs with 











Chemical vapour deposition 
Figure 1.8 shows chemical vapour deposition (CVD) route for SWNT production. For 
CVD production, carbon-rich gases, such as acetylene (C2H2), ethylene (C2H4), ethanol 
(C2H6O) or methane (CH4), when mixed with ammonia, nitrogen or hydrogen, are 
converted into SWNTs.81 These gases are passed through a tube (shown in Figure 1.8), 
which contains a variety of catalysts on a support and which is placed, inside a furnace, 
to form carbon nanotubes. The whole system is normally heated up to ca. 700 ºC, and 
















Figure 1. 8. Schematic representation of the synthesis of SWNTs: chemical vapour deposition 
 
The mechanism of the CVD method involves the dissociation of hydrocarbon 
molecules, catalysed by a transition metal in the heterogeneous phase reaction. This 
step is followed by the dissolution and deposition of carbon atoms on the substrate. The 
precipitation from the saturated metal particles has been reported to induce the 
formation of a tubular structure for the SWNTs.81, 83 The type of nanotubes formed 
could be determined by the temperature and hydrocarbon gas employed. For example 
for multi-walled carbon nanotubes (MWNTs), the most common CVD processes 
employ ethylene and acetylene as the carbon source and the growth temperature was 
normally between 400 to 600 ºC. For SWNTs, the temperature needed is usually higher 
than 700 ºC. CVD constitutes an effective method to synthesise carbon nanotubes in 







the high yield required for most industrial applications. Carbon nanotubes could also 
be directly grown on a desired substrate hence this reduces the risk of contamination or 
product loss during the transfer. As a result, CVD methods have recently emerged as a 
common method of synthesising carbon nanotubes in bulk. 
 
Table 1. 5. A summary of the conditions reported for the Synthesis of SWNTs via chemical 
vapour deposition in different conditions 
 
Method Product Conditions Commonts Reference 
Water-assisted  Vertically aligned 
SWNTs, DWNTs  
With buffer layer  
 







SWNTs, DWNTs  
With buffer layer  
 







SWNTs, DWNTs  






without a buffer 
layer  
High yield 88 
Hot filament-
enhanced  
SWNTs, MWNTs  Fe-Co/SiO2 with or 
without of Si 
support 





High power laser 
pulse alcohol CVD  
SWNTs  
 
Solid metal target  
 
High purity 92 
Alcohol CVD  SWNTs  Ferrocene-ethanol  High purity  90, 91 
Simple CVD  SWNTs  Fe-Mo/Si substrate, 
methane  






substrate, ethanol  






Table 1.5 showed SWNTs can be formed under different conditions, using 
varieties of carbon sources, inert gas, catalysts, support materials, substrates and 
different types of CVD furnaces. In general, SWNTs can be produced by a simple CVD 
at 900 °C using CH4 as carbon sources and Fe/Mo as a catalyst, and their growth has 
been supported on the Si substrate. Individual nanotubes as well as tubes in bundles 
may be formed with a diameter of about 1.15 nm.84 Water-assisted, O2-assisted plasma-







enhanced and microwave plasma-enhanced CVD methods were able to produce high 
yields of SWNTs and double walled carbon nanotube (DWNTs) with the diameter 
range between 1 and 2 nm in a different buffer layer.85-87 However, if only Co-Ti 
catalyst and Si substrates are used in microwave plasma-enhanced CVD without a 
buffer layer, then only vertically aligned SWNTs with diameter at 2 nm have been 
observed in the end.88 Hot filament-enhanced CVD methods produce SWNTs with 
diameters in the range of 0.65 – 1.55 nm. The reaction is catalysed by Fe-Co solid phase 
catalyst and use SiO2 as the mixtures substrate. The advantages of this method is that it 
required a relatively low substrate temperature of 660 °C and a low amount of carbon 
supply, i.e. low C2H2 concentration and low reaction pressure. Because SWNTs 
synthesised by this method vary in diameter, nanotubes were found to be vertically 
aligned when they were large in diameter (0.65 – 1.55 nm). In contrast, when nanotubes 
were smaller than a certain size, they grew perpendicularly across the surface.89 The 
alcohol-based CVD technique was another common method which used a solution of 
ferrocene and ethanol with different ratios to achieve a high purity.90, 91 The ratio 
between ferrocene and ethanol was crucial to the reaction, a low concentration of 
ferrocene causes the mass production of amorphous carbon with only a small amount 
of nanoparticles, whilst too high concentrations of ferrocene has been found to lead to 
the formation of nanoparticles instead of SWNTs. After several experiments, the 
optimium ratio of ferrocene/ ethanol was established at about 1 – 1.5 wt %. The high 
power laser pulse alcohol-CVD method was an advanced method of alcohol-CVD and 
a high power laser pulse was used for the vaporisation of solid metal target. This was 
made up of ethanol and Co catalyst. SWNTs with diameter of 0.96–1.68 nm were 
synthesised in the end.92 Ultrasonic spray pyrolysis CVD used ethanol as carbon 
sources and Co-Mo as the catalyst and silicon as the substrate. SWNTs produced from 
this method mainly depended on the dipping time and catalyst concentration, the 
diameter of the SWNTs was in a range of 0.8 – 1.2 nm.93 
  







1.2.4. Impurities typically found in as-made SWNT and their potential health 
and environment risks  
Regardless of the producing methods used, as synthesised SWNTs samples contain 
certain amount of impurities, including: amorphous carbon, fullerenes, metallic 
nanoparticles, multi-shell carbon nanoparticles, nanocrystalline graphite, various 
contaminations depend on the support, such as silicon substrate. These SWNTs cannot 
be used directly in most applications, because the presence of those impurities after 
synthesis will cause many problems, especially in biomedical applications. The major 
problems come from the metallic catalysts, which are highly reductive and lead to a 
significant rise of the reactive oxidative species (ROS) level in living systems.94 
  ROS refers to free radicals and other oxygen-related reactive compounds, 
including singlet oxygen (1O2), hydrogen peroxide (H2O2) and hydroperoxide 
(ROOH).95, 96 All these compounds are highly reactive to nearby environment, which 
makes ROS able to initiate free radical reaction to convert a non-radical molecule to a 
radical. In the beginning of ROS generation, molecular oxygen is reduced by a reducing 
reagent, such as metallic particles, to form a superoxide radical ion O2
-.. Then a series 
of free radical chain reactions will be initialled by this superoxide.97 Formation of 






        
Scheme 1. 1. Formation of hydrogen superoxide in mitochondria 
 
Scheme 1.1 showed a reaction to form a hydrogen peroxide (H2O2) from 
superoxide (O2
-.). In mitochondria, superoxide is further reduced to hydrogen peroxide 
and molecular oxygen, which is catalysed by superoxide dismutases (SOD). H2O2 is 
more kinetically and thermodynamically stable than superoxide ions and it can diffuse 
to the cytoplasm to enhance radical reactions, unless it has been eliminated by catalase 
or glutathione scavenges biomolecules.  At the end of the radical chain reaction, the 
most reactive and harmful radical, hydroxyl radical (OH.) is produced from H2O2 via 







the Fenton reaction and Haber-Weiss reaction catalysed by transition metals , as shown 
in scheme 1.2.98 The hydroxyl radical has extremely short lifetimes (around 1 ns): this 
makes this radical species extraordinary reactive in living cells have the ability to 
damage all the biomolecules, including DNA,92, 93 RNA,99 lipids, proteins100 and 
carbohydrates101. In fact, hydroxyl radicals are normally consumed at the site of 









→        O2+OH
.+OH- 
 
Scheme 1. 2. Formation of hydroxyl radical from hydrogen peroxide 
 
As a result of ROS level upregulation, there are a series of consequences 
outlined in the Figure 1.9.102 Both hydrogen peroxide and hydroxyl radical can damage 
DNA, and radicals can oxidise purine and pyrimidine bases to introduce strand breaks 
and mutations. Poly-ADP-ribose polymerase is subsequently activated to repair the 
damage via depleting malfunctioned DNA.103 Radicals, such as hydroxyl radicals can 
oxidise sulfhydryl groups and amino acids, leading to the formation of a defective 
protein. In the same way, hydroxyl radicals can also initiate a lipid peroxidation; it 
converts unsaturated lipids to lipid peroxide, and as a consequence, it leads to the 
disruption of the lipid phosphate bilayer structure, and a decrease in the membrane 
fluidity, whilst increasing the structure of membrane permeability and modifying the 
membrane proteins.104 All modification mentioned above will cause cell death by 
necrosis. On the other hand, ROS can also activate redox signalling, release protein 
cytochrome complex (cyt c) and open permeability transition pore (PTP) to initiate cell 
death via apoptosis. In general, both methods of cell death have been shown to lead to 
degenerative diseases or accelerated aging in living organisms.105-107  
 
 









Figure 1. 9. A schematic representation of the effect of the ROS in cellular mitochondria 
 
Carbonaceous nanomaterials, such as amorphous carbon, fullerenes, multi-shell 
carbon nanoparticles and nanocrystalline graphite, are also known to cause problems 
and their presence limits the applications of SWNTs in nanomedicine. Although these 
carbonaceous nanomaterials will not cause direct damage to cells or tissues, they can 
attach to SWNTs (or self-aggregates) to encapsulate metal catalysts. As aggregates, 
they reduce the solubility of the nanomaterials, which makes functionalisation of 
SWNTs impossible. Many articles have pointed out that pristine SWNT strands in 
general will not cause drastic inflammatory or immune responses, until SWNTs are 
aggregated and have a significant larger diameter.108, 109  
In that case, SWNTs will be detected by immune system with the aim to 
eliminate these from the living organisms. In addition, impure SWNTs administrated 
in vivo, can activate platelets in blood vessels to cause thrombosis.110 Finally, 
carbonaceous impurities also affect the functionalisation process of SWNTs, lead to a 
decrease in the degree of functionalisation and solubility of the functionalised SWNTs 
(f-SWNTs). Therefore, purification of SWNTs to remove metallic nanoparticles and 
carbonaceous impurities is an essential step before functionalisation and further 
biomedical applications of SWNTs can be considered. 







1.2.5. Methods for the advanced purification of SWNTs for biomedical 
application 
 As-made SWNTs can be purified via chemical or physical methods. The former 
includes: liquid phase oxidation, gas phase oxidation and electrochemical oxidation. 
The latter method contains filtration, centrifugation, solubilisation with other functional 
groups and high temperature annealing. Many years of research have shown that only 
single purification method, especially physical purification techniques is to date, 
reliable enough to remove all the impurities at once. Therefore, more than two methods 
are typically combined together to enhance the effectiveness of the progress, whilst 
considering the yield of the purification process overall.111  
 For the liquid phase oxidation methods, HNO3 and H2O2 have been used as 
oxidative reagents. Their action breaks sp2 bonds and creates defect sites on the 
hexagonal carbon at framework.112 Due to the fact that carbonaceous materials presents 
on the surface of SWNTs are typically irregular and defective in shape, from the 
catalytic production process, they have larger surface areas than SWNTs strands when 
exposed to the oxidative reagents. Hence, they are vulnerable to be oxidised before the 
pure SWNTs surfaces.113, 114 As a result of this oxidative treatment, carboxyl or 
hydroxyl groups are introduced onto the carbonaceous impurities to make these 
carbonaceous impurities more soluble and dispersible in common organic solvents than 
SWNTs.115, 116 Microwave treatments are an effective method to enhance the liquid 
phase oxidation. This process heats up the metal catalysts encapsulated in the 
carbonaceous impurities that are attached to the surface of SWNTs. As a result, the 
thick carbon shell is cracked by microwave-heated metallic catalyst and this leaves  the 
metal exposed to the outside atmosphere.117 Afterwards, an acid wash is subsequently 
applied to remove those resulting metal ions from SWNTs.118  
On the other hand, in gas phase oxidation methods,119-121 SWNTs can be 
purified via gaseous oxidants, including a mixture of Cl2, H2O, and HCl,
122 H2S and 
O2,
123 hydrogen treatment,124 Air/H2O
125, fluorine126 and water vapour127. Intact 
SWNTs ignite at higher temperature than amorphous carbon, therefore heating as-made 
SWNTs at around 500 ºC in a wet stream can remove amorphous carbon before 
damaging the tubes.128 Ultrasonication of SWNTs in common solvents is normally used 







to assist the previous two methods.129 Ultrasonication itself cannot purify the SWNTs, 
but it can conduct vibration forces through a water bath onto the SWNTs samples, 
providing a high local shear, particularly to the end of the nanotube bundles. This makes 
them temporarily better dispersed in the solvent, in another word, it increases the exposure 
of the surface of raw SWNTs to the oxidative reagent in order to facilitate the purification 
methods.130-132 However, prolonged ultrasonication will also damage the structure of 
carbon nanotubes, so it is important to manage the time of exposure.133 
Apart from the liquid phase and gas phase oxidation technique, electrochemical 
oxidation is another method to modify as-made SWNTs.134 Samples are immersed in 
an acid or a base solution and an electric potential is applied to the solution to etch both 
amorphous carbon and SWNTs. However, carbon materials with fewer defects 
normally show a lower corrosive rate in electrochemical oxidation. Hence, it has been 
assumed that intact SWNTs have a higher electrochemical oxidation resistance than 
amorphous carbon.135 In basic solutions, metal catalysts are exposed after amorphous 
carbons are etched. An acid wash is therefore necessary in the subsequent step to 
remove all metallic impurities. In contrast, in the acid solution, metal ions will be 
directly “dissolved” into the solution giving rise to MXn salts after amorphous carbons 
are etched. At the same time, the tips of SWNTs have been found to be opened in the 
acidic environment and there is no significant tip-open-effect in the basic solution. The 
advantage of this method has been considered to be very effective for SWNTs 
purification from amorphous carbon. The optimum time of the oxidation process for 
SWNT purification can be easily achieved by the redox potential monitoring. It was 
found that this can also open the tips during purification via choosing an acidic solution. 
However, this method cannot identify and remove carbon impurities with fewer defects 
such as polyhedral carbon, graphite particles and carbon onions. Most importantly, the 
amount of SWNTs purified in each batch is too small for many protocol purposes in 
many biomedical applications.136  







1.2.6. Functionalisation methods for SWNTs 
For biomedical applications, it has been reported that functionalisation of SWNTs plays 
an equally important role as purification. After purification of the metallic, amorphous 
carbon and graphitic carbon impurities from the as-made SWNTs, functionalisation is 
used to modify the structure of SWNTs in order to improve the solubility and 
biocompatibility. It has been reported that the functionalisation of SWNTs enhances 
their dispensability into individual tubes in common solvents and further reduces the 




Figure 1. 10. Schematic representations of different methods of functionalisation of 
SWNTs.53 







Figure 1.10 shows the most common methods of functionalisation. In general, 
it can be divided into two categories: covalent and non-covalent methods.  
Covalent functionalisation involve breaking and forming new bonds on the 
defect and sidewall of SWNTs, as it can be seen in Figure 1.10 a and 1.10 b. There are 
ten common methods, described in Figure 1.11, e. g: acid-based treatment, ozonolysis, 
halogenation, reductive coupling, oxidative coupling, polymer grafting, hydrogenation, 





Figure 1. 11. Covalent functionalisation of SWNTs138 
 







The most commonly used covalent method is acid (oxidative) treatment, which 
introduces carboxyl groups at the sidewall, defect sites and open ends of SWNTs.139, 140 
Furthermore, carboxyl groups on SWNTs can be subsequently treated with hydroxyl or 
amino groups to form an ester bond or carboxamide bond. This allows the further 
modification by incorporating of other organic groups molecules onto the surface of 
SWNTs. Alternative ways to add functional groups on the side of SWNTs is for 
example through halogenation reactions. Once a halide is inserted onto the hexagonal 
framework surface of the carbon nanotubes, in subsequent steps this can be converted 
through standard organic chemistry, e.g. by carrying out substitution reactions onto 
halide-functionalised SWNTs. 
As for non-covalent functionalisation, this is based upon supramolecular 
interactions between the surface of SWNTs and other intact molecules, such as 
polymers, polysaccharides, porphyrin oligomers etc. Instead of breaking and forming a 
new bond between the functional group and the sp2 carbon of the SWNTs (which causes 
the local disruption of the synthetic structure), the functional groups or molecules attach 
onto or “wrap-around” the SWNTs via van der Waals interactions or aromatic stacking. 
Polyethylene glycol (PEG) and pyrene have been commonly normally used for non-
covalent functionalisation to achieve dispersions of SWNTs.141 Pyrene-based groups 
attach to SWNTs via - stacking. Pyrene can act as a scaffold molecule. Whilst further 
modifications can be performed to the attached pyrene to future functionalise the 
SWNTs constructs (figure 1.10 c).  
PEGs are commercially available polymer chains that can wrap or coat SWNTs. 
PEGs have both hydrophobic and hydrophilic functionalities, thus it have been found 
that they are aiding the dispersion of SWNTs in aqueous media.142 Further 
functionalisation can be performed onto the PEG chains to introduce a variety of 
different molecules (1.10 d). The major advantage of the non-covalent method is that it 
does not damage the existing structure of SWNTs. Secondly, polymers can wrap the 
whole SWNTs, thus all of the surface area can be used for loading much larger 
molecules are than via the covalent method. Finally, the polymer layer not only acts as 
an anchor, but also as a protecting layer. This shields the SWNT surface from the 
environment and also may avoid further damage created by SWNTs to the surrounding 







cells. Non-covalently wrapped-SWNTs have been shown reduce the cytotoxicity of 
functionalised SWNTs to cancer cells in the MTT assays.143  
Apart from covalent and non-covalent functionalisation on the outer surface of 
SWNTs, an alternative possibility to functionalise them is the method known as internal 
functionalisation. This refers to the filling of SWNTs with ions or small molecules. The 
most important advantage is that the encapsulated molecules can be protected by the 
SWNT walls; hence it can lead to the stabilisation of reactive species inside the tubes, 
as well as to the prevention of contaminations or loss of molecule. However, this 
method is still under development regarding the precise control of the filling yield.144 
There are still many problems, for example, the capacity of filling is limited and the 
mechanism of controlled release of particles trapped within carbon nanotubes is still 
under investigation.145, 146   
 
1.2.7. Developments and applications of SWNTs in the biomedical field 
SWNTs is a relatively new inorganic material, however in the past two decades there 
were intensive studies and researches based on it to explore the properties and 
applications of this novel material at the interface with biological research fields.147-149   
 
 
Figure 1. 12. Properties and application of SWNTs in biomedical field 
 







Figure 1.12 highlights five basic properties having the potential applications in 
the biomedical field, namely: chemical properties, electrical properties, magnetic 
properties, optical properties and field emission properties. Because raw, as-made, even 
purified SWNTs are very difficult to dissolve into all ranges of the solvents, chemical 
properties were initially investigated aiming to improve its solubility. After chemical 
modification, the new bonds formed, for example, amide bonds, carboxyl or hydroxyl 
groups are introduced on the surface or on the side of the SWNTs via covalent 
functionalisation. On the other hand, polymer or oligomers can be functionalised on 
SWNTs by van der Waals intermolecular forces or π – π stacking via non-covalent 
methods. Both ways not only improves the solubility of the SWNTs, but also extend 
the potential application of SWNTs towards biomedical areas.150 For example, a 
carboxyl group formed from covalent functionalisation can be reacted further with a 
hydroxyl group to form an ester bond, or with an amine group to form a peptide bond. 
As such, there are many different compounds or small molecules, (like radiolabelled 
probes, fluorescent molecules, DNAs and proteins), which can be introduced to process 
different biomedical tasks. For instance, SWNTs can be functionalised and act as a 
vector, in order to deliver drugs to desired site, or modified to act as a sensor to detect 
overexpressed growth factors in cancer cells.151 
 Optical properties of the SWNTs are the other important factor which 
determines the application of SWNTs in the biomedical field. There are two main 
optical properties of SWNTs, (1) abilities to absorb all light in the visible region, hence, 
resulting in the colour of the SWNTs completely black. And (2) the absorbed light at 
wavelength between 700 and 1100 nm is emitted as fluorescent signals, or lead to 
convert the energy into heat. The former situation is applied as an imaging tool to track 
and imaging cells, whilst the latter their application in killing the targeted cells. 152, 153 
  Electrical properties of SWNTs have also been used to detect molecules, but 
rather than bind to target molecule and cause fluorescent intensity change, these lead to 
changes in their changes electrical potential instead.154, 155  
 Magnetic properties of SWNTs can be normally introduced via internal cavity 
filling of metal: such as, metal ions of Ti, Fe, Co, Ni, Cu, Ga, In, Zn, Gd and Fe–Co 
alloys have been incorporated.156 The external coating of the SWNTs with magnetic 







nanoparticles have also been reported.157 These magnetic CNTs are generally employed 
as a scaffold, in order to prepare more complex multifunctional vectors for biological 
applications. These vectors are able to carry fluorescent molecules, proteins, DNA, 
targeting ligands and therapeutic drugs, and these multifunctional vectors can also be 
used in cellular imaging, cell tracking, lymphatic targeting, cancer lymph node 
metastasis treatment and cancer gene therapy.158  
Field emission property of SWNTs is the last important properties of SWNTs. 
Electrons are readily emitted from the tips of the SWNTs, either due to oxidized tips or 
because of the curvature of the SWNTs. when a potential is applied between a carbon 
nanotube surface and an anode, this is generated by the continuous and pulsed X-rays, 
using a SWNTs-based field emission cathode. Miniaturized SWNTs-based X-ray 
device have been reported to have been inserted into the body by endoscopy to achieve 
a precise X-ray radiation therapy directly toward a desired area to be imaged and 
minimise damaging the surrounding healthy tissues.159, 160  
 
1.2.8. Characterisation techniques for SWNTs 
Characterisation of SWNTs is the final, yet most important stage of investigation prior 
to any application. Due to different methods of synthesis, as-synthesised batches of 
SWNTs samples contain tubes which are slightly different in diameter, length, chirality, 
purity, catalysts, impurity species and nature number of defects. After purification and 
functionalisation of SWNTs, and despite the standard removal of catalysts and 
impurities, one or both of the SWNT ends may be open, and the length of SWNTs 
strands are often reduced during the purification. Also, functional groups on the 
SWNTs are modified and some characterise defects are introduced onto the backbone 
of the SWNTs. Therefore, characterisation of SWNTs is essential to determine the 
quantity, quality and properties of each individual batch.  
There are many techniques that have been reported and used to examine SWNTs, 
including, photoluminescence spectroscopy (PES), X-ray photoelectron spectroscopy 
(XPS), Electron microscopy (SEM & TEM), Scanning tunnelling microscopy 
(STM), X-ray diffraction (XRD), Neutron diffraction, Raman spectroscopy, Thermal 
analysis (TGA/DTG) and absorption spectroscopy (UV, Vis and IR). Electron 







microscopy (SEM & TEM), absorption spectroscopy and Raman spectroscopy are the 
most widely used characterisation techniques due to accessibilities in standard labs and 




Figure 1. 13. A schematic representation of transmission electron microscopy typically used 
to characterise SWNTs 
 
Three most commonly-used electron microscopies are TEM, SEM and atomic 
force microscopy (AFM). In TEM (Figure 1.13), a beam of electrons is accelerated and 
projected onto an ultra-thin specimen. Subsequently electrons collide with the atoms in 
the sample and deflect into different directions in a process, known as three-
dimensional angle scattering. The size of the scattering depends on the density and 
thickness of the sample (typically nanometre scale). The image is magnified and 
focused onto an imaging device, either a fluorescent screen, on a layer of photographic 
film, or to be detected by a sensor such as a charge-coupled device (CCD) camera. TEM 







consists of three parts: the electron gun and condenser system, imaging producing 
system and imaging recording system.  An electron gun produces a beam of electrons, 
and then the beam is focused onto the object via the condenser system. Subsequently 
the beam is passed through the objective lens, intermediate and projector lenses, which 
focus the electrons onto the fluorescent screen to form a magnified image. Eventually, 
the image-recording system converts the electron image into an image visible to human 
eyes and additionally pictures can be captured and presented computationally. In 
addition, a vacuum system consists of a pump, gauges and valves are equipped to keep 
the whole system under vacuumed and with temperature control. Due to the extremely 
small wavelength of electrons, TEM (nm ~ µm) can produce a much more detailed 
image of an ultra-small objective than a light microscope (µm ~ mm) does. The range 
of image scale used in this project is usually in between 1 nm and 1 µm, which makes 
TEM a perfect tool to analyse the structure of the SWNTs functionalised hereby. In 
TEM, the shape and quality of SWNTs will be visualised, the average diameter and 
length of the carbon nanotube will be calculated and the impurities remaining on the 
tube will be revealed. The existence of impurities particularly in the heavier elements 
present, also can be confirmed via energy-dispersive X-ray spectroscopy (EDS) which 




Figure 1. 14. Scanning electron microscopy adopted to characterise SWNTs 








SEM (Figure 1.14) also uses a beam of electrons to produce images, however 
in a significantly different way compared to TEM. In a typical SEM, a beam of electrons 
is generated from an electron gun, and then this electron beam carries energy (0.2 keV 
to 40 keV), which is focused onto an area about 0.4 to 5 nm in diameter. Subsequently, 
this electron beam will be deflected in the x and y axes through a deflection coil, in 
order to scan a rectangular area onto the sample surface. The electron beam loses energy 
during the scanning process due to repeated random scattering and absorption occurs 
in the interaction volume (Figure 1.15).  
The interaction volume is a pear-shaped area created on the sample surface via 
the impact of the primary electron beam, the energy exchange between the electron 
beam and the sample results in the reflection of high-energy electrons. The secondary 
electrons are reflected from a 10 to 100 nm depth in the sample, which can then be used 
to determine the shape of the sample. Backscattered electrons come from 1 – 2 µm and 
provide information about the atomic number of the elements found in the sample. 
Characteristic X–rays from very deep areas of sample (2 – 5 µm) can be detected by 
EDS to identify element information. All signals from the sample will be collected by 
specific detectors and amplified via electronic amplifier to create images. Similar to 
TEM, SEM technology is used to characterise SWNTs by measuring the diameter and 
length of the tube, examining the shape and quality of the tube and also scanning 
impurities via EDS analysis. 
 














Figure 1. 16. (a) Energy-dispersive X-ray spectroscopy adopted to characterise SWNTs 
(b) Representation of the basic principle of EDS  
 
Energy-dispersive X-ray spectroscopy is a common materials analysis 
technique, which coupled with TEM and SEM, is an extremely powerful tool used to 
study the elemental composition or chemical characterisation of SWNTs samples. The 







basic principle of EDS is each element has a unique atomic structure leading to a unique 
X-ray emission spectrum after excitation (Figure 1.16 a). A standard EDS consists of 
two parts, electron gun and X-ray detector. The former generates a high energy electron 
beam, which has been focused on the sample in order to excite an electron in the inner 
shells; the excited electron is then ejected from the electron orbital and as a result it 
leaves an empty space in the inner shell. Subsequently, an electron from an outer orbital 
will be shifted into inner shell to fill the empty space. Energy will be lost when the 
electron shifts from the outer shell to the inner shell and converted into a characteristic 
X-ray. The emitted X-ray can be collected and measured by an X-ray detector. In this 
project EDS is used to examine the purity of SWNTs, especially the metal catalyst 




Figure 1. 17. Atomic force microscopy adopted to characterise SWNTs 
 
Atomic force microscopy (Figure 1.17) is a very sensitive and high-resolution 
type of scanning probe microscopy but more suitable for small samples of SWNTs, 
contains well dispersed strands. The information is collected via monitoring the force 
change between sample surface and probe tip. The AFM consists of three parts: a tip 







and cantilever system, laser generator and photodiode system and detector and feedback 
control system. A silicon nitride tip is attached on a silicon nitride cantilever; the tip 
interacts with the sample surface at the atomic level and scans in a raster fashion over 
a rectangular area of the sample surface. A laser beam is pulsed on the back of the 
cantilever and reflected on a photodiode, in order to monitor the force difference and 
vibrations of the tip. The detector collects data to generate images and the feedback 
system sends feedback to the cantilever or platform, which moves the cantilever up and 
down across the surface or moves the platform up and down to avoid damage of tips or 
sample surface and keeps the force of the cantilever constant. AFM is commonly used 
to characterise nanoscale structures, including SWNTs, to study the surface condition, 




Figure 1. 18. Raman microscopy applied to characterise SWNTs 
 
Raman spectroscopy (Figure 1.18) is another spectroscopic technique which is 
widely accesible to study the structure of SWNTs in bulk, including the purity and 







integrity of SWNTs batches. During the process, a monochromatic laser beam is pulsed 
on the sample, which absorbs and reemits the photons, whereby the photon scattering 
can be either elastic or inelastic. In fact, most of the photons will be reemitted in an 
elastic manual, which means the frequency of the photon remains the same. Those 
photons reemitted in a different frequency are known as inelastic scattering, which will 
be collected by spectrometers and used for Raman spectroscopy. Frequency of inelastic 
scattered photons can be shifted either lower or higher, which are known as “Stokes 
shift” and “anti-Stokes shift” respectively, both types of Raman shift reveal the 




Figure 1. 19. A typical Raman spectrum of SWNTs161 
 
In a typical Raman spectrum of SWNTs, there are three characteristic peaks, 
namely, radial breathing mode (RBM), G band and D band. RBM determines the 
diameter of the tube, D band counts the defect site, the height of the D band depends 
on the degree of defects on the SWNTs. G band stands for the integrity of the tubular 
structure, similar to D band, the more intact the structure is, the higher the peak is. 







However, the height of the peak can sometimes be relative due to the size of the SWNTs; 




Figure 1. 20. UV-VIS spectroscopy method to characterise SWNTs in dispersed phase 
 
Ultraviolet–visible spectroscopy (UV-Vis) (Figure 1.20) is a spectroscopic 
technique used to quantitatively measure the absorption of light in between ultraviolet 
and near-infrared spectral regions. Light energy is absorbed by molecules containing π-
electrons or non-bonding electrons in order to excite these electrons to a higher energy 
state. In general, electrons with a lower energy gap will be easier to excite and can 
absorb light of a longer wavelength. The instrument of UV-Vis spectroscopy consists 
of five parts, namely: (a) light source, (b) monochromator, (c) sample chamber, (d) 
detector and (e) signal reader and readout. There are two different light sources in the 
machine, firstly a deuterium lamp produces the UV light via the following method (3): 
 
                    D2+ electrical energy → D2
* → D'+ D''+ hv (3) 
 
 







UV light is generated in the range of 160 – 375 nm. Secondly, the tungsten lamp 
provides light in the visible range from 350 to 2500 nm. Two beams of light will be 
merged and refracted by a mirror, then the reflected light passes through filter and lands 
onto the monochromator, only the light with the desired wavelength will be selected to 
pass to the beam splitter. Subsequently, the light beam is split into two equal intensity 
beams, one passes through a transparent cuvette containing the sample solution, the 
other beam passes through the identical cuvette containing only the solvent for a 
reference reading. Afterwards, both beams are directed into data processor via a 
photodiode, where the information is analysed and readout. The Beer-Lambert law is 
the common method used to quantitatively determine the concentration of sample in 




( I0 I⁄ ) = ε c L 
 
(4) 
Where A = absorbance (A. U.), I0 = original wavelength of the light, I = transmitted 
wavelength of the light. L = length of the cuvette, c = concentration of the sample and 
ε = extinction coefficient, ε measures the molecular absorption properties of sample in 
a given solvent at a certain temperature and pressure. In SWNT dispersion 
characterisation, there are a characteristic peaks, which appear between 200 to 250 nm 
and depending on the quality of the SWNTs in the dispersing agent used.162 







1.3. Introduction to fluorescence imaging and design of boronic acid- 
based fluorescence probes                          
1.3.1. Basics of fluorescence spectroscopies 
The majority of light emission can be categorised into two classes due to their sources, 
one is known as incandescence, which is generated by thermal radiation, i.e. heat. The 
other one is called luminescence emission, during which there is no heat generated.  In 
luminescence, sources of light can be further divided into three kinds, namely, 
biological luminescence, chemical luminescence and physical luminescence, in which 
light is emitted by an organism, a chemical reaction and physical process, respectively. 
In physical luminescence, there are seven subtypes of luminescence due to different 
physical activities, for example, photon, mechanical, phonon, crystallisation, heat, 
electro and radioactive. Fluorescence belongs to one type of the photoluminescence and 
is different from phosphorescence (Figure 1.21).163    
The primary observation of fluorescence could be traced back to the 17th and 
18th centuries, but it was the British scientist Sir George G. Stokes who described this 
phenomena in a paper entitled “On the change of Refrangibility of Light” in 1852.164 
this paper describes for the first time, a beam of spectrum from a prism was passed 
through a test tube contained quinine solution, and then observed that when crossed 
into the ultraviolet region, the colour of the solution turned from colourless into blue, 
whereas no emissions observed in visible region. Stoke subsequently concluded that 
the wavelength of the transmitted light was longer than that of the incident light, 
wherefore it could be observed.165 Stoke named this phenomenon as fluorescence in his 
second paper.166   
There was a remarkable growth in the application of fluorescence spectroscopy 
in the past 20 years in many different fields of life science, such as biotechnology, flow 
cytometry, medical diagnostics, DNA sequencing and genetic analysis. The first 
fluorescence microscopes were developed between 1911 and 1913 by German 
physicists Otto Heimstädt and Heinrich Lehmann as a by-product from the ultraviolet 
instrument.167  
 









Figure 1. 21. List of different types of luminescence 
 
In the beginning, these microscopes were used to observe bacteria, animal and 
plant tissues which were auto-fluorescent. Stanislav Von Provazek (1914) applied 
fluorescence microscopy to study tissues and living cells labelled with fluorescent dye. 
Finally, in the early 1940s, Albert Coons developed a technique for labelling antibodies 
with fluorescent dyes, which give rise to the field known as immunofluorescence 
nowadays.168 In twenty-first century, fluorescence microscopy is widely used in 
biological and pharmaceutical areas, due to the high specificity selectivity and 
sensitivity of fluorescent sensors to their target. The labelled molecules can provide 
information on many different types of processes on the molecular or nanoscale level. 
For example, interactions between solvent and fluorescent molecules, distribution of 
fluorescent biomolecules, distance between different sites of fluorescent molecules, 
conformational changes of a fluorescent molecule and binding of fluorescent molecules. 
In addition, most fluorescent probes are cheap and non-radioactive; and hence minimise 







the cost of the experiment and damage to the living organism. Therefore, fluorescence 
is often applied to cellular imaging and single molecule detection. Furthermore, 
fluorescent sensors can be easily conjugated to other functional groups, such as amides, 
carboxyl groups and boronic acids, to induce more specificity and selectivity and make 
the whole device or sensor multifunctional. 
 
1.3.2. Jablonski energy diagram 
Fluorescence is a physical chemical process and one form of photoluminescence; which 
occurs as molecules emit light from their electronically excited states formed by 
absorption of light. Figure 1.22 represents Jablonski diagram, a well-known diagram to 
describe the energy state change of fluorescent molecules between light absorption and 
emission during fluorescence.169 When a high energy beam, such as UV light or laser 
beam hit a fluorescent molecule, an interaction occurs between the photon and 
oscillating electric field of electrons in the molecule. During the process, energy is 
transferred from the photon to the fluorophore, known as absorption. Absorption only 
occurs when there is enough energy transferred. In the most cases, a collision occurs 
between molecules and photons generate more energy than required to promote an 
electronic transition, the excess energy will be converted into vibrational energy. 
Therefore, following on light absorption by a fluorophore, it is subsequently excited to 
a higher vibrational state as it is shown in the Figure 1.22.170 
From the Jablonski diagram, it can be clearly revealed that the fluorescence 
process consists of three essential parts, each stage occurs at an extremely short 
timescale, in the range of microsecond (10-6 second) and femtosecond (10-15 second). 
Excitation of a fluorescent molecule from the ground state (S0) to the excited singlet 
state (S1) takes place immediately (10
-15 sec) via an incoming photon. Excited 
molecules are subsequently relaxed to the lowest energy level at excited singlet states 
via internal conversion in between 10-10 and 10-14 seconds. Finally, a longer wavelength 
of light is emitted and returns the fluorescent molecule to the ground state, this process 
occurs in the relatively long time period of nanoseconds (10-9 s). Although the entire 
process of fluorescence lifetime is extraordinary short, it clearly inspects the interaction 







between light and matter, in order to collect the information for the development of 
steady state and time-resolved fluorescence spectroscopy and microscopy, which have 
extremely sensitive emission profiles, spatial resolution, and high specificity of 
fluorescence investigations, the technique is rapidly becoming an important tool in 




Figure 1. 22. Jablonski energy diagram 
 
The energy absorbed from a photon strongly influences the excitation of 
fluorophores from ground state to excited state, and also directly affect the emission of 
light in fluorescence or phosphorescence. This amount of energy is measured in 
quantum terms, which is expressed by the equation (5):  
 












This equation (8) known as Planck's Law, represents the relationship between energy 
(E) and frequency (v), h is Planck’s constant, c is the speed of light and λ is the 
wavelength of the incoming photon. According to Planck's Law, the energy absorbed 
from a photon is either directly proportional to the frequency or inversely proportional 
to the wavelength of incoming photon, in another words, light at shorter wavelength 
contain more energy, which can excite more fluorescent molecules to an  state and 
eventually more light can be emitted from those molecules.172  
Immediately after excitation of a fluorophore (6), most molecules relax, for 
example, from S2=3 or S1=4 to S1=0, i.e. the lowest vibrational energy level of the first 
excited singlet state without emission of light, and a subsequent return to the ground 
state. This process is known as internal conversion or vibrational relaxation, where 
energy loss in the absence of light emission, the amount of lost energy is converted into 
heat, which is then absorbed by surrounding solvent molecules. This process can be 
expressed in the following equation (7):  
 
Excitation: S0 + hvex →S1   
 
(6) 
                                    Emission: S1 → S0 + hvem + heat                                                
 
(7) 
Phosphorescence differs from fluorescence in that excited molecules can also undergo 
a spin conversion to a triplet state T1, in which the electron in the excited orbital has the 
same spin orientation as the ground-state electron. Transitions to the ground state are 
forbidden, in another words, moving from T1 to S0 state is kinetically unfavourable. 
Although it still takes place in the long term, the emission rates are significantly slower 
than fluorescence (10-3 – 103 second). The progress of phosphorescence is expressed 
below (8): 
 
S0 + hv →S1 →T1 →S0+hv' 
 
(8) 







Conversion from S1 to T1 is called intersystem conversion (IC). Emission from T1 to S0 
is known as phosphorescence. As a result of a slow emission rate, phosphorescence 
typically have longer excitation lifetimes and generally shift to longer wavelengths, i.e. 
lower energy, compared to fluorescence.173 
 
1.3.3. Important parameters in fluorescence: extinction coefficient, quantum 
yield and fluorescence lifetime  
Extinction coefficient (), quantum yield (), and fluorescence lifetime () are three 
fundamental parameters commonly used in the measurement of fluorescence to identify 
different fluorophores. The extinction coefficient represents the ability of a fluorescent 
molecule to absorb light at a certain wavelength in a given solvent, whereas the 
quantum yield indicates the efficiency of excited fluorescent molecule to produce an 
emitted photon. Fluorescence lifetime describes the average time a fluorescent 
molecule spends in the excited state before returning to the ground state. 
The extinction coefficient is emerges from measurements, it is carried out on a UV-
vis spectrophotometer, via the Beer-Lambert law, which is expressed as (9): 
 
A = ε c l → ε = A /c l 
 
(9) 
Where A stands for absorbance, which is the result collected from the UV-vis spectrum. 
c refers to the concentration of the fluorescent molecules in a certain solvent and l 
represents the path length of the light, normally it is the diameter of the quartz cuvette. 
As it can be seen in the equation, the extinction coefficient is determined by measuring 
the absorbance of light at a certain wavelength for a given concentration of the chemical 
in a cuvette with a one-centimetre path length. The chosen wavelength is normally the 
wavelength that causes the maximum absorption in the ultraviolet to the visible light 
spectrum. Hence, the extinction coefficient is the parameter that can directly measure 
the strength of a fluorophore to absorb light.174  
 The relative quantum yield is the parameter calculated from a UV-vis and 
fluorescence spectrum. The quantum yield equation (10) is expressed as follow: 








the number of photons emitted
the number of photons absorbed



















 stands for the quantum yield of a fluorophore molecule, D is the area of the emission 
spectrum, A refers to the absorption reading from a UV-vis spectrophotometer, I 
represents the intensity of the fluorescent spectrum and n determines the average 
refractive index value of the solvent. Quantum yields normally range between zero and 
one, the higher the quantum yield, the greater the likelihood that excitation will result 
in emission. In fact, most imaging applications favour a fluorophore with a high 
quantum yield, however, the quantum yield of a fluorophore is usually sensitive to the 
environmental factors, such as pH, concentration, temperature and solvent polarity.175 
Fluorescence lifetimes are the parameter measured via fluorescence-lifetime 











Where It stands for fluorescence intensity measured at time t, I0 is the initial intensity 
observed immediately after excitation, and  is the fluorescence lifetime. In general, the 
fluorescence lifetimes are near 10 ns. However, lifetimes of fluorescence vary between 
10-6 and 10-9 second. Several conditions may lead to a difference in lifetime, of which 
solvent can have a dominant effect. For example, the fluorescence of a single 
fluorophore will behave completely differently in a uniform or in a mixed solvent.  
As can be seen in Figure 1.23 (a) and (b), uniform solvents will have a mono-
exponential trend. However, in a mixed solvent, such as in a tissue fluid or inside living 
cells, there is a multi-exponential curve (Figure 1.23 (c)) detected.  In addition, several 
other processes can compete with fluorescence emission for return of excited state 
electrons to the ground state, including internal conversion, phosphorescence 
(intersystem crossing), quenching and photobleaching, by which lifetime of the 
fluorescent molecules can also be changed.176 
 









Figure 1. 23. Fluorescent lifetime decay profiles 
 
Quenching is another route that leads excited electrons returning back to the 
ground state via a non-radioactive relaxation, i.e. without the photon emission pathway. 
Molecules which can act as fluorescent quenchers usually compete with fluorophores 
in the interaction of light with a higher affinity. As a result, fluorescent quenchers can 
easily absorb energy from light or the fluorescent molecule, and cause significant 
reduction or elimination of fluorescence emission. In turn this leads to a reduction in 
the excited state lifetime and intensity of fluorophores in this work, due to extended 
conjugated network and -electrons, SWNTs are considered the quencher system. 
(Figure 1.24)177 
Fluorescent quenchers typically studied are usually non-fluorescent molecules, 
such as oxygen, halogens, amines, and many electron-deficient organic molecules such 
as acrylamide, etc. These collide with fluorophores in excited states. Energy is lost as a 
result of electron transfer, spin-orbit coupling and intersystem crossing to the excited 
triplet state finally to return to the fluorophores’ ground state.178  
 









Figure 1. 24. Fluorescence quencher via Collison quenching  
 
In addition to quenching via collision, there are two other types of quenching 
methods (Figure 1.25). One is known as static quenching, whilst the other is called 
dipolar resonance energy transfer (dynamic quenching). The former type of quenching 
occurs when the fluorophores form a non-fluorescent and reversible complex with the 
quencher molecule in the ground state. This mechanism does not rely on diffusion or 
molecular collisions. Therefore, the whole process aims to limit the absorption by 
reducing the population of active and excitable molecules without altering the 
fluorescence lifetime of the molecule.178 In the excited state, fluorophores can also be 
quenched by a dipolar resonance energy transfer mechanism. The direct contact is not 
generally required to transfer energy, but, depending on the requirements of the sensing 
device, the distance between fluorescent molecule and fluorescent quencher need to be 
shortened to a certain range in order to transfer the excited state energy from the 
fluorescent molecule to the quencher non- radiative manner. As a result, fluorophores 
can lose energy and return to the ground state.179    
 









Figure 1. 25. Fluorescent molecules quenched by different types of quenching 
 
Photobleaching is a phenomenon when a fluorophore permanently loses the 
function to be fluorescent due to prolonged excitation. This in turn leads to irreversible 
chemical damage and structural modifications. Photobleaching is normally due to an 
intersystem crossing from excited singlet state to the excited triplet state. The triplet 
state is longer-lived compared to the excited singlet state, therefore a triplet excited 
fluorophore has a much longer period of time available to undergo chemical reactions 
with other molecules whilst in the excited state. This can lead to irreversible damage to 
the fluorophore, which can accumulate and eventually cause irreversible 
photobleaching.180, 181 each fluorophore has different average numbers of excitation and 
emission cycles, which is determined by its molecular structure and the environment, 
e.g. the solvent system used.  
In fluorescence sensing research, only those fluorophores that are robust and 
can undergo millions of cycles before bleaching are sought. In addition, there is another 
type of photobleaching mechanism, which is known as photodynamic. This particular 
photobleaching process includes all fluorophores and is whereby the fluorophore can 
react with both light and oxygen to produce singlet oxygen species (also known as 
reactive oxygen species, ROS). As mentioned previously, ROS are very reactive and 







can chemically modify other molecules in living cells. As a result of photodynamic 
photobleaching, the structure of the fluorophores is destroyed. Cell death occurs due to 
apoptosis and necrosis, and in the most severe cases, some cells undergo 
transformations and become tumourgenic, due to DNA damage induced by ROS. Since 
more and more fluorescent sensors are employed into biological and medicinal research, 
photobleaching, especially photodynamic photobleaching has become a matter of 
concern. Hence, there are currently three methods in use to minimise the photodynamic 
effect. The first and simplest way is to reduce the time period of exposure to the light 
source or to lower the excitation energy. However, this method reduces the fluorescent 
signal as well. Alternatively, deoxygenated solutions of fluorophores or cell 
suspensions are induced, but this method is not feasible for use with living cells and 
tissues.182 Finally, an approach is induced that limits the exposure of the fluorophores 
to intense light source by using neutral density filters. These are coupled with anti-
photobleach reagents which can be added to the solution and cell culture media.183  
 
1.3.4. Current design for fluorescence based sensor  
There are two main systems under current investigation as mono-fluorophore 
fluorescent sensor. One type is based on the theory of Photo-induced Electron Transfer 
(PET), the other one is based on a method known as Intramolecular Charge Transfer 
(ICT).184  
Photo-induced electron transfer is the most commonly used principle in the 
design of fluorescent molecular sensors due to the “off-on” system to control the 
activation of fluorescence of the sensor.185 A typical photoinduced electron transfer 
sensor consists of three parts: (a) fluorophore, (b) spacer and (c) receptors. The 
fluorophore part can absorb light and excite electrons to give a fluorescence emission. 
The receptor is the core part for the molecule recognition and activation of fluorescence. 
The spacer is an organic or inorganic functionality which connects the fluorophore with 
a receptor to form a stable and functional system. The spacer normally contains a lone 
pair of electrons which can be filled either into the empty electrical orbital of the excited 
fluorophore or the receptor. In case of filling into the fluorophore, the excited electron 
from the fluorophore is unable to return to the original orbital and prolonged excitation 







of the electron leads to the quenching of fluorescence emission. This state is known as 














Photo-induced electron transfer 
Photo-induced electron transfer 
 
 
Figure 1. 26. Schematic representation of a PET fluorescent sensor: (a) Photo-induced 
electron transfer sensor without the target molecule; (b) Photo-induced electron transfer 
sensor incorporating the target molecule.  
 
Once receptors are attached to target molecules, the binding constant of 
receptors will be changed; hence, the lone pair of electrons from the spacer will be 
donated preferentially to the receptor instead of to the fluorophore. As a result, the 







excited electron of the fluorophore returns to the ground state to complete a 
fluorescence cycle and a fluorescent signal will be again detected. This is called “on” 
















Figure 1. 27. Schematic representation of an ICT fluorescent sensor, (a.) Without a target 
molecule (b.) With target molecules binding  
 
Intra-molecular Charge Transfer (ICT) systems are also widely used in this research 
area due to its simplicity. ICT type fluorescent sensor consists of two parts, i.e. a 
fluorophore and a receptor; there is no spacer in between. As a result, charge transfer 
from fluorophore to receptor plays an important role in the molecule recognition and 
fluorescence emission. In the resting state, (Figure 1.27 a) ICT-based systems normally 
emit no fluorescent signals. Once receptors bind onto the target molecules, the binding 







complexes will affect the electron density in the fluorophore, leading to a change in the 




Figure 1. 28. Schematic representation of a fluorescent excimer sensor 
 
Figure 1.28 shows the schemes of excimer fluorescent sensor. This is a multi-centre 
fluorophore sensor. This contains more than one fluorophore in its structure and when 
fluorescent sensors bind to target molecules; the conformation of the sensor will be 
altered. As such the distance between two fluorophores will be shortened and an 
intermolecular excimer will be formed. The excimer carries a broader and stronger 
wavelength emission than their individual monomers, as a result, the intensity of the 
fluorescence is increased. The distance between the fluorophores plays an important 
role in the formation of the excimer, if it is too large, the excimer will not be formed.189 
If the distance is too short, the fluorophores have been found to stack and quench each 
other’s fluorescence. Therefore, the distance between two fluorophores need to be 











1.3.5. Design of biocompatible fluorescent sensors  
A fluorophore is itself normally non-selective, non-specific and non-sensitive to meet 
a given biomedical purpose, and also as mentioned previously, many fluorophores can 
introduce ROS during the process of photodynamic photobleaching. Hence, a further 





Figure 1. 29. Schematic representation of a typical fluorescent sensor developed  
 
As it can be seen in figure 1.29, a typical fluorescent sensor designed recently in James 
and Pascu typically groups consists of three parts including: a fluorescence group, a 
spacer and a targeting group. The fluorescence group is the core part of the fluorescent 
sensor, which absorbs the light energy, excited to give a fluorescent signal, the 
wavelength of the light emission depends on the chosen fluorophore.192-194  
  








Types of fluorophore Emission wavelength (nm) 
POPOP 409 
Quinine 451 
Fluorescein  524 
Acridine orange 526 
Rhodamine B 615 
Pyridine 1 650 
 
Figure 1. 30. Different fluorophores at different emission wavelengths  
 
There are six commonly used commercial fluorophores that absorb and emit 
light that cross the whole visible spectrum range (Figure 1.30). These fluorophores can 
absorb light at individual excitation wavelength and emit at characteristic wavelength. 
For instance, in the case of fluorescein, an excited state is obtained by absorbing light 
at 488 nm. Subsequently, a fluorescent emission takes place at 524 nm in an aqueous 
environment.  In general, the majority of the fluorophores used in research are excited 
between 300 ~ 450 nm, which gives a refined fluorescent signal. However, this is not 
perfect for biomedical imaging applications, because the light source is high energy and 
will not only bleach fluorophores, but also cause damage to the tissue of a living 
organism. As mentioned above, high power lasers increase oxidative stress levels in 
living cells and tissues, leading to mutations in cells and resulting in cell apoptosis or 
tumours. Hence, near inferred fluorophores are preferred for the labelling of biological 







molecules. Whereas a low energy light source raises another problem, most fluorescent 
molecules will not be excited, as a result, the intensity peak of the spectrum will be 
significantly lower than those of the UV side fluorophores.  This also explains why a 
fluorescent sensor structure is developed, because anchoring a fluorophore to a spacer 
not only increases the distance between the fluorescent molecule and receptor molecule 
to avoid the interruption of the receptor molecule to the fluorophore, but also the signal 
of the fluorescence can be vary depend on the length of the spacer. The targeting group 
on the sensor is applied to recognise a molecule of interest, for example, in Figure 1.31, 
the molecule attached is a boronic acid group, which has a considerably high affinity 
for di-ols, Therefore, this type of molecular sensor will have sensitivity to detect and 
target monosaccharides, polysaccharides and glycoproteins in biological 
experiments.195 Binding to these target molecules has been shown to lead to an 
electrochemical change of the receptor molecule. This alteration of the electronic state 
is conducted via the spacer to the fluorescent molecule and initiates either enhancement 
or quenching of the fluorescence, which can in tern be monitored by fluorescence 
microscopy.  
In addition, there has been some recent work involving the use of an extra 
functional group, which was applied onto an earlier sensor design from the Pascu group. 
This is a biomarker and enables the fluorescent sensor to apply for the biological 
purpose, for example, to detect and label cancer cells. Biomarkers can vary dependent 
on the cancer type and typically have a very high affinity to bind to those cancer cells.196 
Unlike the common sensor based on photo-induced electron transfers, a sensor 
incorporate a biomarker is a dual targeting sensor. Therefore, the fluorescence cannot 
only be switched on and off, but also be enhanced or quenched once the sensor binds 
to the selected biological target.   
 
1.3.6. Applications of boronic acids as receptor molecules 
The receptor section of the fluorescent sensor takes responsibility for molecular 
recognition and activation, and a variety of receptors can be utilised dependent on the 
purpose and the guest molecule that it is interested in. As for the applications in a 







biocompatible fluorescent sensor, boronic acid-related receptors are becoming the 
focus of increased attention due to several distinct advantages: Firstly, boronic acids 
have a significantly high affinity to react with a hydroxyl group to form an ester in 
aqueous solutions. As can be seen in Figure 1.31, boronic acids covalently react with 1, 
2- diols (or 1, 3- diols) to form five (or six) membered cyclic esters in aqueous solution. 
Therefore, binding to hydroxyl-rich compounds, such as sugar, will considerably 
increase the solubility of the fluorescent sensor and also improve the biocompatibility 
at same time. On the other hand, this reaction is reversible, which means that the 
equilibrium can be affected by changing the pH of the reaction environment; as a result, 




Figure 1. 31. Equilibrium reactions between a boronic acid and dihydroxyl groups in a 
functional diol 
 
Regardless of the ability of boronic acids to improve the biocompatibility of a 
fluorescent sensor, there are two other properties of boronic acids, which have been 
shown to draw the interest of researchers. One is their solubility and the other is the 
“off-on” system introduced by boronic acids in a PET system. Boronic acids are Lewis 
acids and can be easily be dissolved in water and form two different conformations.  
 
 
Figure 1. 32. Behaviour or a boronic acid functionality in aqueous media 










Figure 1. 33. Different possible routes for the of boronic acid binding to diols 
 
As shown in Figure 1.32, the original geometry of the boronic acid is trigonal 
plane, but it can also form a tetrahedral form in water by receiving a hydroxyl group 
from a water molecule. Both two conformations coexist in the system and can react 
with diol groups to form cyclic ester ring structures, as shown in Figure 1.33. As a result, 
there is more than one binding constant in the system, i.e. K2, K3 and Keq. K2 stands for 
the binding constant of the triangular boronic acid to the trigonal ester. K3 refers to the 
binding constant of tetrahedral boronate to its ester form. However, both forms of the 
boronic acids coexist randomly in the solvent. Therefore, both K2 and K3 cannot 
represent the overall binding constant. As a result, the overall binding constant Keq is 
introduced, regardless of the conformation of the boronic acid groups in the solvent. 
All binding constants used in this project are Keq.




Figure 1. 34. Electron transfers of lone pair electrons in photoinduced electron transfer 
fluorescent sensor: Case A. PET sensor not bind to any target molecule. Case B. PET sensor 
bind to target molecule 








The “off-on” response is another characteristic feature of a boronic acid PET 
fluorescent sensor. The response is introduced by a boronic acid and controlled by the 
pH level of the solvent system. The basic principle for the “off-on” system is shown in 
Figure 1.34, at the “off” state (A), a lone pair is donated from the amide group to the 
fluorophore and so quenches the fluorescent signal.198 The optimum pH for boronic 
acid receptor binding to target molecules is 8.3, whereby the boronic acid receptor can 
easily bind to sugar molecules. The dissociation constant of boron centre then drops 
from 8.8 to 7 and as a result, lone pair from amide groups will more appreciated to be 
donated into boron ester group.199 Therefore the fluorescent signals are no longer be 
quenched (Figure 1.34). A boronic acid PET sensor with “off-on” system is sensitive 
to both target molecule binding and pH change.200, 201 At the “off” state there is no 
fluorescent cycle and therefore no photo-bleaching. Hence, such a system is believed 
to have a rather low toxicity to living organisms and thus, could be considered as an 
ideal tools for both in vivo and in vitro sensing and imaging experiments.202 
 
1.3.7. Characterisation of fluorescence sensors  
Confocal laser-scanning microscopy is an optical imaging technique, which involves a 
laser light excitation. An intense, narrow wavelength beam of light is generated from 
the laser generator and focused through the microscope lens to a single spot in the focal 
plane (see Fig. 1.35). The emission generated in the sample at the focal position is 
collected by a fast detector, usually a photomultiplier tube (PMT) and the laser beam is 
consecutively shifted by scan mirrors to a large number of raster positions. An image 
of the sample at a certain focal plane can be reconstructed from the time course of the 
recorded signal and the predefined path of the laser focus. Three-dimensional 
reconstructions can be formed by stacks of images from different focal planes. The 
main difference between conventional fluorescence microscopy and confocal 
microscopy is there is a confocal pinhole in front of the detector in the confocal 
microscopy.  This pinhole prevents light reflected from above or below the focal plane 
in the sample from reaching the detector. As a result, out-of-focus emission is 







eliminated, leading to an excellent spatial resolution and enables acquisition of refined 
optical sections from within thick biological samples.  
However, there are also some drawbacks of confocal microscopy when applied 
to live imaging. First of all, with the existence of the pinhole, the sensitivity of confocal 
microscopy is significant reduced due to majority of light is blocked by the pinhole. In 
order to improve the resolution of images, the strength of light intensity will be 
increased simultaneously. As a result, photo damage introduced to the tissue as well as 
the fluorescent dye was bleached. Therefore, the ratio between excitation intensity and 
signal photons may become unacceptable in deep tissue layers, particularly in strongly 
scattering specimens. Confocal microscopy is a useful methodology in this project for 
investigating the fluorescence distribution of the sensor and the morphology of cells. 
Laser










Confocal microscopy  
 
Figure 1. 35. Schematic presentation of confocal microscopy 
 
Fluorescence-lifetime imaging microscopy (FLIM) is an imaging technique 
which can produce an image based on the differences in the exponential decay rate of 
the fluorescence from a fluorescent sample. The lifetime decay of the fluorophore 
signal, (rather than its intensity), is used to create the image in FLIM. An average 







fluorescence lifetime of a fluorophore is calculated at an individually spatially 
resolvable element of a microscope image. The nanosecond excited-state lifetime is 
independent of the probe concentration or light path length but dependent upon excited-
state reactions. Hence, it minimises the effect of photon scattering in thick layers of the 
sample. 
 The FLIM consists of four parts, namely, pulse laser generator, scanner, 
detection PMT and Time-correlated single-photon counting (TCSPC) card. A beam of 
laser light is generated and pulsed onto a scanner, the scanner redirects the laser and 
scans the sample in a raster manner. Subsequently, the light is reflected and directed 
towards detection PMT via a dichroic mirror. The fluorescent signal is enhanced by the 
PMT and analysed by the computer, the data is recorded in a computer. In this project, 
FLIM is applied as a reliable method for determining the lifetime of a fluorescent sensor 
in a given environment, and also the lifetime change when a fluorescent sensor binds 




Figure 1. 36. Schematic representation of FLIM microscopy setup 
  







1.4.  Applications of SWNTs and  their decoration with fluorescent 
taps in cancer research 
1.4.1. Introduction to cancer 
Cancer is a group of various diseases involving unregulated cellular growth. In general, 
cancer cells can divide and grow rapidly and unlimitedly to form malignant tumours, 
and as a result, cancerous cells invade nearby tissues and parts of the body. Cancer is 
normally caused by genetic combined with environmental factors. In fact, only 5 – 10% 
of cancer is due to genetic defects alone. Most cancers are caused by environmental 
factors, such as smoking, obesity, life-style, certain infections, exposure to ionizing 
radiation and pollutants, all of which can alter the gene expression of healthy body cells, 
to form cancerous cells. In the early stage, the majority of the cancer cells possess 
similar characteristics to the other cells in the body, which makes early diagnosis of 




Figure 1. 37.  Stages of cancer progression 
 
As seen in the Figure 1.37, tumour genesis is initiated with a cell mutation to form an 
oncogenic cell, which can replicate itself to increase the number and size of the 
oncogenic cell, this progress is known as hyperplasia. As the mutation of the oncogenic 
cell further accumulates, dysplasia subsequently occurs, which converts the oncogenic 
cell into a primary tumour cell. A group of primary tumour cells will form a carcinoma 
in stiu (CIS). In the clinic, CIS is categorised as stage 0, all cancer cells are located in 
the place and replicate themselves, stage 0 and stage 1 cancer do not have abilities to 







invade nearby tissues. This stage of cancer is often highly curable, usually by removing 
the entire tumour mass with surgery. However, as mentioned above, these cells also are 
the most difficult stages to detect. As the cancerous cells keep growing, tumour mass 
becomes enlarged in size and grown more deeply into nearby tissue and subsequently 
it can spread to neighbouring lymph nodes. However, the number of cancer cells at this 
stage are not large enough to spread to other parts of the body. When cancer develops 
further to stage 4, the cancer has invaded to other organs or parts of the body, which is 
known as metastatic cancer. Stage 4 cancer is the last stage, at which cancer cells breach 
the nearby tissue and enter the circulatory system, as a result, cancer cells are 
transferred to all parts of the body making it impossible to be cured at present.203, 204  
 
1.4.2. Applications of SWNTs in therapeutic drug delivery 
Nanomedicines, including those based on functionalised SWNTs in recent work, have 
been considered as excellent tools for cancer research due to their quasi-one-
dimensional nanostructure, unique optical, mechanical and electronic properties, 
ultrahigh surface area, remarkable cell membrane penetrability and facile 
functionalisation by different methods. Hence, they are highly biocompatible and have 
been used in biomedical detection and imaging and CNT based therapeutics, including 
drug delivery, thermal therapy and gene therapy.205 
Fully functionalised SWNTs are ideal vectors in many research applications, 
such as sensors, probes, actuators, composites, nano-electronics devices and drug 
delivery systems within biomedical applications.206 In recent research SWNTs have 
been applied as a sensor synthetic scaffold and drug carriers or nanocapsules for 
biomedical research. In terms of the molecular vectors aspect of SWNTs, their 
behaviour depends on the method of functionalisation. Functionalised SWNTs have the 
potential to carry small molecules, peptides, proteins, genes, and DNA across cell 
membranes often with little cytotoxicity.207  
 









Figure 1. 38. Schematic representation of the general functionalization of SWNTs with cis-
platin and EGF factors yielding a drug delivery system attached to a cancer cell 
 
Epidermal growth factor (EGF) and EGF receptors, for example, are normally 
very low on healthy cell surfaces, however, they are often over expressed on cancer 
cells, and hence, it is an ideal target site for cancer recognition. Table 1.6 listed a series 
of cancer receptors that may be overexpressed in cancerous tissues and their 
corresponding biomarker and anticancer drugs. Figure 1.38 shows a recent research 
report concerns how a SWNT-based device can be designed as a drug delivery system 
(DDS) towards cancer cell targeting. First of all, SWNTs can be functionalised via a 
covalent method, carboxylic groups can be subsequently introduced onto the open ends 
and sidewalls of carbon nanotubes. Then an epidermal growth factor (EGF) was added 
to SWNTs via formation of carboxyl-amide bonds: this functionalised SWNT including 
its biomarker complex is known as an immunosensor. This can help in targeting of the 
recognition molecules on the surface of cancer cells.  
Cis-platin, as well as the other anticancer drugs showed in the table 1.6 can be 
tagged onto SWNTs and delivered to the cancer cells. It is attached onto the defect site 
of carbon nanotubes via ester bonds. The whole drug delivery system (DDS) is 
modified in order to improve the water solubility as well as to selectively deliver to 
cancer cells. Once EGF on the functionalised SWNT binds to the EGF receptors, the 
whole DDS will be endocytosed into the cancer cell. Anticancer drugs have been found 
to be released inside cells and subsequently terminate cancer cells.208  
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 The research work into the cellular biocompatibility of SWNTs has started 
almost immediately, once the SWNTs were first functionalised, in study of their 
potential applying to the biomedical field. Lacerda et al. have shown that SWNT based 
drug delivery system (DDS) can easily cross the blood brain barriers (BBB) without 
any external transporter device.216 The SWNTs DDS commonly enter cells rapidly in 
the first hour of internalisation and they distribute in the cytoplasm. There are generally 
two pathways for the cellular uptake of SWNTs: (a) directly insertion or passive 
diffusion through the cell membrane. And (b) indirect incorporation via endocytosis. 
The choice of the uptake route depends on the size of the SWNTs, in general, individual 
SWNTs can enter cell membrane directly, whereas bundles of SWNTs have been 
shown to enter cells by endocytosis.147 For in vivo experiments, apart from the 
conventional oral and injection administration routes, there are also anther two ways 
developed, namely transdermal and ophthalmic drug delivery. The former is designed 
based on the tiny needle shape of SWNTs and super drug load capacity. Im et al. 
assembled an electro-sensitive transdermal DDS, which combine carbon nanotubes 
with polyethylene oxide and pentaerythritol triacrylate polymer and use electrospinning 
method to control drug release.217 As for the SWNTs-based DDS, these have been 
targeting for ophthalmologic applications designed for several eye disease. Ophthalmic 
drugs commonly have a short residence time (<5 min) and only 1–5% of applied 
therapy may penetrate the cornea and applied to the intraocular tissues. However, the 
CNTs enhanced ocular DDS has significantly improved the bioavailability of few 
ophthalmic medications, which have the potential to overcome the limitation of 
traditional ophthalmic DDS. CNTs could also be used for ocular targeting of different 
therapeutic agents to the different ocular sites.94, 148  
 
1.4.3. Applications of SWNTs in cellular imaging 
The unique physical properties of SWNTs and their facile functionalisation, make these 
extremely popular in the biomedical imaging field. SWNTs can be applied in bio-
imaging areas in two different ways: (a) SWNTs can be directly used as a contrast 
reagent. (b) SWNTs materials are used as synthetic scaffolds to carry imaging probes 







to the site of interest. The former one is applicable to imaging techniques, including 
fluorescence imaging and Raman and photoacoustic (PA) imaging. Semi-conducting 
SWNTs have a very narrow band gap, which allows SWNTs to emit fluorescence in 
the near-infrared regions of the spectrum, between 700-1400 nm.218 Similarly, SWNTs 
contain a strong resonance Raman scattering with extremely large scattering cross-
section. This makes SWNTs promising Raman imaging probes in biological sensing 
and imaging techniques.218 Photoacoustic (PA) imaging is a recently developed 
imaging technique, where a non-ionizing laser pulses are delivered into biological 
tissues. Some of laser energy will be absorbed and converted into heat, resulting in 
ultrasonic emissions. This ultrasonic emission are collected by ultrasonic 
transducers and then analysed to produce images.219 The latter application of SWNTs 
in bio-imaging areas include magnetic resonance imaging (MRI),220 positron emission 
tomography221 (PET) and optical imaging. These techniques mainly depend on the 
contrast agents as probes attached onto the surface of SWNTs. 
Figure 1.39 (a) represents schematically a covalent method of assembling DDS 
probes, which is similar to the assembling method showed in Figure 1.38. As such, 
SWNTs are oxidised and carboxyl groups are introduced and, subsequently, both EGF 
and fluorophores are loaded at the defect site and at the end of SWNTs. Hence, the 
complex can selectively target cancer cells and is traceable in vitro. Instead of the 
covalently insert of functional groups, a non-covalent wrapping method is normally 
adopted to coat SWNTs with a water soluble polymer, such as polyethylene glycol 
(PEG) 222or β-D-glucan223 (Figure 1.39 b.). Compared with covalent functionalisation, 
which allows the use of only a limited number of defect site and ends, glucans have 
many binding sites available on their surface. Hence, the loading capacity of fluorescent 
sensors onto glucan-functionalised SWNTs is likely to be improved. In addition, 
SWNTs have a strong quenching effect to many fluorophores, hence, the direct 
attachment of fluorescent molecules will cause the loss of fluorescence emission. 
Furthermore, pristine SWNTs have been shown to be toxic to cells. Therefore, coating 
SWNTs with biocompatible polymers has been of interest for biological experiments 
in using these materials.224, 225  
 








Figure 1. 39.  Schematic representations of fluorescent sensor/ SWNTs complex used in 
cancer imaging (a) Covalent method; (b) Non-covalent wrapping methods with 
polysaccharides. 
 
1.4.4. Photothermal therapies mediated by the use of SWNTs  
Photothermal therapy is a physical-chemical therapy for cancer treatment, which uses 
optical radiation in the near-infrared wavelength range (700 - 2000 nm). When a laser 
is focussed on a tissue, photons are absorbed by inter and intra cellular areas and the 
energy of photons are converted into heat. As a result, the tissue temperature increases, 
leading to cell and tissue death. NIR light ranged between 700 and 1000 nm and tissue 
transparency is ideal for optical imaging and phototherapies. Both MWNTs and 
SWNTs can exhibit strong optical absorption in the near-Infrared (NIR) regions.226 
Once a SWNT is exposed to the NIR light, this generates heat by light absorption and 
induce thermal destruction of cancer cells containing significant concentrations of 
SWNTs (Figure 1.40).227  
 









Figure 1. 40. Application of SWNTs in photothermal therapy in cancer site 
 
Carbon nanotube-associated thermal therapy can be combined with time-
resolved infrared imaging techniques, and thus enable photothermal therapy to be more 
selective and traceable for targeting individual cancer cells or their small clusters 
labelled with carbon nanotubes. This approach can be utilised for the early stage of 
cancer treatment and it is very efficient for the treatment of small tumours, the edges of 
tumours and micro-metastases.228 In recent research, PEG-functionalised SWNTs as 
described above are normally injected into the tumour mass site.226 They are found as 
accumulated in the nearby muscle and skin tissues after the tumours are destroyed and 
then slowly translocate into the liver and spleen, from which nanotubes are gradually 
excreted. This research shows that carbon nanotube enhanced photothermal therapy can 
potentially become a non-invasive and harmless way of treating cancer.229  
 
1.4.5. Photodynamic therapy (PDT) using SWNTs 
Photodynamic therapy (PDT) is a developing technique currently used for malignant 
tumours and microbial parasites treatment. It is a very similar technique to PTT, and both 
techniques kill tumour cells from inside. The probes used and they are nontoxic in the 
absence of light, then become highly toxic under illumination (Figure 1.41). However, they 
are having fundamental differences from each other, in that cancer cells are killed by heat 
radiation in PTT, whereas in PDT cells are eliminated via a rising level of ROS generated 
in situation.   







 A typical PDT device consists of three components: a photosensitiser, a light source, 
and tissue oxygen. The photosensitiser is the core part of the system and, it can generate 
reactive oxygen species from tissue oxygen under illumination.  Porphyrins are considered 
as good photosensitisers due to their low cytotoxicity in the dark, high absorption 
coefficient in the red spectral region and high quantum yields for singlet oxygen 
production.230 Furthermore, in the recent work, quantum dots have been functionalised onto 
porphyrin framework. These were used as a resonant compound,231 able to harvest light 
and transfer energy to porphyrin in order to further enhance the ROS production. Finally, 
a DDS consisting of SWNTs, a porphyrin and quantum dots has been assembled and data 
has shown that DDS had a higher capability to generate ROS than the SWNTs alone. It also 




Figure 1. 41. Application of SWNTs in photothermal therapy in cancer site 
 
1.4.6. SWNTs-enhanced gene therapy  
Gene therapy is an alternative method to traditional chemotherapy in cancer treatment. 
The basic principle of gene therapy is replacing the damaged or missing genes with 
healthy genes.233 However, the major challenge for this technique is the gene delivery 
itself. In the past, researchers have used non-pathogenic viruses as vectors, which 
occasionally led to a significant immune response.234 Hence, an ideal vector design is 







important for this therapy. Many reports have shown that carboxyl-functionalised 
SWNTs can act as a vector for gene-encoding nucleic acids and plasmid DNA that 
enhance the gene therapeutic capacity in comparison with DNA alone.235 At the same 
time, some reports showed that siRNA can combine with SWNTs for efficient gene 
delivery. The siRNA (known as short interfering RNA), is only 20-25 nucleotides long 
and known to be complementary to the mutated gene. Into the cytoplasm, it can bind to 
the mutated gene and disable its action the cytoplasm. This process is called gene 
silencing.236, 237 From the presented works it is clear that direct injection of siRNA is 
not an effective approach, whereas the siRNA and SWNT complex can be easily taken 
up by cancer cells and then revealed by immune recognising cells to induce an immune 
response for the particular gene, in order to kill cells with damaged genes.237 
Furthermore, SWNTs can also be functionalised by single-stranded DNA and 
subsequently coated with DNA probes. Thus, DNA probes are protected from the 
enzymatic cleavage and interference from nucleic acid binding proteins in the 
circulation. After being taken up by cells, most comprising of SWNT modified with 
DNA could target a specific mRNA inside living cells, with increased self-delivery 
potential and intracellular bio-stability when compared with free DNA probes. Hence, 











1.5. Specific objectives of  this project  
The overall aim is to create a new biosensor devise based on functionalised single 
walled carbon nanotubes for applications toward cancer cell imaging and therapy.  
In the first instance, new types of biotin boronic acid-based fluorescent 
molecules having the ability to act as fluorescence sensors will be designed and 
synthesised. Afterward, the titration between different types of fluorescent sensors and 
𝛽-D-glucan will be carried out and compared with own sensors, in order to determine 
the binding constant in this boronic acid-glucan interacts prior to the incorporation into 
the SWNT. Then individual fluorescent sensors will be delivered to different cells to 
perform MTT assays to study the cytotoxicity effect and also obtain cell images through 
confocal microscopy techniques, including fluorescence lifetime.  
For the SWNTs scaffold material part, SWNTs (CVD-made) is available from 
Thomas Swan were purified by a steam purification method. Then resulting SWNTs 
will be functionalised by 𝛽-D-glucan through non-covalent methods. After 
characterisation by TEM, SEM and Raman spectroscopy, these glucan-wrapped 
SWNTs will be delivered to HeLa cells to investigate any effect on the cytotoxicity. On 
the other hand, purified SWNTs and opened will be used to encapsulate small ions, 
such as Zr4+, Na+ and Cu2+ as models for unconventional PET imaging agents (64Cu, 
89Zr) and their carriers (NaOAc). After wrapping with 𝛽-D-glucan, the composites will 
be characterised by TEM and Raman spectroscopy. Eventually, these two types of 
functionalised SWNTs will be incorporated with fluorescent sensors and rendered 
usable towards in cancer imaging in vivo.  
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Chapter 2. Synthesis and characterisation of 
fluorescent sensors 
2.1. Overview 
This project builds on some initial work carried out in the Pascu 1 and James group 2, 
Each group have previously used biotargeting molecules, in the Pascu group this was 
with the aim of cancer targeting, whereas in the James group a boronic acid was used 
to sense sugar molecules. The main purpose of this project was to find a way of 
combining both methods, to optimise the process and finally to develop a dual-function 
fluorescence sensor, which can both target cancer and interact with sugar molecules. 
Biocompatibility and sensitivity for the respective target were the next concerns. 
Fluorescein isothiocyanate (FITC) is the first fluorophore chosen for the synthesis, due 
to its relatively strong fluorescence and weak cytotoxicity. Biotin can target sodium-
dependent multi vitamin transporters (SMVT) which are generally overexpressed on 
cancer cells. Boronic acid was used to interact with a -D-glucan functionalised 
nanoparticle. Finally xylene di-amine was used as a spacer to separate the other three 
groups.3, 4. All groups assembled together could create a fluorescence device for cancer 
targeting and imaging in different cancer cell lines. 
There were four main steps involved in the synthesis of the biotin boronic acid 
fluorescent sensors for incorporation onto the surface of -D-glucan functionalised 
SWNTs. Initially, the synthesis involved the use of a commercially available biotin, 
xylene di-amine, 4-formyl boronic acid and fluorescein isothiocyanate (FITC) 
(Aldrich), and each step was followed by thin layer chromatography after completion. 
Furthermore, purification was achieved by column chromatography on a silica column 
using MeOH: DCM 2:98. The major product collected was characterised by 1H NMR 
spectroscopy and ESI mass spectrometry. After synthesis of the sensor was confirmed, 
the biocompatibility of the resulting compound was examined by MTT assays, the bio-
distribution of the fluorescent sensor was tested in confocal fluorescence microscopy 
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in several different cell lines, such as cervical cancer cells (HeLa)5 and epithelial 
fibroblast cells (FEK-4), breast cancer cells (MCF-7)6 and prostate cancer cells (PC-3)7. 
 
2.2. Optimisation of synthetic route. 
The protocol of synthesis has been modified several times during the period of project, 
it gradually changed from the initial scheme, which used 1, 6-hexanediamine as linker 
and synthesis in a fairly unpleasant solvent, like pyridine, to an alternative plan, by 
replacing the linker 1, 6-hexanediamine with p-Xylylenediamine. Then several 
different solvent systems were followed. Eventually, different reaction route were tried 
to optimise the efficiency of the reaction. 
 
Method A:  
As it can be seen in Scheme 2.1, N, N-Dicyclohexylcarbodiimide (DCC) was used to 
enhance the electrophilicity of carboxylate, the carboxyl group on biotin is deprotected 
and act as a nucleophile, attacking the central carbon in DCC. This allowed DCC to 
attach temporarily onto biotin and form a highly electrophilic intermediate (Biotin-NHS 
intermediate), which is unstable and attacked by NHS. Biotin-NHS and 
dicyclohexylurea were formed as products.8   
 
  Chapter 2. Synthesis and characterisation 









Scheme 2. 1. Schematic representation for the synthesis of Biotin-NHS and proposed 
mechanism 
 
From the 1H NMR spectroscopy results (recoded at 300 MHz, in d6-DMSO at 
room temperature) there are two peaks 4.0 and 4.2 ppm. These are characteristic 
resonances of the alkyl protons (NHCH) of the ureido moiety within the biotin ring. A 
characteristic peak was also found at 2.8 ppm which integrates 3.8 with respect to the 
ureido CH resonances calibrated to 1.0. This resonance was assigned to the protons 
from the NHS group. In addition, mass spectrometry displays a main peak at m/z 
342.2089, which corresponds to the mass proposed for compound 1 plus one proton, 
[C14H20N3O5S]
+. Therefore, the spectroscopic data confirm the formation of compound 
1 as the desired biotin-NHS. 
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Scheme 2. 2. Schematic representation for the synthesis of biotin- hexanediamine and 
proposed mechanism 
 
Scheme 2.2 shows the synthetic pathway of compound 2; the reaction was 
initiated with compound 1 from step 1 on reaction with 1, 6-hexanediamine. Due to the 
instability of intermediate (Biotin-diamine intermediate) formed and the NHS group 
was a good leaving group, therefore, NHS groups would be cleaved from the 
intermediate. As a result, biotin-hexanediamine was formed.9  
There are several problems that needed to be solved in order to improve the 
yield and the purity of the product emerging from this step in further experiments. First 
of all, a large excess of amine was added to prevent compound 1 from reacting with 
each end of the hexanediamine. Next, a pressure equalised dropping funnel was used to 
control of dropping rate of compound 1. Compound 1 needed to be added slowly to 
ensure that compound 1 only attacked at one end of the hexanediamine, but this slow 
addition rate appeared to limit the whole reaction rate. Finally, pyridine / water (50% / 
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50%) mixture was found to be the most suitable solvent to dissolve both compound 1 
and hexanediamine in this experiment. However, pyridine was a rather toxic chemical 
especially in the higher quantities required to dissolve the biotin NHS and control the 
pH of the reaction. Therefore, a DMF / TEA mixture was found to replace pyridine in 
further experiments, to reduce the toxicity risks. At the same time, in order to avoid 
biotin- NHS being attacked at both ends of the amine, a tert-butyloxycarbonyl (tBoc) 
protecting group was introduced to protect one end of the hexanediamine, prior to 
biotin-ester formation. The Boc protecting group could subsequently be easily removed 
by treatment with TFA: CH2Cl2 (1: 1). However, this method increased the number of 
steps and experimental costs overall but seemed to lead to a purer product that was more 
easily separated from the starting materials.  
As described in the experimental part, it was clear that both 1H NMR 
spectroscopy and MS spectra showed positive results. As such in 1H NMR the 
diagnostic peaks were at 1.83–1.34 ppm and mass spectrometry showed a peak at m/z 
= 341.2040.  
Scheme 2.3 represented the reaction between compound 2, pinacol and 1, 4-
formyl phenylboronic acid to produce compound 3. In Figure 2.3 a schematic 
mechanism showing how pinacol could react with boronic acids via a condensation 
process, resulted in the formation of a ring structure, in such that the boronic acid is 
protected by pinacol.  
Then Scheme 2.3 b, shows how the primary amine reacted with the aldehyde 
group on phenylboronic acid via a reductive amination.10 The amine first reacted with 
a proton to form a hemiaminal species, which reversibly lost one molecule of water 
via alkylimino-de-oxo-bisubstitution, to form an imine. The equilibrium between 
aldehyde and imine could be shifted toward imine formation by removal of the formed 
water through physical means, herein molecular sieves (3Å) were added to the mixture 
to absorb H2O and drive the thermodynamic equilibrium towards imine formation.  
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Scheme 2. 3. Schematic representation for the synthesis of biotin-hexanediamine-boronic 
acid and proposed mechanism 
 
The 1H NMR spectroscopy (300 MHz, d6-DMSO) and ESI
+ mass spectrometry 
results obtained were not as conclusive for compound 3, indicating that a possible 
mixture of products remains present. 1H NMR spectroscopy showed the occurrence of 
some large, sharp resonances at 1.10-1.80 ppm and several other weaker resonances (at 
2.0 - 3.0 pm range) inhibit the spectrum baseline. Consequently, NMR spectra 
suggested that compound 3 was impure with presence of remaining starting materials 
and solvent. As for mass spectra, there are several other un-assignable peaks which 
could be assignable to the starting materials. Hence, it was necessary to further purify 
the resulting product at least two or three times. In this project column chromatography 
on silica was used to separate product from impurities by using a mixture of MeOH: 
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DCM 2:98% as the mobile phase. The resulting white powder resulting from the 




Scheme 2. 4. Schematic representation of the synthesis of Fluorescein isothiocyanate linked 
biotin-boronic acid fluorescent sensor and proposed mechanism 
 
Scheme 2.4 shows the reaction between compound 3 and Fluorescein 
isothiocyanate (FITC). The isothiocyanate group of FITC was reacted with the NH 
group of compound 3 under mildly alkaline conditions to form a thiourea derivative, 
which was compound 4. 
In conclusion, synthesis of the FITC boronic acid fluorescent sensor was well 
established here and well defined conditions were put in place up to Step 3, according 
to size, lipophilicity and complex separation issues occurring in the synthesis of 
compound 4  
These made compound 4 difficult to characterise and, the formation of compound 4 
was confirmed by the mass spectrometry. However, due to the low yield, neither 1H 
NMR nor 13C NMR were sufficiently concentrated to characterise compound 4.11  
  Chapter 2. Synthesis and characterisation 







Compound 3 had been modified by replacing the 1, 6-hexanediamine group 
with p-Xylylenediamine to produce compound 7. This should make the structure more 
rigid and alter the solubility properties of the compound. Hence, it would be easier to 




Once the condition of the reaction and solvent system was confirmed, the rigid linker 
was introduced and the new compound was synthesised as described below and in 
experimental section. However, the difficulty to synthesise the fluorescent sensor varies 




Scheme 2. 5. Schematic representation for the synthesis of Fluorescein linked biotin-boronic 
acid fluorescent sensor with a p-Xylylenediamine linker (route 1). 
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Figure 2. 1. NMR spectrum of compound 5, (a) 1H NMR spectrum (b) 1H COSY spectrum and 
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Figure 2. 2. 1H NMR spectrum of compound 7 in deuterated methanol 
 
As can be seen in the Scheme 2.5, the initial route was the same as the route used 
to assemble compound 4. Both routes started with biotin-NHS and the desired linker, 
subsequently boronic acid and pinacol were introduced. The fluorescent group was 
introduced at the final stage, to produce the target compound 5. The formation of 
compound 5 is characterised in Figure 2.1 (a), the characterisation peaks appeared at 4.3 
and 4.1 ppm, which referred to two protons from biotin structures, as well as a typical 
peak at 1.39 ppm, which represents the boc protection group from the xylylenediamine 
group. The presence of the biotin apparent in Figure 2.1 (b) and (c), which indicated the 
correlation between N-H and  protons of biotin ring. 1H NMR spectrum of compound 
7 is represented in Figure 2.2, Characteristic resonances of the  protons of the biotin 
appeared at 4.30 and 4.10 remained in the same region of the spectrum for compound 5 
in Figure 2.1. However, the resonance of a boc group at 1.39 ppm was not observed, 
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which indicated that the boc protection group was successfully removed. There were 
more resonance peaks added in the aromatic region between 6.0 and 8.0 ppm, which 
integrates 16.8 with respect to the ureido CH resonances calibrated to 1.0. This 
resonance reveals the attachment of the boronic acid group and fluorophore group.  The 
peaks appeared at 4.70 ppm suggest the presence of the alkyl proton in the boronic acid. 
Finally, there was no resonance detected at 1.27 ppm, which indicated that the pinacol 
protection group was removed during the synthesis. 
Despite the simplicity of this method, one problem remained, which was that 
Biotin-NHS was difficult to dissolve in common solvents. Therefore, all reactions were 
carried out in DMF. As a result, the evaporation of DMF was time consuming and this 
made this route rather inefficient. More importantly, due to lack of solubility of the 
reaction compounds, a significant amount of the starting material remained as an 
impurity, and was difficult to remove this from the product. Hence, in order to improve 
the efficiency of the synthesis, a different route was attempted, as displayed in Scheme 
2.6. 
 
Scheme 2. 6. Synthesis of Fluorescein isothiocyanate linked biotin-boronic acid fluorescent 
sensor with a p-Xylylenediamine linker (route 2) 
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Route two started with a reaction between boc protected xylylenediamine and 
fluorescein isothiocyanate. Subsequently, biotin was introduced to form compound 9. 
Route two did not proceed further due to the strong electronegativity of the sulphur 
group, which drew the lone pair electron on the xylylenediamine toward itself, 
preventing a further reductive amination. The advantages of this approach is that 
xylylenediamine and fluorescein isothiocyanate are soluble in DMF, which improve the 
rate and efficiency of the reaction. However, due to the strong interaction of –NH–CS–, 
additional boronic acid could not be functionalised onto compound 9 via a reductive 
amination. Finally, compound 9 was used as a comparison to compound 7, in order to 
investigate the difference between a compound with a boronic acid group and the other 
without a boronic acid group in both chemical and biological experiments.  
 
 
Figure 2. 3. 1H NMR spectrum of compound 8 in d6-DMSO 
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Compound 8 formed in Scheme 2.6 was characterised by the result of 1H NMR 
spectrum showed in Figure 2.3. There were many peaks appeared in low field region 
between 6.5 and 8.5 ppm, indicated the aromatic protons from the boc protected 
xylylenediamine and FITC group, the characteristic resonances at 1.39 ppm revealed 
the presence of the boc protection group. Finally, the m/z result found at 624.1861 (ESI-
MS) in negative mode also in support of the formation of compound 8. 
 
 
Figure 2. 4. 1H NMR spectrum of compound 9 in deuterated methanol 
 
Figure 2.4 shows the 1H NMR spectrum of compound 9. Characteristic 
resonances of the  protons of the biotin ring at 4.30 and 4.10 remained in the same 
region of the spectrum as showed in Figure 2.1 for compound 5. However, the 
resonances of the boc group at 1.39 ppm were not observed.  In the low field region of 
the spectrum, a new peak was detected and confirmed at 10.70 ppm by using 2D COSY 
techniques (Appendix D.5). This was assigned to the carboxyl group of the FITC moiety. 
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Furthermore, there were more resonance present in the aromatic region between 6.0 and 
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Scheme 2. 7. Schematic representation of the synthesis of Fluorescein isothiocyanate linked 
biotin-boronic acid fluorescent sensor with a p-Xylylenediamine linker (route 3) 
 
 
Figure 2. 5. 1H NMR spectrum of compound 10 in deuterated methanol 
 
As can be seen in Scheme 2.7, Route three was established to replace Route two 
in order to synthesise compound 7. The reaction began with boronic acid reacting with 
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pinacol to form a pinacol-protected boronic acid (compound 10).12 Compound 10 was 
then reacted with boc protected xylylenediamine to form compound 11. Subsequently, 
a FITC group was introduced and generated compound 12. Finally, the t-boc group was 
removed by TFA and the biotin-NHS was added to the system to form compound 7. 
The 1H NMR spectrum in Figure 2.5 represents the characterisation of 
compound 10 synthesised in Scheme 2.7. It is apparent that there were two characteristic 
resonances detected at the low field region at 10.05 ppm and 7.95 to 7.85 ppm 
respectively, which integrates 3.63 with respect to the aldehyde proton calibrated to 1.0. 
This resonance was assigned to the protons from the aromatic group. Subsequently, 
pinacol protons were found at 1.35 ppm as a single peak, which integrates 11.9 with 
respect to the aldehyde proton resonances calibrated to 1.0. There remained some 
starting materials and the yield calculated from integration was 81.9%. 
This route was an efficient pathway to produce compound 7. The main 
advantage of this route was that the first two steps could be processed in common 
solvents, which made the reaction efficient, and the products were easier to collect and 
analyse. However, there were still some drawbacks, for instance, introduction of boronic 
acid significantly increased the difficulty of purification via column chromatography, 
affecting the final yield of the product. At the same time, an early import of FITC group 
would make the NMR assignment extremely challenging. Finally, early activation of 
FITC consumes the life of the fluorescence, if compound 12 was not protected properly, 
the quality of the final compound would be influenced remarkably. Therefore, the FITC 
group was considered to be added in the last step, this lead to the establishment of route 
four, which is given in Scheme 2. 8. 
Route four was the final method designed to assemble this boronic acid-based 
fluorescent sensor. This route was very similar to route three, apart from the fact that it 
involved the synthesis of the linker before introducing the fluorescent groups. Although 
it had the disadvantage in aspects of purification caused by earlier addition of the 
boronic acid group and the fact that only a small yield of compound 7 could be collected 
from column chromatography, the amount was enough for both chemical and biological 
experiments. Therefore, this route would be suitable for small laboratory scale synthesis 
of the boronic acid based fluorescent sensor for optical imaging experiments.  
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Scheme 2. 8. Synthesis of Fluorescein isothiocyanate linked biotin-boronic acid fluorescent 
sensor with a p-Xylylenediamine linker (route 4) 
 
2.3. Kinetic stability tests for fluorescent sensors 
All experiment involved in this section were with the purpose of testing the stability of 
the fluorescent sensors under aqueous environments. There were two conditions tested 
for: (1) time dependency, in which samples were examined at regular time intervals and 
(2) solvent dependency, in which samples were dissolved in different solvent and 
examined, by fluorescence spectroscopy.13, 14 Although both UV-Vis and fluorescence 
spectroscopy techniques can be used to study kinetic stability of fluorescent molecules, 
fluorescence spectroscopy can provide extra information in quenching and 
photobleaching, hence, fluorescence spectroscopy was chosen to examine the stability. 
  
  Chapter 2. Synthesis and characterisation 









Figure 2. 6. Fluorescent stability study of compound 7 in a period of time in methanol: water 
mixture (1:40) 
 
Figure 2.6 displayes the stability test results of compound 7 in a methanol: water 
mixture (1:40). The fluorescence of solution was measured every 30 minutes in 4.5 
hours. Although there was little fluctuation in the intensity, the variation of intensity 
was in the range of ± 10 A.U., in addition the peak of all measurement stayed constant 
at 525 nm. All signs indicated that compound 7 was a stable fluorescent sensor and its 
emission was not affected over the time period.  
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Figure 2. 7. Fluorescent stability study of compound 7 in different solvent system 
 
This part of the experiment was specifically designed for the fluorescent sensors 
that were used for biological applications. Samples would be used for applications in 
living cells cultured in serum media or serum-free media, therefore the variations in the 
fluorescence emission need to be recorded first under similar conditions but in the 
absence of cells. Figure 2.2 shows that, there was a significant growth in interaction 
from 270 A.U. to 420 A.U. and 630 A.U. in the fluorescence intensity for serum media 
and serum free media in samples recorded under same conditions. It indicated that the 
fluorescence of compound 7 was enhanced in the culture media and it was favoured in 
the biological applications. Simultaneously, there was a slight red shift from 525 nm to 
550 nm in the emission wavelength for both media, this phenomena indicated compound 
7 may bind to some biomolecules present in the media and altered its emission 
wavelength.15  
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Figure 2. 8. Fluorescence emission stability assay of compound 7@ glucan@ SWNTs in a 
period of time in water 
 
Figure 2.8 showed fluorescent stability of compound 7@ glucan@ SWNTs 
(synthesised as described in experimental section) over 4.5 hours. It was obvious that 
compound 7@ glucan@ SWNTs was not stable in water, the initial intensity was 250 
A.U., with it ending at 400 A.U. The increased rate was fast at the beginning, however 
the increase gradually reduced until it was insignificant towards the end. In addition, all 
peaks appeared at 525 nm, hence, no conformational changes occurred during the 
experiment. This might be due to SWNTs aggregating and precipitating out of the 
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2.4. Qualitative avidin binding tests for the fluorescence sensors  
In this project biotin had been chosen as  a general biomarker for all as made fluorescent 
sensors due to the strong binding affinity of biotin avidin. Therefore, an avidin binding 
test was necessary to investigate whether the binding between biotin and avidin would 




Figure 2. 9. Fluorescence spectra of compounds in methanol and water mixture (1:100) 
before and after addition of avidin (1:1) 
 
As described in Figure 2.9, compound 7 alone had a relatively intensive 
fluorescence peak at 425 A.U., once avidin was added, there was a significant drop in 
the fluorescence intensity to 110 A.U.. Thus activation of the biotin- avidin complex 
would remarkably quench the fluorescence intensity of compound 7. More interestingly, 
compound 9 which lacks a boronic acid group possessed a reduced intensity peak at 250 
A.U. and it behaved similarly to compound 7 in that once it was bound to avidin, there 
was a dramatic decrease in fluorescence emission intensity from 250 A.U. to 60 A.U.. 
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As a result, it could be summarised that a compound accompanied with a boronic acid 
would have a stronger fluorescence emission intensity and binding to avidin would 
quench the fluorescence regardless of boronic acid existence.  
 
2.5. Direct interaction between fluorescence sensor and purified 
SWNTs 
Most of the fluorescent sensors in this project were functionalised on to -D-glucan 
wrapped SWNTs. Experiments were designed to explore whether or not the fluorescent 




Figure 2. 10. Fluorescence emission measurement of compound 7, compound 7 @ SWNTs 
and compound 7 @glucan @SWNTs 
 
The resultant spectra (Figure 2.10) showed that a direct contact of SWNTs 
would immediately quench the compound 7 and it was also obtained that this quenching 


















 Compound 7 @ SWNTs
 Compound 7 @ glucan @SWNTs
  Chapter 2. Synthesis and characterisation 







dose not recover during time. This result demonstrated that covalent functionalisation 
of SWNTs would not be ideal. The quenching effect might be due to a strong surface 
energy of SWNTs, hence, this effect would be reduced via increasing the distance 
between compound 7 with pristine SWNT strands. -D-glucan wrapping was not only 
blocking the direct contact of compound 7 from SWNTs, but also increased the distance 
between compound 7 and SWNTs. Hence, it would significantly reduce the 
fluorescence quenching effects. Although there was still a remarkable drop in the 
fluorescence intensity from 840 A.U. to 240 A.U., there was a clear fluorescence 
emission detected at 525 nm, compared with compound 7 @ SWNTs.  
 
2.6. Fluorescence titration of designed sensors 
A fluorescence titration was performed to examine the binding constant of fluorescent 
sensors to -D-glucan. Theoretically, once the fluorescent sensor binds onto -D-
glucan, there would be a change in the fluorescence intensity via either quenching or 
enhancing of fluorescence. All peaks of the intensity at increasing concentration of -
D-glucan were collected and plotted in Figure 2.11 in order to work out the binding 
constant.  The titration began with testing the fluorescence of solvent, -D-glucan and 
-D-glucan @SWNTs, there was no significant fluorescence emission from the 
conditions mentioned above. 
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Figure 2. 11. Fluorescent titration of compound 7 and compound 13 and estimates of binding 
constant to -D-glucans. Note: an r2 of 0.74 denotes a low level of reliability for this fitting 
regarding compound 13: this could be due to the interaction between Bodipy moiety and the 
glucan, and generation of multiple binding equilibria in solution, 
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It was clearly showed in Figure 2.11 that the fluorescence emission of both compound 
7 and 13 were quenched by -D-glucan. The binding constant for compound 7 and 13 
were 6.5 ×104 M-1 and 5.6×105 M-1 respectively. A greater binding constant refers to a 
more stable binding, because compound 13 had two boron groups in its structure and 
this extra boron group might facilitate to make the binding between compound 13 and 
glucan more stable. Figure 2.6 also shows that compound 13 binds less reliably than 7 
suggesting that multi binding events may take place. The binding constant is determined 
by the following equation: 
I = 










Where y is I/I0, P1 stands for binding constant  KD
-1 , P2 refers to If/I0, x is the 
concentration of compound.  
 
2.7. Quantum yields of fluorescence sensors  
The quantum yield of compound 7 and compound 7@glucan @SWNTs has been 
calculated using the equation mentioned in the introduction,20, 21  
 
 = 
the number of photons emitted
the number of photons absorbed


















Fluorescein was chosen as a reference and 0.4 × 10-6 mol of compound 7 was dissolved 
in methanol, the data collected are given, in Table 2.1. The reference quantum yield of 
fluorescein (QR) is 0.91, hence, the results of compound 7 and compound 7 @glucan 
@SWNTs were calculated as 0.62 and 0.46 respectively, which indicated there was a 
decrease in the quantum yield after functionalisation of fluorescein onto the biotin-
xylylene-boronic acid linker and the quantum yield was reduced further after compound 
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7 functionalised onto the glucan wrapped SWNTs. These values are still promising for 
applications in cellular imaging assays. 
 
Table 2. 1. Quantum yield calculation of compound 7 and compound 7 @glucan@SWNTs 
 
 D A I n 
Fluorescein 76900 0.0622 854.22 1.33 




28509 0.0666 583.66 1.33 
 
2.8. Summary of chapter two 
Several synthetic pathways to make a dual function fluorescent sensor were established 
and tested. The route that assembled biotin-xylylene-boronic linker first and then 
attached with different fluorophores, was found to be the most efficient and flexible 
method. The products were purified with column chromatography and then 
characterised by mass spectrometry, NMR spectroscopy and HPLC. These studies were 
followed by UV-Vis spectroscopy (Appendix G) and fluorescence spectroscopy 
investigations, to calculate the quantum yield (QY). The results showed that there was 
a decrease in the QY compared with the reference fluorophore, which indicated a 
quenching effect was induced to the fluorophore after the attachment to the linker group 
and boronic acid. A further decrease in the QY occurred when the fluorescence sensor 
was bound to the glucan @SWNTs, which demonstrated that anchoring onto the glucan 
would also quench the fluorophore. A fluorescent titration confirms the results of QY, 
with the concentration of glucan increasing in the solvent there was a significant drop 
in the intensity of the fluorescence. The stability test of the fluorescent sensor 
represented that it was stable in the solvent systems tested, binding to SWNTs would 
make fluorescence of devices quenched. The fluorescence of the compounds tends to 
increase over time in a given solvent. The fluorescence of fluorescent sensor was 
  Chapter 2. Synthesis and characterisation 







enhanced in the biological solvent, such as serum free medium and serum medium 
without precipitation occurring. This indicated the fluorescent sensor is usable in the 
cellular experiment. The avidin binding test confirmed that biotin is a good biomarker 
and binding to the target receptor will result in quenching of the fluorescence.  
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Chapter 3. Purification and characterisation 
of SWNTs 
3.1. General information 
The results discussed in this section include the purification, modification and 
characterisation of the SWNTs scaffold. These involve the Raman spectroscopy, TEM, 
SEM microscopy and EDX analysis of SWNTs, in order to investigate their quality. 
Biotin and boronic acid-based fluorescent tags, containing one of the following 
fluorophores: fluorescein isothiocyanate (FITC), coumarin, rhodamine and bodipy, 
were subsequently synthesised and analysed via mass spectrometry, 1H NMR, UV-vis 
and fluorescence spectroscopies in order to shed light into the structure, purity, 
absorption, quantum yield and emission intensity of the fluorescent systems synthesised. 
A series of anticancer reagents in different cancer cell lines were studied to establish a 
robust protocol for MTT assays, then this assay method was applied to examine the 
cytotoxicity of SWNTs and different fluorescent sensors in different cancer cell lines. 
Eventually, confocal microscopy or epi-fluorescence microscopy imaging was 
performed for the different fluorescent sensors in cells. 
 
3.2. Purification methods for SWNTs 
SWNTs were made by different methods, hence the products yielded normally 
contained different impurities. More interestingly, the purification methods needed 
depend on the method of synthesis for the as-made SWNTs. SWNTs were purified by 
modifying the method originally used in Pascu’s group and which was widely used 
within the Oxford Nanotube Group since 2004. TEM, SEM, and EDX analysis were 
carried out at the University of Bath between 2011 and 2012. 
As it can be seen in Figure 3.1 the raw SWNTs, (Elicarb variety, as-made which 
were provided by Thomas Swan Ltd and which are related to the batch in use at the 
Oxford Nanotube Group) produced by a CVD method, present three main impurities: 
amorphous carbon, metal catalyst and multi-shell carbon nanoparticles. The presence 
of metallic impurities, such as Fe, was confirmed by EDX analysis.  
  Chapter 3. Purification and 







Two different methods to purify the raw SWNTs were used, one of which is 
steam purification,1 the other one is a solvent-based oxidation method,2, 3 both of which 
were modified based on literature protocols. The fundamental principle of purification 
is to remove a maximum amount of impurities, whilst causing minimum damage to the 
SWNT structure. Because multi-shell carbon nanoparticles have a similar structure to 
SWNTs, they resist high temperature and hence cannot be removed by the gas oxidation 
method. Whereas, in the solvent oxidation method, multi-shell carbon nanoparticles are 
“cracked” via a microwave pre-treatment, which makes carbon nanoparticles more 
vulnerable to oxidative treatment.4 Therefore, the solvent oxidation method was chosen 








Figure 3. 1. TEM Micrograph of raw SWNTs with varieties of impurities 
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Complete characterisation of these products was subsequently carried out via 
TEM, EDX and Raman spectroscopy. A TEM micrograph showing typical as-made 









Figure 3.2. TEM micrograph of purified SWNTs via (a). As-made arc-made SWNTs supplied 
by Carbolex (Rice University) and solvent oxidative purification in this work (b). Commercial 
SWNTs available from Thomas Swan (CVD made, Elicarb® and steam-purified by S. Pascu 
and her collaborators with the Oxford Nanotube Group). 
 
As it can be seen in Figure 3.2a, the SWNTs can be purified via solvent 
oxidation method. For comparison in Figure 3.2b, shows SWNTs purified by the steam 
method, which were provided by Dr Pascu and originated, for consistency reasons, from 
a large scale batch purified for Thomas Swann using a method devised within the 
Oxford Nanotube Group (Professor Malcolm Green). It is apparent that although 
purification via solvent oxidation removes most of amorphous carbon from the SWNTs 
(Figure 3.2a), there is a thick layer formed by stacking of SWNTs, and also some 
impurities, such as metal catalysts and contaminants like silica, remain in the layers, 
which indicates that the oxidation method cannot completely eliminate all the metal 
a. b. 
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catalysts and due to the multistep methodology, it was highly contaminated. Therefore, 
the quality of the SWNTs in the Figure 3.2a was lower than that in Figure 3.2b. Though 
there was still some amorphous carbon left in the industrially supplied sample Figure 
3.2b, most carbon nanotubes were clean and the structure of SWNTs was intact, and 
therefore ready for use in the majority of the experiments which require relatively large 
scale of materials. In this work, most of the experiments were carried out using the 




Figure 3. 3. EDX analysis of purified SWNTs via solvent oxidation method 
 
Result represented in Figure 3.3 showed the EDX analysis obtained from 
purified SWNTs. It clearly reveals that the target area of SWNT is very clean. Although 
there are signals from copper, silicon and oxygen, they usually came from copper grid 
and glass (SiO2) used in the procedure. However, with this results it is not possible to 
confirm the 100% purity of the whole batch of SWNTs. Because the laser beam was 
focused onto an extremely tiny spot (nm size), hence, this spectrum only refers to a 
small area of the sample. Thus in order to prove that the bulk of SWNTs was purified, 
multiple site of SWNTs have been examined, and the results encouraged us to proceed 
into their sample.  
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Figure 3. 4. SEM micrographs and EDX analysis of purified SWNTs via solvent oxidation 
method. These micrographs were recorded on samples purified for this programme, jointly 
with Zhiyuan Hu, and the technical support was that of Dr John Mitchels (MAS Bath) 
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SEM microscopy was done after TEM to analyse the surface morphology of 
purified SWNTs. As it can be seen clearly from Figure 3.4, there are many SWNT 
bundles in between supporting particle aggregates. An EDX analysis was subsequently 
carried out. The results clearly show that no significant amount of metal catalysts 
remained. Although there was still aluminium and gold elements detected, they were 
from substrate and coating elements used respectively. Hence, it can be concluded that 
only carbon is detected in the actual SWNT sample. However, similar to TEM, 
information from one site is not representative for the whole SWNTs batch, therefore 
six sites were analysed shown in Figure 3.5 in order to understand the purity of SWNTs 
overall. The first two sites have been examined as a spot and then the rest sites have 
been investigated via an EDX spectra. As displayed in Figure 3.5b there are signals 
from Br and Rb from site one, which are contaminations at the site presumably from 
the instrument. Finally, there were oxygen peaks found in four sites, which means there 
were certainly functionality still exist, which carried oxygen (O2), due to the presence 
of absorbed the O2, H2O and CO2 from air at these sites. Therefore, results conclude 
that metal catalysts are removed reliably from SWNTs, but SWNTs may be partially 
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Figure 3. 5. a.) SEM micrograph of purified SWNTs via a solvent oxidation method with b.) 
Six corresponding EDX spectra 
 
3.3. Functionalisation methods of SWNTs 
In general, two methods were applied to functionalise SWNTs: non-covalent coating of 
SWNTs with -D-glucan, and filling of SWNTs with metal ions. The functionalised 
SWNTs were characterised by TEM, SEM microscopies and Raman spectroscopy. 
Purified SWNTs were provided by S. Pascu with the Oxford Nanotube Group and 
functionalised by modifying the method originally used by Dr Pascu as a member of 
the Oxford Nanotube Group (2005-2007) and which was repeated and adapted by Dr. 
Zhiyuan Hu. However, there were concerns about the purity of  the material and 
therefore an adapted method was devised, which shows reliability for biomedical 
investigations. Here, TEM, SEM, and EDX analysis were carried out (at the University 
of Bath between 2011 and 2012) and Raman spectroscopy were record at University of 
Bath between 2013 and 2015 and the Research Complex at Harwell under the training 
provided by Prof Tony Parker. 
b. 
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Scheme 3. 1. Schematic presentation of non-covalent functionalisation of SWNTs 
 
Scheme 3.1 represents a non-covalent functionalisation of SWNTs with-D-
glucan.5, 6 Subsequently fluorophores are loaded on the surface of -D-glucan. A 
fluorescence modified with a boronic acid may bind to diol on glucan coated SWNTs 




  After filtering and washing with water, the final product was prepared for TEM 
microscopy and Raman spectroscopy.  
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Figure 3. 6. TEM micrographs of SWNTs wrapped with -D-glucan and tagged onto 
compound 7 through – B (OH) 2 group, micrographs take from (a) site 1 (b) site 2 
 
Micrographs exhibited in figure 3.6 presents SWNTs wrapped with glucan and 
fluorophore. There are two types of SWNTs revealed under TEM, one is a curved 
SWNT bundle (Figure 3.6 a) and the other one is a straight SWNT bundle (Figure 3.6 
b). Both types of SWNT bundles are covered by a polymer layer and there are several 
black spots on the layer. These are likely glucan particles layer present on SWNTs 
bundle shown, and also there is more aggregated glucan accumulated at the base of the 
SWNTs. 
A series of Raman experiments have been carried out to examine the 
interactions between SWNTs and glucan and fluorophores (for this programme, by this 
author, at the University of Bath, 2015). The experiments were carried out under 
different laser conditions with several different types of SWNTs in order to compare 
them. Experiments started using a laser with an operation wavelength of 532 nm. In the 
obtained spectra (Figure 3.7) peaks corresponding to SWNTs are observed for both 
samples, but no useful information can be obtained at their wavelength. A significant 
rise in the baseline of the Raman spectrum was observed for the sample SWNTs 
a. b. 
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contains both glucan and fluorophores, which indicates a luminescence phenomenon 
occurring from glucan and fluorophore functionalised SWNTs, which prevents a 




Figure 3. 7. Raman spectra of pristine SWNTs and SWNTs functionalised with glucan & 
fluorophores in using laser at 532 nm wavelength  
 
The results represented in Figure 3.8 show the opposite outcome, using a 785 
nm wavelength laser, a wavelength at which SWNTs started to illuminate. There was a 
significant increase in the intensity between 1600 to 3500 cm-1 Raman shift. Whereas 
in SWNTs with glucan and fluorophore, SWNTs seemed to be protected by glucan 
layer, hence there was no luminescence emitted from SWNTs and the Raman spectrum 
baseline remained steady. Data from 785 nm were believed to be more informative than 
data from 532 nm due to an improvement in the resolution. Therefore, ID/IG ratio of 
SWNTs was 18.18 % and ID/IG ratio of SWNTs with glucan and fluorophore was 
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7.69 %, hence, there was a remarkable increase in the quality of SWNTs after non-
covalently functionalised with glucan.  
 
Figure 3. 8. Raman spectra of SWNTs and SWNTs functionalised with glucan & 
fluorophores in laser at 785 nm wavelength 
 
Figure 3. 9. Raman spectra of SWNTs and SWNTs functionalised with glucan and 
fluorophores in laser at 958 nm wavelength 
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By contrast, the Raman spectra data from a laser at 958 nm wavelength, which 
is at a visible light region, was carried out (figure 3.9). It is obvious that the baseline of 
glucan coated SWNTs raised again in this spectra, it was probably caused by 
fluorophores anchored onto the glucan, which absorbed and reflected visible light. 
However, due to a low laser energy import, the resolution of spectra was too low to be 
analysed.   
 
Scheme 3. 2. Schematic presentation of SWNTs filling with metal ions and capping with 
fullerenes. 
 
Scheme 3.2 shows the method be used to fill SWNTs’ internal cavity with metal 
ions. Purified and opened SWNTs after the steam purification protocol, available from 
Oxford Nanotube Group, were dispersed and stirred in a zirconium acetate solution. 
Then C70 fullerenes are dispersed and stirred in the solution. After filtering and rinsing 
with excess of water and toluene, a zirconium filled SWNT capped with C70 was 
prepared for a TEM investigates and Raman spectroscopy.7, 8 (Zr4+ filled SWNTs were 
obtained by modifying the method developed by Dr Sofia Pascu at Memorial Sloan 
Kettering 2011 and repeated initially by Zhiyuan Hu. However, both of those available 
samples showed extremely low filling yields and this project set out to investigate the 
reasons why this was the case. This project reports the adapted and improved synthetic 
method (see Experimental section). TEM, SEM, and EDX analysis were carried out by 
this author at the University of Bath between 2011 and 2012. Raman spectroscopy was 
carried out at Research Complex at Harwell in 2013 on the samples provided by the 
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author by Dr. Boyang Mao under the supervision of Dr Sofia Pascu and Prof Tony 
Parker. The interpretation and processing of the raw data belongs entirely to this author. 
Figure 3.10 exhibits TEM micrographs of a SWNT and a bundle of SWNTs 
filled with Zr4+ ions, the result images clearly showed the surface of either SWNT or 
SWNT bundle is clean, but the resolution of TEM is not high enough to reveal the detail 
of the internally trapped metal ions. Hence, an EDX analysis focused on SWNT strand 





Figure 3. 10. TEM micrographs of zirconium filled a. SWNT and b. bundle of SWNTs 
 
a. b. 
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Figure 3. 11. EDX of zirconium-filled SWNTs 
 The EDX analysis certainly contains zirconium peaks. However, it also shows 
the overlapping peak of Mo and other elements from impurities in the microscope, 
copper and nickel from sample holder and preparation. Sulphur elements might come 




Figure 3. 12. SEM images of (a) bundle of SWNTs at 1K magnification. (b) A bundle of 
SWNTs at 33K magnification, filled with zirconium acetate 
 
 Figure 3.12 represents the result of SEM micrographs at x1000 and x33000 
magnifications resolutions. As can be observed, at lower magnification, SWNTs 
bundles appear simulatively with carbon supporting materials. At the higher 
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magnification, it is shown that the surface of individual SWNT bundles is clean, and 
there appear to be no amorphous carbon or nanoparticles attached to these. However, 
there are no further details available as revealed by this method due to the limitation of 
the SEM equipment available. When a high voltage was applied to SWNTs in order to 
improve the quality of image, there was an electronic charge on the surface of SWNTs 
and as a result, a highly bright micrograph is obtained without improving the resolution. 
 
 
Figure 3. 13. (a) SEM micrograph of zirconium acetate filled SWNTs, and (b) Five 
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 Figure 3.13b shows EDX spectra of zirconium acetate-filled SWNTs, there are 
many peaks from different elements in the EDX spectra. In spectra 1, 2, 4 and 5, the 
majority of elements are C and O from SWNTs, gold (Au) from gold coating, Pt (from 
many catalyst) and F from instrument contamination. There are also force peaks from 
Fe detected due to a contamination from tweezers during the sample preparation. There 
are no zirconium signals in these explored four sites. This may be caused by the 
covering of SWNT bundles with a thick carbon layer. Site 3 may have SWNTs 
presented at the spot, but the peak of aluminium element is dominant, which hides the 




Figure 3. 14. Raman spectra of zirconium and copper filled SWNTs compared with purified 
SWNTs. This data was recorded at the Research Complex at Harwell under the supervision of 
Prof Tony Parker, by the Pascu Group of original samples by this author. 
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 For comparison, a copper acetate filling experiment was carried out, as it can be 
seen in Figure 3.14, SWNTs are filled with either zirconium acetate or copper acetate 
respectively. The results clearly show that all characterisation peaks are remained the 
same at 250 cm-1, 1250 cm-1 and 1600 cm-1. This means the structure of SWNTs are 
intact and stable, the calculated ID/IG ratio of SWNTs filled with zirconium and copper 
are 19.97 % and 18.15 % respectively, which is higher than the ID / IG ratio of SWNTs 
functionalised with -D-glucan alone (7.69 %). However, this ratio is close to the ratio 
of purified SWNTs, which is 14.52 %. Hence, it proves that filling of SWNTs with ions 
will neither damage the structure of SWNTs nor improve its structure. Furthermore, 
The RBM of filled SWNTs are different from purified SWNTs, which indicate a change 
in the diameter of SWNTs and refers to SWNTs were filled with Zr4+ or Zr4+ and Na+. 
The RBM is not changed during two different filling process, which indicates that 
filling SWNTs with either zirconium or copper ions will not cause a significant change 
in the diameter of SWNTs.   
 
 
Figure 3. 15. Raman spectra of zirconium and zirconium & sodium filled SWNTs compared 
with purified SWNTs. This data was recorded at the Research Complex at Harwell under the 
supervision of Prof Tony Parker, by the Pascu Group of original samples by this author. 


































  Chapter 3. Purification and 







 As it is represented in Figure 3.15, a zirconium filled SWNT is compared with 
a SWNT carrying both zirconium acetate and sodium acetate in a 1:1 mixture. It is 
obvious that characterisation peaks stay at the same position, hence the structure of 
SWNT is unchanged. However, the ID/IG ratio of SWNTs increase to 20.93 %, which 
refers to an increase in the defect rate when SWNTs are filled with two metal ions. In 
addition, the RBM has reduced to half of its original value, which indicate that the 




Figure 3. 16. Raman spectra of zirconium ions and simultaneously present C70 fullerene and 
zirconium acetate and sodium acetate and C70 fullerene in filled SWNTs and compared with 
purified SWNTs. This data was recorded at the Research Complex at Harwell under the 
supervision of Prof Tony Parker, by the Pascu Group of original samples by this author. 
 
C70 fullerene, which has a similar size (11.2 Å)
9 to the diameter of SWNT, is 
used in this experiment to seal the open end of SWNTs in order to block metal ions 
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inside SWNTs. Similar to the case of the other two Raman spectra recorded, there is no 
shift in the characterisation peaks. The ID/IG ratio of [Zr
4+ + C70] and [Zr
4+ +Na+ + C70] 
filled SWNTs are 19.06 % and 18.76 % respectively; although a small improvement 
from 19.97 % and 20.93 % was observed, it appeared to reduce the defect ratio slightly 
and makes SWNT higher quality. In addition, the RBM of filled SWNTs are overlaid 
after introduction of C70 fullerene, hence there was no modification of the diameter of 
SWNTs.  
 
3.4. Summary of chapter three 
Results from TEM, EDX, SEM and Raman indicates that the solvent oxidation method 
appeared to as-made SWNTs (either as-made or CVD available) successfully removes 
all of the metal catalysts and most of the amorphous carbon from SWNTs. However, 
the efficiency and quality of the products was still not comparable to the commercially 
available purified SWNTs from Thomas Swann Company and provided by S. Pascu 
from Oxford Nanotube Groups. The SWNTs purified via steam-based gas phase 
oxidation methods have been shown to be good enough to be used for research purposes 
through TEM, Raman spectra and MTT assays. However, because the resolution of 
TEM available so far was rather low, higher resolution TEM imaging of metal salt filled 
SWNTs is still needed to clearly demonstrate the expected filling and estimate the 
filling yield. -D-glucan and fluorophore coated SWNTs were successfully 
characterised by TEM imaging and Raman spectra, with further investigations of the 
SWNTs hybrids carried out in Chapter 4 and 5 to explore the potential of this 
biocompatible device in the biomedical research areas.  
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Chapter 4. Investigations into the cellular 
cytotoxicity  
4.1. Overview  
As described in the introduction, the majority of the organic fluorophores are aromatic 
molecules which can react with oxygen to produce reactive oxygen species (ROS), 
which can in term damage structures of the living cell. The same principle applies to 
the SWNTs, impure or not well functionalised SWNTs can elevate oxidative stress in 
the cell due to their high surface energy.1, 2 Therefore a preliminary study of cytotoxicity 
prior to their application in biological experiments is necessary, in order to determine 
the safe concentration to avoid causing damage to cells, and this was devised and will 




Figure 4. 1. Schematic representation of mechanism of MTT assay 









The MTT assay is a quantitative colorimetric assay and it is the major assay 
used for cytotoxicity test in this project. In this assay, a yellow tetrazolium salt MTT 
(3- [4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide) is reduced by living 
cells to formazan crystals, which can be dissolved in DMSO. This formazan solution 
can absorb energy at 570 nm which can be measured by a spectrometer. The mechanism 
is shown in Figure 4.1; NADP (nicotineamido adenine dinucleotide phosphate) is 
reduced to NADPH (nicotineamido adenine dinucleotide phosphate reduced form) in 
cellular mitochondria of living cells. Then an electron of NADPH is transferred to 1-
methoxy PMS, which is an electron carrier on the cell membrane and subsequently 1-
methoxy PMS is reduced to the 1-methoxy PMS reduced form by NADPH in the 
cytoplasm. Finally, tetrazolium is reduced by the 1-methoxy PMS reduced form in the 
medium.  
 
4.2. MTT assays of raw, as-made SWNTs 
The result of MTT assays were collected and plotted into a dose response curve and an 
EC50 value was calculated. EC50 stands for the half maximum effective concentration, 
which is the concentration of a sample solution that induces a response halfway between 
the baseline and maximum after a period of time. In this case EC50 values represent the 
toxicity of the sample solution. Therefore, the higher the EC50, the higher the 
concentration required to cause 50% cell toxicity Compounds with an EC50 value 
greater than 100 mg/L (0.1 mg/mL) can be considered nontoxic.3  











Figure 4. 2. Dose response curves and calculated EC50 of un-purified SWNTs in HeLa cells 
(a) for 24 hours, EC50 = 1.78×10-8 ± 1.03 × 10-9 mg/mL (b) for 48 hours. EC50 = 1.14×10-8 ± 












The dose response curves of HeLa cells treated with SWNT-OX were determined, and 
the results are given in Figure 4.2 (a) and (b). Both MTT assays used pristine 
commercial available SWNTs prior to purifications in HeLa cells over two different 
time periods (24 hours and 48 hours respectively). Data shows a significant level of cell 
death which occurred in both conditions. The EC50 value for 24 hours was 1.78×10
-8 
mg/mL and for 48 hours it was 1.14×10-8 mg/mL. In both cases, samples were found to 
be roughly 1×107 fold more toxic than the desired non-toxic criteria for any material. 
Exposure of cells to un-purified SWNTS for 24 hours gave a 35.96% lower EC50 value 
than that compared to 48 hours EC50. SWNTs become more toxic to cells or cells 
become more vulnerable to SWNTs over a longer time of exposure, i.e. more cells were 
killed by the same quality of SWNTs on time. The results prove that raw SWNTs were 
toxic in cells and that toxicity increases with increased exposure time. Therefore, 














Figure 4. 3. Viability of HeLa cells after treatment after (a) 24 hours (b) 48 hours, where 
SWNT-OX is the pristine SWNTs commercially available from Thomas Swan Ltd, used in 
Oxford Nanotube Group for purification and functionalisation 
 
Bar graph plots were also drawn with the data from the MTT assays. It shows that the 
viability of HeLa cells dropped slowly from 100 % to 47 % as the concentration of 
SWNTs increased from 5×10-10 mg/mL to 5×10-7 mg/mL. Similar results were obtained 
from cells treated with SWNTs for 48 hours. As can be seen in Figure 4.3 b, the viability 
of HeLa cells decrease gradually from 100 % to 47.23 %, when the concentration of 
the SWNTs increased from 5×10-10 mg/mL to 5×10-7 mg/mL. In conclusion, unpurified 
SWNTs were toxic to HeLa cells, but did not cause 100 % cell death. HeLa cells 
adapted to SWNTs during prolonged incubation as there were a similar percentage of 
cells that survived in the same concentration of SWNTs after 48 hours treatment, 
compared with 24 hours treatment. 
  
(b) 








4.3. MTT assays of purified SWNTs 
Two different batches of purified SWNTs, one is from Thomas Swan Elicarb and the 
other one is from the Oxford Nanotube Group, were examined by MTT assays. In order 




Figure 4. 4. Dose response curve determines EC50 of purified SWNTs in HeLa cells (a) from 
Thomas Swan Elicarb, purified by solvent method, EC50 = 3.38×10-7 ± 1.51 × 10-7 mg/mL (b) 
Steam purified and CVD-made SWNTs, available from Oxford Nanotube Group, EC50 = 
1.17×10-7 ± 5.12 × 10-8 mg/mL.  
(a) 
(b) 








As can be seen in Figure 4.4, two batches of purified SWNTs were tested for cell 
toxicity by MTT assay. One was purchased from Thomas Swan Ltd (Elicarb), and the 
other one was also from Thomas Swan but steam purified by S. Pascu with the Oxford 
Nanotube Group. The dose response curve clearly showed that purified SWNTs 
whether by solution methods, or by steam purification still caused cytotoxicity and led 
to cell death. However, compared with EC50 from Figure 4.2, the toxicity had roughly 
decreased by 10 fold. The EC50 of Elicarb© solvent purified (CVD-made) SWNTs was 
3.38×10-7 ± 1.51 × 10-7 mg/mL and Oxford steam purified (CVD-made) SWNTs was 
1.17×10-7 ± 5.12 × 10-8 mg/mL. The EC50 of Elicarb SWNTs was therefore higher than 
that of the steam-purified SWNTs so Elicarb SWNTs were ca. 50 % less toxic than the 














Figure 4. 5. Viability of HeLa cells after 48 hours treatment of CVD-made purified SWNTs 
from (a) Elicarb (b) steam-purified and provided by the Oxford Nanotube Group. 
 
The viability of HeLa cells was reduced at a slower rate and at a higher concentration 
for both purified SWNTs (whether solution purification, or steam-purification), 
compared with raw SWNTs after 48 hour treatment. Both batches of SWNTs led to a 
high survival rate at concentrations of 1×10-8 mg/mL and 1×10-7 mg/mL, then the 
viability of HeLa cells treated with steam-purified SWNTs suddenly dropped from 
94.36% to 49.94% at the concentration of 2.5×10-7 mg/mL, whilst the viability of HeLa 
cells treated with Elicarb© SWNTs (solution purified) was gradually reduced from 
93.65% to 87.23%.  Subsequently, both SWNTs batches induced drops in the viability 
of HeLa cells tested to levels between 50.47% and 55.04%.  
 
4.4. MTT assays of -D-glucan functionalised SWNTs 
Figure 4.6 represents the MTT assays using β-D-glucan wrapped SWNTs in HeLa cells 
over 48 hours. From the plot, EC50 for sugar wrapped SWNTs was estimated to be 
(b) 








5.03×10-6 mg/mL. This is 100 fold greater than the result described in Figure 4.2 and 
10 times greater than that shown in Figure 4.4.  
 
 
Figure 4. 6. The dose response curve of HeLa cell line treated -D-glucan functionalised 
SWNTs over 48 hours, EC50 = 5.03×10-6 ± 1.12 × 10-7 mg/mL 
 
 
Figure 4. 7. The viability of HeLa cells after 48 hours treatment of -D-glucan SWNTs 







The viability of HeLa cells after 48 hours 
























The viability graph (Figure 4.7) shows that the survivability of HeLa cells was 
stable at around 100%, after treatment with SWNTs at concentrations ranging between 
1×10-9 mg/mL and 1×10-6 mg/mL. Then the viability reduced steadily from 98.27% to 
69.69% when 5×10-6 ± 1.12 × 10-7 mg/mL of -D-glucan functionalised SWNTs was 
applied to HeLa cells. Therefore, it can be concluded that -D-glucan functionalisation 
of SWNTs significantly reduced the cytotoxicity of SWNTs and rendered these more 
biocompatible as a vector for medical applications or life sciences assays. This data 
also proved that -D-glucan was an ideal material to functionalise SWNTs, it not only 
provide a scaffold for boronic acid to anchor, but also isolate SWNTs from the 
environment to avoid causing damage to living organisms, as a consequence, more 
volume of sugar wrapped SWNTs can apply to the cells, which would significantly 




Figure 4. 8. The dose response curve of PC-3 cells treated with compound 7 @glucan 
@SWNTs over 48 hours 
 
Figure 4.8 displays the dose response curve of PC-3 cells treated with compound 
7 @glucan @ SWNTs composition. Only very few of the cells died in the experiment, 







Dose response curve of PC-3 cells treated with 
























thus the EC50 value could not calculated with precisely from the graph given in the 
Figure 4.8. However, more than 80% of cells were survived during the experiment, 
which indicated the composition is largely non-toxic. As it can be seen in the viability 
data in Figure 4.9, cells died at an extremely slow rate under the conditions used, from 
100 % at 1×10-9 mg/mL to 84 % at 5×10-6 mg/mL. There was a significant improvement 
in the survivability compared with 50% for purified SWNTs at 5×10-6 mg/mL in Figure 
4.5, but there was also a clear reduction in the survival rate compared with 98% at 5×10-
6 mg/mL in Figure 4.7. This might have been caused by the inclusion of compound 7 




Figure 4. 9. The viability of HeLa cells after 48 hours treatment of compound 7 @ 
SWNTs@-D-glucan  
 
4.5. MTT assays of boronic acid-based fluorophore 
After MTT assays were carried out for a series of different types of SWNTs. MTT 
assays were also performed on HeLa cells treated with the boronic acid-based 
fluorescent compounds synthesised and some related molecules as benchmarks. As 






















The viability of HeLa cells after 48 hours treatment 
of Compound 7@SWNTs@glucan








shown in Figure 4.8, the viability of HeLa cells was calculated as EC50 = 5.32×10
-4 ± 
1.03 × 10-5 M (0.53 mg/mL). This value was higher than the lowest toxic standard, 
which was 0.1 mg/mL, As a result, compound 7 was considered non-toxic in this cell 
line and therefore safe to use to the biological experiments and assays in a concentration 
range between 10-9 and 10-4 M.  
 
 
Figure 4. 10. The dose response curve of compound 7 was raised for an assay in HeLa cells 
carried out over 48 hours, EC50 = 5.32 × 10-4 ± 1.03 × 10-5 M. 
 










Figure 4. 11. The viability of HeLa cells estimated after 48 hours after the treatment of 
compound 7 
A viability diagram (Figure 4.11) was plotted to examine the survivability of 
HeLa cells after 48 hours treatment of compound 7 at different concentration. The 
viability of compound 7 was similar to that observed for the glucan functionalised 
SWNTs. Both samples cause little toxicity at lower concentrations followed by a 
gradual drop to their highest concentration. This viability plot further shows that 
compound 7 was a biocompatible compound for cells and it is safe for a biological 
application into the concentration ranges used hereby (10-9 – 10-4 M).  
The cytotoxicity of some fluorescent sensors designed and provided by 
collaborators were also tested in MTT assays to try and estimate whether the ranges 
defined hereby were with available ranges and consistent with that of a large library of 
probes. These fluorescent sensors were structurally similar to the fluorescent sensor 
synthesised in this project so could contribute to a deeper understanding of the 
relationship between the cytotoxicity and the structure of the compound through the 
comparison amongst the compounds including in the library. The compounds of the 
library studied are given at the beginning of this project (Appendix C). 
 







Viability of HeLa cells after 48 hours treatment 


























Figure 4. 12. The dose response curve of HeLa cell lines after their treatment with compound 
24 over 48 hours, EC50 = 4.08 × 10-6 M. 
 
The result in figure 4.12 shows, 4.08×10-6 M (2.2×10-3 mg/mL) of compound 
24 caused half of the cells to die during 48 hours. This effective concentration was 
below 0.1 mg/mL, thus this compound was theoretically cytotoxic. The toxicity of 
compound 24 was higher than toxicity of compound 7 by comparing Figure 4.11 and 
4.13. There was more than 90% cell survival at 1×10-6 M concentration when cells were 
treated with compound 7 whereas, only 78% of cells remained when treated with 
compound 24. These data suggests that inclusion of a diamine linker and of a biotin 
group in the structure can make compounds more biocompatible.  
 










Figure 4. 13. The viability of HeLa cells estimated after 48 hours for treatment with 
compound 24 
 
This viability diagram (Figure 4.13) can be used to compare results between 
compound 7 and compound 24. The general trend showed that compound 24 was 
generally nontoxic over the concentration range used because even at the maximum 
concentration of 5×10-6 M, the cell survival is still 58.43 %. However, the initial drop 
in viability caused by compound 24 appeared at the concentration of 2.5×10-7 M. Then 
the survival rate of cells then reduces slowly. Compared with data in Figure 4.11, there 
was only one sharper decrease at the concentration of 2.5×10-4 M. These results prove 
the toxicity of compound 24 was higher than the toxicity of compound 7. Therefore, 
compound 7 is still the most biocompatible is the series and suitable to be used in 
biological experiments. 
 


































Figure 4. 14. The dose response curve and determined EC50 of compound 13 in PC-3 cells 
over 48 hours, EC50 = 5.20 × 10-5 ± 6.74 × 10-6  M. 
  
Compound 13 is a derivative of compound 7, in which a fluorescein group is replaced 
by a boron-dipyrromethane (bodipy) group. As a result, the cytotoxicity is examined to 
analyse the difference introduced by this replacement. The EC50 value calculated from 
Figure 4.14 was 5.20 ×10-5 ± 6.74 × 10-6  M, which is smaller than the EC50 value of 
compound 7 (5.32×10-4 ± 1.03 × 10-5 M) from Figure 4.11. By replacing the fluorescein 
with a bodipy group the cytotoxicity is increased 10 fold. It is also evident that changing 
the fluorophore in the fluorescent sensor will alters the cytotoxicity significantly of the 
fluorescent sensor.  
As can be seen in Figure 4.15, the viability of cells was above 95% at the 
concentration of 1×10-9 M and 5×10-7 M, which indicated compound was non-toxic in 
this concentration range. Then from 1×10-6 M to 5×10-5 M the survival rate of cells 
dropped slowly from 80% to 70%, indicating only a weak toxicity to cells. Finally, from 
1×10-4 M, a strong toxicity was introduced by compound 13 that reduced the viability 
of cells down to 14%. 
 














Figure 4. 16. Dose response curve of PC-3 cells treated with compound 15 over 48 hours, 
EC50 = 1.41 × 10-4 ± 1.42 × 10-5 M. 
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Particularly, compound 15 is another boronic acid derivative related to 
compound 7 and compound 13, where a coumarin group (instead of bodipy group or a 
fluorescein) is attached onto the biotin-diamine-boronic acid linker. As mentioned 
previously, introducing a different fluorophore could change the toxicity of the 
fluorescent sensor. Results displayed in Figure 4.16 shows compound 15 causes a 
different cytotoxic effect than compound 7 and compound 13. The EC50 of compound 
15 was 1.41×10-4 ± 1.42 × 10-5 M, which was less toxic than compound 13 (5.20×10-5 
± 6.74 × 10-6  M), but more toxic than compound 7 (5.32×10-4 ± 1.03 × 10-5M). 
The viability plot (Figure 4.17) also proved compound 15 was toxic but not less 
so than compound 13. The viability of cells drops slowly down to 61% from 1×10-9 M 
to 1×10-4 M, followed by a sudden decline to 20% at 2.5 ×10-4 M. This trend indicates 
compound 15 has a more stable cytotoxicity profile than compound 13 and therefore 
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4.6. Summary of chapter four 
Two sets of MTT assays were established successfully to investigate samples in either 
molar concentration or mass concentration. All the fluorescent molecules and 
nanomaterials synthesised hereby were tested for cytotoxicity prior their application in 
confocal imaging. In general, SWNTs were found to be rather toxic, but after 
purification and functionalisation of biocompatible materials, a significant drop in their 
cytotoxicity was observed. Therefore, a great potential in the biomedical research can 
be forecast based on these evolution. As for the fluorescent sensors applied in this 
project, the cytotoxicity of the fluorescent sensors mainly originates from the 
fluorophore tags. Thus the cytotoxicity of fluorescent sensors varied from one system 
to another. From MTT assays of the fluorescent sensors, it was obvious that majority 
of these sensors seemed non-toxic at low concentrations until it reached the threshold 
at high concentration. The most common concentration used in confocal imaging in this 
project was 100 µM over 15 minute observation. Most of the fluorescent molecules in 
the assays studied could easily maintain more than 50% of cell survival at that 
concentration for over 48 hours observation. Therefore, most of the fluorescent 
specimens are appeared to be non-toxic in the applications in cancer cells, or can be 
tolerated in the cell experiments over 48 h observations. 
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Chapter 5. In vitro fluorescence imaging of 
fluorescence sensors and functionalised 
SWNTs 
5.1. Overview 
Following on from purification and functionalisation protocols for SWNTs-based 
materials, as well as from the characterisation of organic fluorophores equipped with 
boronic acids. and synthesis & characterisation of fluorescent sensors, these two parts 
have been combined as described in Figure 5 – 1 to form a drug delivery device (DDS) 
which was then tested in biological experiments.  
 
 
Figure 5. 1. Schematic pathway to assemble a drug delivery system for cell imaging and 
cytotoxicity assays 
 
As seen in Figure 5.1, purified SWNT samples were functionalised with β-D-
glucan in a biocompatible environment such as DMSO and water mixtures. (SWNTs 
were functionalised by modified the method used in S.I.P. group during 2008-2011).  
Then fluorescent sensors were loaded on the surface of glucan wrapped SWNTs via 
boronic acid-diol functionalisation using interactions involving the hydroxyl groups on 
the glucan backbones. Subsequently, these fluorescent sensor and SWNTs devices were 
filtered, rinsed and delivered to cancer cells and imaged.  
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The biological experiments in Chapter 5 include laser scanning confocal and 
epifluorescence imaging techniques to examine the morphology and fluorescent 
distribution of the fluorescent sensor in cells. This was followed by a fluorescence-
lifetime imaging microscopy (FLIM) using two photon imaging to analyse the lifetime 
change of fluorescent sensors in cells. A variety of different conditions were 
investigated including: (a) different fluorescent organic dyes in cells, (b) different 
fluorescent tags anchored upon SWNTs in cells, (c) the same fluorescent systems tested 
under different conditions, such as, concentrations, incubation times and temperatures.  
 
5.2. Cell imaging of biotin-boronic acid based fluorescent sensors 
(compounds 4 and 7) 
  
Compound 7 was incubated for an hour at 100 µM, 1% DMSO (Figure 5.2). The figure 
clearly shows that the compound passed the cell membrane and distributes within HeLa 
cells. From the DIC image Figure 5.2 (c), the structure of the cells appears to be visually 
intact in terms of morphology, although some bubbles appeared due to a prolonged 
exposure to a laser. This may be led to the ROS generated from photodynamic effect 
accumulated over time and thus changing the homeostasis of the cells. According to 
MTT assays, more than 90% of cells survived at 100 µM for 48 hours with compound 
7 alone. Under the laser condition (ex = 488 nm for one photon, ex = 910 nm for two 
photon), this cellular disruption occurred within minutes. The HeLa cell control 
experiment showed in appendix A.1 also proved that HeLa cells were slightly disrupted 
under the laser conditions, even in the absence of the compound. As a result, it can be 
concluded that compound 7 has a strong membrane penetrability and a lower power 
laser needed to be tried to test whether it could reduce the damage.  
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Figure 5. 2. Confocal microscopy images of HeLa cells treated with 100 µM of compound 7 
in 1% DMSO, incubated at 37 ºC for 1 hour. The sample was excited at 488 nm wavelength 
and long-pass filtered at 515 nm. Image (a) was merged image of images (b) and (c). Image (b) 
was green fluorescence channel. Image (c) represented for image took from DIC. Scale bar: 20 
µm. 
 
Figure 5.3 shows an experiment designed to determine the co-localisation of 
compound 7. Hoechst was applied to CHO cells to enable distinction of the nuclei and 
to determine whether compound 7 underwent nuclear uptake. The green fluorescence 
observed upon excitation with 488 nm (representing the compound 7 nuclear stain) 
could be overlaid with an image of the blue fluorescence with excitation at 405 nm 
(representing Hoechst). In the overlay, where nuclear uptake of compound 7 had 
occurred, a cyan colour can be observed. Similar to HeLa cells, compound 7 showed 
good membrane penetrability into CHO cells, nuclei of CHO cells were successfully 
stained by Hoechst. A clear colocalisation between the green and blue stains was 
observable in Figure 5.3 (a). Therefore, this shows that compound 7 not only enters 
cells and travels to the cytoplasm, but also could access the nucleus of the CHO cell. 
There was another observation is found from Figure 5.3 (b), which was that most nuclei 
remain intact under the confocal microscopy. This may suggest that both compound 7 
and Hoechst dyes leave cells undamaged. As it is shown in using images from in Figure 
5.3 (d), most of the cells appear undamaged in terms of morphology. Figure 5.3 (d) also 
showed that were some less well-defined cells had appeared, in this situation, the 
problem was not only raised by the cytotoxicity of compound 7 under a prolonged 
incubation, but also involved an overgrowth issue, which could further have elevated 
the oxidative stress effects and break the homeostasis of the cells.     
b. a. c. 
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Figure 5. 3. Confocal microscopy images of Chinese hamster ovary (CHO) cells treated with 
100 µM of compound 7 in 1% DMSO, incubated at 37 ºC for 1 hour. Followed by a 15 minute 
treatment with Hoechst. The sample was excited at 488 nm wavelength. Image (a) was merged 
image of images (b), (c) and (d). Image (b) was captured at > 450 nm wavelength, Image (c) 
was green fluorescence channel. Image (d) represented for image took from DIC. Scale bar: 20 
µm. 
 
Figure 5.4 represents the confocal microscopy images of HeLa cells treated with 
compound 4. As seen in Figure 5.4 (a) and (b), compound 4 could pass through the cell 
membrane, but the distribution of fluorescence was similar to that of compound 7. The 
fluorescence emission is observed as spread across the cytoplasm and there was no 
b. a. 
c. d. 
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prove that compounds across the cytoplasm into cell nucleus. Although the morphology 
of cells altered slightly (the surface of the cells became less well defined), the integrity 
of the nuclei were unchanged (Figure 5.4 c). Therefore, cells appeared to remain alive 
with the duration of the observation. Perhaps the poorer definition observed could be 
explained accumulation of compound 4 on the surface of the cell membrane. This 
phenomenon could also be observed in Figure 5.4 (a) and (b), there was a significant 
amount of compound 4 aggregated on the surface of cells due to the solubility problem, 
this aggregation could interrupt the structure of the cell membrane and cause damages 
to the morphology. A diluted concentration might help to improve the quality of the 
image. In conclusion, a replacement of the diamine linker in the fluorophore used would 
not affect the permeability of the fluorescent sensor, but this change of linker seemed 
to reduce the membrane damage caused by compound 7. Further LDH assays could 




Figure 5. 4. Confocal microscopy images of HeLa cells treated with 100 µM of compound 4 
in 1% DMSO, incubated at 37 ºC for 15 minutes. The sample was excited at 488 nm wavelength 
and long-pass filtered at 515 nm. Image (a) was merged image of images (b) and (c). Image (b) 
was green fluorescence channel. Image (c) represented for image took from DIC. Scale bar: 20 
µm 
  
Figure 5.5 (b) and 5.6 (b) represents the HeLa cells imaged after treating with 
compounds 7 and compound 4 respectively. Furthermore, after incubation with these 
compounds, a Lysotracker (red) dye was applied to both dishes of cells. Lysosome red 
tracker is a red dye that stains lysosomes in cells and emits a red fluorescent signal at 
590 nm wavelength. As seen in the results, both cells showed a well distributed of 
b. a. c. 
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Lysotracker in the cytoplasm in Figure 5.5 (c) and 5.6 (c). HeLa cells with compound 
7 had undamaged morphology and intact nuclei, which indicate compound 7 and 
lysotracker did not cause any disruptions towards cells. Whilst in Figure 5.6, the 
aggregation of compound 4 appeared again on the cell membrane and that the 
fluorescence of the compounds and lysotracker gathered in corresponding areas of the 
cytoplasm, these altogether indicate distribution of fluorescent samples and 
morphology of cells. The results clearly showed that compound 4, 7 and lysotracker 
were absorbed by cells, in Figure 5.5, compound 7 emitted a green signal (Figure 5.5 
b), and lysotracker gave a red fluorescence (Figure 5.5 c), thus a merged image of (b) 
and (c) exhibited in yellow, which indicate compound 7 stained lysosome as well. 
Compound 4 behaved in a similar manner to compound 7, as shown in Figure 5.6, 




  Chapter 5. In vitro fluorescence imaging of 









Figure 5. 5. Confocal microscopy images of HeLa cells treated with 100 µM of compound 7 
in 1% DMSO, incubated at 37 ºC for 1 hour. Followed by a 15 minute treatment with 
Lysotracker Red. The sample was excited at 488 nm. Image (a) merged image of images (b), 
(c) and (d). Image (b) long-pass filtered at 515 nm, Image (c) long-pass filtered at 605 nm. 






  Chapter 5. In vitro fluorescence imaging of 








Figure 5. 6. Confocal microscopy images of HeLa cells treated with 100 µM of compound 4 
in 1% DMSO, incubated at 37 ºC for 1 hour. Followed by a 15 minute treatment with 
Lysotracker Red. The sample was excited at 488 nm. Image (a) was the merged image of 
images (b), (c) and (d). Image (b) long-pass filtered at 450 nm, Image (c) green fluorescence 
channel. Image (d) represented for image took from DIC. Scale bar: 20 µm. 
 
5.3. Cellular imaging of biotin-boronic acid based fluorescent 
sensors attached onto -D-glucan and -D-glucan functionalised 
SWNTs 
This section describes the series of confocal microscopy cell images captured using 
compound 7 after its attachment to -D-glucan or -D-glucan @ SWNTs nanomaterials. 
Together with HeLa and PC-3, additional cell line (CHO, Chinese Hamster Ovarian) 




b. a. c. 
c. d
. 
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Figure 5. 7. Confocal microscopy images of HeLa cells treated with 100 µM of compound 7 
functionalised with 1 mg/mL -D-glucan in 1% DMSO, incubated at 37 ºC for 15 minutes. The 
sample was excited at 488 nm and long-pass filtered at 515 nm. Image (a) was the merged 
image of images (b) and (c). Image (b) green fluorescence channel. Image (c) represented for 
image took from DIC. Scale bar: 20 µm. 
 
Figure 5.7 represents the confocal images captured from cells incubated with 
compound 7 @-D-glucan. The result clearly shows that compound 7 @glucan could 
pass though the cell membrane and enter the nuclei, moreover the shape of the cell 
membrane and the nuclear membrane were still intact, i.e. the structure of cells remains 
unchanged. In addition, there was significant fluorescence observed on the surface of 
the cells, which might be due to the solvent system change from DMSO to serum free 
medium environment, resulting in aggregation of -D-glucan to form a cluster too large 
to endocytose. As a conclusion compound 7 @glucan had good cell permeability and 




Figure 5. 8. Confocal microscopy images of CHO cells treated with 100 µM of compound 7 
functionalised with 1 mg/mL -D-glucan in 1% DMSO, incubated at 37 ºC for 15 minutes. The 
sample was excited at 488 nm and long-pass filtered at 515 nm. Image (a) was the merged 
image of images (b) and (c). Image (b) green fluorescence channel. Image (c) represented for 
image took from DIC. Scale bar: 20 µm. 
 
As seen in Figure 5.8, HeLa cells were replaced by CHO cells in these 
experiments. It has been observed that compound 7 @glucan does enter CHO cells, 
however, most of the compounds remains attached to the cell membrane and only a 
small amount of the compound migrated into the cytoplasm. This might be due to the 
type of cells in Figure 5.8 being different from that in Figure 5.7, therefore, the uptake 
b. a. c. 
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rate of compounds and glucan could be distinct. The shape of cells was well defined 
that indicated cells remained healthy and undamaged.  Thereby, compound 7 @glucan 
showed a major difference depending on the types of cell line (HeLa cell line VS the 
CHO cell line). 
 
Figure 5. 9. Confocal microscopy images of CHO cells treated with 50µL of 20 mM compound 
7 functionalised with 1 mg/mL -D-glucan wrapped SWNTs (1:1) in water, incubated at 37 ºC 
for 15 minutes. The sample was excited at 488 nm and long-pass filtered at 515 nm. Image (a) 
was the merged image of images (b) and (c). Image (b) green fluorescence channel. Image (c) 
represented for image took from DIC. Scale bar: 20 µm. 
 
Figure 5.9 displays confocal images of CHO cells treated with compound 7 
@glucan @ SWNTs. Compounds were dispersed in water, thus stock samples could be 
applied to more than 1% of the total volume on the cell plate. As a result of increase in 
the concentration of the sample, there was significantly greater uptake, this therefore 
enhanced the fluorescent intensity and the cytotoxicity inside cells. Thereby, compound 
7 @glucan @SWNTs distributed all over the cell, it was believed to have entered the 
nucleus. Subsequently, cells become unstable and cells morphology altered slightly, 
which indicate that cells could not tolerate this amount of compounds. The aggregation 
of compound nearby cells could also demonstrate there were excess samples in the 
environment. In conclusion, the compound 7 @ glucan @SWNTs could facilitate 
compound 7 into the cytoplasm. Dispersed 1 mg/mL compound 7 @ glucan @SWNTs 
in water was a good way to reduce the cytotoxicity of compound 7 @ glucan @SWNTs, 
but excess of samples could still cause harmful effect to cells. 
 
b. a. c. 
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Figure 5. 10. Confocal microscopy images of CHO cells treated with 100 µM of compound 9 
functionalised with 1 mg/mL -D-glucan wrapped SWNTs in water, incubated at 37 ºC for 15 
minutes. The sample was excited at 488 nm and long-pass filtered at 515 nm. Image (a) was 
the merged image of images (b) and (c). Image (b) green fluorescence channel. Image (c) 
represented for image took from DIC. Scale bar: 20 µm. 
 
Compound 9 was a compound found through the alternative synthetic route 
from the compound 7 synthesis, which was formed at the end of Route two in the system 
shown in scheme 2.6. The compound 9 was considered as a precursor of compound 7. 
The newly synthesised compound 9 and used as a comparison for compound 7. In this 
experiment, compound 9 @ glucan @SWNTs was incubated with CHO cells at 37 ºC 
for 15 minutes. The results showed that compound 9 @ glucan @SWNTs could not 
pass through the cell membrane and did not enter the cells, the intensity of the 
fluorescence in Figure 5.10 (b) indicated that most of compound 9 @ glucan @SWNTs 
were rinsed away. The remaining compounds, accumulated on the CHO cell membrane 
and there was only a slight sign for the aggregation of compound 9 @ glucan @SWNTs 
on the cell surface. As a result, the observed cellular damage introduced by compound 
9 was not as evident as that showed in in Figure 5.9.  
In conclusion, introduction of boronic acid group does not only affect the 
effectiveness of this types of fluorophores functionalised onto the glucan wrapped 
SWNTs, but also influences greatly the permeability of compounds through the cell 
membrane.  Notably, fluorescein alone is shown not to be taken up by cells in the 
absence of extensive functionalisation.1 
b. a. c. 
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5.4. Cell imaging of biotin-boronic acid based fluorescent sensors 
under different environmental conditions 
Aliquots of compound 7 and compound 7 @glucan were added to cells, and incubated 
at different temperatures and over different period of times to investigate how these 
conditions might affect the compounds’ uptake and to assess any damages in the 




Figure 5. 11. Confocal microscopy images of CHO cells treated with 100 µM of compound 7 
in 1% DMSO, incubated at 37 ºC for 15 minutes. The sample was excited at 488 nm and long-
pass filtered at 515 nm. Image (a) was the merged image of images (b) and (c). Image (b) green 
fluorescence channel. Image (c) represented for image took from DIC. Scale bar: 20 µm 
This series of imaging experiments started with CHO cells treated with 
compound 7 at 37 ºC for 15 minutes (Figure 5.11). The results clearly show that most 
compounds accumulated on the surface of cell membrane in Figure 5.11 (a). This might 
due to a low concentration of compound or due to the fact that there was not enough 
incubation time, considering the number of cells visible in the picture below. However, 
the cells’ morphology was undamaged and the shape of cells was well defined.  
 
b. a. c. 
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Figure 5. 12. Confocal microscopy images of HeLa cells treated with 100 µM of compound 7 
in 1% DMSO, incubated at 37 ºC for 1 hour. The sample was excited at 488 nm and long-pass 
filtered at 515 nm. Image (a) was the merged image of images (b) and (c). Image (b) green 
fluorescence channel. Image (c) represented for image took from DIC. Scale bar: 20 µm. 
 
In Figure 5.12, HeLa cells were treated with compound 7 for one hour at 37 ºC, in order 
to examine whether a prolonged incubation of compound 7 would affect the state of the 
cells. As displayed in Figure 5.12 (b), compound 7 successfully entered the cell 
membrane, and in some of the cells, compound 7 also appeared to stain the nuclei. 
However, the morphology of cells became unstable when compared to Figure 5.11 (c). 
The cell membrane became indistinct and some cells detached from dishes. All these 
results indicated that prolonged incubation of compound 7 would increase the intensity 
of fluorescence in HeLa cells and simultaneously increase the toxicity of compound 7 
towards HeLa cells. 
Subsequently, the temperature of the incubation condition dropped from 37 ºC 
to 4 ºC. Regarding the uptake method of compound 7 in cells, there could be three 
different pathways to uptake compound 7; including (a) diffusion (b) active transfer 
and (c) endocytosis. However, the active transfer and endocytosis are known to be 
inhibited by the low temperature, 2-4 and diffusion could occur at a slow rate.5, 6 Then, 
compound 7 was loaded again (with new cells) to test whether there were any difference 
caused by temperature. The result displayed in Figure 5.13 (b) clearly showed that 
fluorescent signal was detected, but unlike data showed in Figure 5.13 (b), the 
compound 7 did not distributed across cells, and most of the fluorescent signals were 
emitted nearby the cell membrane instead. This phenomena indicated that a decrease in 
b. a. c. 
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temperature can lead to a decrease in the rate of uptake. As for the morphology of cells, 
although the shape of cells was intact, the surface of the cell membrane became ill-
defined during the observation. Thus this demonstrated some problems had occurred 
due to accumulation on the cell membrane which affected the quality of the image 
captured or disrupted the structure of the cell membrane.  From these experiments it is 
possible to conclude that compound 7 has either entered the cell membrane or has 
accumulated on top of it. Due to the slightly less distinct nature of the cell membrane it 
may be more likely that the compound is on top of the cell membrane rather than in it. 





Figure 5. 13. Confocal microscopy images of HeLa cells treated with 100 µM of compound 7 
in 1% DMSO, incubated at 4 ºC for 15 minutes. The sample was excited at 488 nm and long-
pass filtered at 515 nm. Image (a) was the merged image of images (b) and (c). Image (b) green 
fluorescence channel. Image (c) represented for image took from DIC. Scale bar: 20 µm. 
 
Similarly to the case shown in Figure 5.13, a prolonged incubation experiment was 
repeated. In Figure 5.14 HeLa cells were treated with compound 7 at 4 ºC for 60 minutes. 
After 60 minutes, compound 7 remained on or in the cell membrane. However, the 
distribution of fluorescence and morphology of the cells seems didn’t change compared 
with cells in figure 5.13 (b). it indicated that a low temperature would not cause damage 
to the cells in a short period of time and slow the absorption of compound 7. 
b. a. c. 
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Figure 5. 14. Confocal microscopy images of HeLa cells treated with 100 µM of compound 7 
in 1% DMSO, incubated at 4 ºC for 60 minutes. The sample was excited at 488 nm and long-
pass filtered at 515 nm. Image (a) was the merged image of images (b) and (c). Image (b) green 




Figure 5. 15. Confocal microscopy images of HeLa cells treated with 20µL of 10 mM 
compound 7 functionalised with 1 mg/mL -D-glucan in 1% DMSO, incubated at 37 ºC for 15 
minutes. The sample was excited at 488 nm and long-pass filtered at 515 nm. Image (a) was 
the merged image of images (b) and (c). Image (b) green fluorescence channel. Image (c) 
represented for image took from DIC. Scale bar: 20 µm. 
 
 The following four imaging experiments described in (Figure 5.15-5.18) 
represent HeLa cells treated with compound 7 @glucan, but instead of 10 µL, 20 µL of 
the compound was applied to cells in these experiments. (Figure 5.8) 
 The results in Figure 5.15 clearly showed compound 7 @ glucan could pass 
through the membrane and also access to nuclei.  Obviously, there were many intensive 
fluorescence signals appeared in cells. These were believed to be aggregated compound 
7 @ glucan attached inside the cell. Simultaneously, most of cells retained their shape, 
b. a. c. 
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this indicated that compound 7 @ glucan has limited toxicity to this cell line at 37 ºC 
within 15 minutes observation. 
   
 
 
Figure 5. 16. Confocal microscopy images of HeLa cells treated with 20µL of 10 mM 
compound 7 functionalised with 1 mg/mL -D-glucan in 1% DMSO, incubated at 37 ºC for 60 
minutes. The sample was excited at 488 nm and long-pass filtered at 515 nm. Image (a) was 
the merged image of images (b) and (c). Image (b) green fluorescence channel. Image (c) 
represented for image took from DIC. Scale bar: 20 µm. 
 
 Figure 5.16 showed the results of a prolonged incubation of compound 7 @ 
glucan for 60 minutes at 37 ºC.  There was a significant change in the morphology of 
the cells, most of cells became unstable and began to die. The fluorescence of the cells 
in 5.16 (b) indicated that the structure of cell nuclei was also altered, likely leading to 
an interruption of the nuclei’s normal function and resulting in a moderate damage of 
cells’ morphology.   
 
 
b. a. c. 
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Figure 5. 17. Confocal microscopy images of HeLa cells treated with 20µL of 10 mM 
compound 7 functionalised with 1 mg/mL -D-glucan in 1% DMSO, incubated at 4 ºC for 15 
minutes. The sample was excited at 488 nm and long-pass filtered at 515 nm. Image (a) was 
the merged image of images (b) and (c). Image (b) green fluorescence channel. Image (c) 
represented for image took from DIC. Scale bar: 20 µm. 
 
The results in Figure 5.17 demonstrated experiment which incubated cells with 
2% of compound 7 @glucan at 4 ºC, the hypothesis is there were less uptake of 
compositions at low temperature. In fact, there were less absorption of compound 7 
@glucan observed in Figure 5.17 compared with the outcome as shown in Figure 5.16, 
although compound 7 @ glucan still enter cells, with some appearing to enter the 
nucleoli. The overall morphology of cells, however looked better than that in Figure 
5.16 (c). Although there were cells in a poor morphological state, there were no cell 
structures collapsed in the picture. Therefore, a reduced temperature method of 
incubation not only decreased the uptake rate of compounds, but also decreased the 
cytotoxicity effect of compounds. As a result of the slow uptake, compound 7 @ glucan 
aggregated outside cells and then accumulated on the cell membrane or diffused into 
cells, thereby there were more fluorescence signals on the cell membrane or emitted 




Figure 5. 18. Confocal microscopy images of HeLa cells treated with 20µL of 10 mM 
compound 7 functionalised with 1 mg/mL -D-glucan in 1% DMSO, incubated at 4 ºC for 60 
minutes. The sample was excited at 488 nm and long-pass filtered at 515 nm. Image (a) was 
the merged image of images (b) and (c). Image (b) green fluorescence channel. Image (c) 
represented for image took from DIC. Scale bar: 20 µm. 
  
b. a. c. 
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In Figure 5.18, HeLa cells were incubated with compound 7 @ glucan for 60 
minutes, the intensity of fluorescence increased as the increment of incubation time, 
because more of the compound available on the plate was absorbed into cells cytoplasm 
or remained attached onto the cell membrane. However, it was surprising that even a 
prolonged incubation of cells with these compounds did not cause many cells to die. As 
it was described in Figure 5.16. This result further suggested that the low temperature 
incubation techniques would significantly reduce the cytotoxic effect to cells, even over 
prolonged periods of incubation.  
 
5.5. Fluorescence-lifetime imaging microscopy (FLIM) data 
of boronic acid-based fluorescent sensors 
Two-photon fluorescence lifetime imaging (FLIM) is an imaging technique which  
combined with laser confocal microscopy, has the ability to build on the information 
resulting from a highly sensitive single-photon counting lifetime measurements to 
examine the fluorescence intensity, distribution and lifetime of small molecules in cells. 
The fluorescence lifetime is an invaluable datum obtained from this technique, which 
is characteristic to an individual fluorescence molecule. The stability of the excited state 
and therefore the fluorescent lifetime, may be affected by interactions with intracellular 
ions or oxygen, conformational changes caused by binding to other molecules or pH 
difference in the environment during the experiment. As a result, FLIM is also an ideal 
tool to study the aggregation, viscosity and distance between molecules.  
 FLIM was used in this project to investigate the lifetime of various fluorophores 
and its interactions with other molecules or ions. Experiments began with testing the 
lifetime of compounds in solvent (Time Correlated Single-Photon Counting, TCSPC),7, 
8 followed by an in vitro FLIM investigation.9 These experiments were performed at 
the Rutherford Appleton Laboratory (RAL) in central Laser Facilities (CLF) and 
assisted by Prof S. W. Botchway, Dr P Burgos, Mr A. McKenzie and Mr A. Henman.10 
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Table 5. 1. Two-photon Time Correlated Single Photon Counting data of fluorescein, 
compound 4 and compound 7 at 10 mM concentration in DMSO, the laser for both fluorescein 
and compound 4 were excited at 810 nm, and for compound 7 was excited at 910 nm, laser 
power was in between 4.0 – 7.0 mW.    
 
Compound Fluorescein Compound 4 Compound 7 
Solvent system DMSO DMSO DMSO 
2 1.11 1.17 1.13 
1 (ns) 3.9 1.3 0.9 
1 % 100 59.1 81.7 
2 (ns) - 3.2 4.3 
2 % - 40.9 18.3 
 
A series of compounds, including fluorescein, compound 4 and compound 7, 
were tested by TCSPC and the results are displayed in Figure 5.19. Each photon 
detected and collected in TCSPC would be plotted to calculate the lifetime of 
fluorescence. The results obtained from TCSPC consists of three parts, a chi square, 
lifetime and lifetime percentage, if more than one component was modelled. As seen in 
Figure 5.19, fluorescein only had one lifetime, which was 3.9 ns, which represents the 
duration within which this molecule existed in an excited state. Whereas, both 
compound 4 and 7 contained two components, which meant there were more than one 
component that was fluorescent and the fluorescence lifetimes were individually 
different.  
  Chapter 5. In vitro fluorescence imaging of 









Figure 5. 19. TCSPC decay curves for commercially available fluorescein, compound 4 and 
compound 7 at 10 mM concentration in DMSO, the laser for both fluorescein and compound 4 
were excited at 810 nm, and for compound 7 was excited at 910 nm, laser power was in between 
4.0 – 7.0 mW.      
 
This variation between components could be due to several reasons, for instance, 
existence of isomers, conformation change in the solvent, or pH-dependent protonated 
and un-protonated analogues of a molecule. The percentage of lifetime given represents 
the portion of lifetime individual results contributed to the overall lifetime (m). As for 
the chi squared, there are three different range of χ2 values in the results, the best χ2 
value is 1.0, which indicates an optimal fitting. Then when χ2 value is in between 1.0 
and 1.3 demonstrates incomplete single exponential fit, whilst χ2 value is greater than 
1.5, indicates there was significant noise within the TCSPC setup or more than on 
component decay profile. Therefore, all results in Table 5.1 are reliable. Due to the 
structural similarities, compound 4 and 7 would carry a similar lifetime to fluorescein, 
thus the lifetimes of compound 4 and 7 were 2 = 3.2 ns (40.9%) and 2 = 4.3 ns (18.3%) 
respectively. Because of the high purity of the sample a single component was expected, 
however it can be speculated that a second conformation of the compound was present 















 Compound 4 fit curve: 
         
 Fluorescein
 Fluorescein fit curve: 

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due to interactions with the solvent (e.g. polarity effects, protonation/deprotonation 
etc.). Therefore, 1 = 1.3 ns (59.1%) and 1 = 0.9 ns (81.7%) for compound 4 and 
compound 7 respectively.  
 
Table 5. 2. Two-photon Time Correlated Single Photon Counting data of compound 7 at 10 
mM in DMSO, compound 7 @glucan at 1mg/mL in DMSO, compound 7 @glucan @SWNTs 
at 1mg/mL in water and compound 9 @glucan @SWNTs at 1mg/mL in water. ex = 910nm, 




Compound 7 @ 
-D-glucan 
Compound 7@  
-D-glucan @SWNTs 




DMSO DMSO Water Water 
2 1.13 1.25 1.3 1.26 
1 (ns) 0.9 1.0 3.6 3.5 
1 % 81.7 56.5 100 100 
2 (ns) 4.3 2.8   
2 % 18,3 43.5   
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Figure 5. 20. TCSPC decay curves for compound 7 at 10 mM in DMSO, compound 7 @glucan 
at 1mg/mL in DMSO, compound 7 @glucan @SWNTs at 1mg/mL in water and compound 9 
@glucan @SWNTs at 1mg/mL in water. ex = 910nm, laser power was in between 2.5 – 8.7 
mW. 
 
In Figure 5.20, 10 mM compound 7, 10 mM compound 7 @ -D-glucan in 1% 
DMSO and 10 mM compound 7 @ -D-glucan @ SWNTs (1:1) in water were tested 
by TCSPC. Two components were found to be in both compound 7 (1 = 0.9 ns, 2 = 
4.3 ns) and compound 7 @ glucan (1 = 1.0 ns, 2 = 2.8 ns), 1 of compound 7 and 
compound 7@glucan were slight differ in DMSO, it is not only because of interactions 
with the solvent, but also compound 7 bind to glucan lead to a conformational change. 
Compound 7 has a 4.3 ns lifetime and inducing from glucan therefore slightly 
accelerates the lifetime of compound 7 to 2 = 2.8 ns. It indicated the lifetime of excited 
state of compound 7 @ glucan is less than compound alone in DMSO, hence the 
fluorescence of compound 7 @glucan returned to the ground state faster. Because 
compound 7 @glucan @SWNTs were dispersed in water, the polarity of solvent 




 Compound 9 @-D-glucan @ SWNTs







 Compound 7 @-D-glucan @ SWNTs
 Compound 7 @-D-glucan @ SWNTs fit curve
          

 Compound 7
 Compound 7 fit curve 
 Compound 7 @-D-glucan
 Compound 7 @-D-glucan 
          fit curve: 
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increased in the water could resulted in one component model was favoured for 
compound 7 @glucan @SWNTs and compound 9 @glucan @SWNTs.  
 
Figure 5. 21. FLIM images of cells treated with 100 µM of compound 4 or 7 in 1% DMSO, 
cells were incubated at 37 ºC where (a) two photon fluorescence intensity diagram of compound 
4 in HeLa cells, (b) the fluorescence lifetime map of m of compound 4 in HeLa cells (c) two 
photon fluorescence intensity diagram of compound 7 in HeLa cells, (d) the fluorescence 
lifetime map of m of compound 7 in HeLa cells, (e) two photon fluorescence intensity diagram 
of compound 7 in CHO cells and (f) the fluorescence lifetime map of m of compound 7 in CHO 
cells. 
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Figure 5.21 represents the two photon FLIM mapping and intensities, which 
allow comparisons between compounds 4 and 7, in HeLa and CHO cells. Each 
experiment was modelled to fit two components, the fluorescence observed from the 
fluorescence lifetime map was represented by the fluorescence lifetime intensity map 
and its fluorescence lifetime map, whereby the colour indicates the lifetime (red 
signifies a shorter and blue is a longer lifetime), which are used to calculate the mean 
m.  
From the Figure 5.21 (a) and (c), it can be observed that compound 4 enters the 
cells as well as appearing to accumulate on the cell surface. In comparison, however, 
images of compound 7 in cells are much brighter, indicating either significantly better 
uptake of compound 7, or quenching of compound 4. In Figure 5.21 (c) there was no 
obvious sign of compound 7 precipitating on the surface of the cells, however, 
compound 7 also disturbed the normal function of cells, thus cells looked less healthy 
than cells in Figure 5.21 (a). Subsequently, a comparison could be made between Figure 
5.21 (c) and (e), which indicated that compound 7 could enter both HeLa and CHO cell 
lines.  
The fluorescence lifetime map was used to display the fluorescence distribution 
across the whole diagram’s field of view. This fluorescence map explored the overall 
fluorescence lifetime (m), individual lifetime (1 and 2) and their portion of 
contribution to the overall fluorescence. The fluorescence lifetime map summarised 
each individual fluorescence detected from the cells and their environment, thus to fully 
analyse of each individual spot on the maps was not appropriate.  
Table 5.3 and figure 5.22 together exhibited the corresponding fluorescence 
lifetimes obtained from the cell FLIM data.  First of all, a 2 value of approximately 1 
indicated these data were reliable results. Then the lifetime of compound 4 in HeLa was 
found to be 2 = 3.4 ns, 51.9 %, FWHM was 1.2 ns. The full width at half maximum 
(FWHM) was calculated from the lifetime distribution curve (Figure 5.23) and it is a 
distance between points on the curve at which half its maximum value was reached. 
The results of FWHM were used to assess the error. The smaller the FWHM, the sharper 
the peak is, hence, the more reliable the data is. Compared with compound 4 in solvent, 
which was 2 = 3.2 ns, 40.9% in Table 5.1. Because the value of 3.4 ± 1.2 ns is covered 
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in the range of 2.2 ns – 4.6 ns (error range), it undoubtedly showed that there was no 
significant change in the fluorescence lifetime once compound 4 entered cells. Whereas, 
1 = 1.3 ns was dropped remarkably to 0.6 ± 0.6 ns, due to compound 4 interacted with 
the complicated cellular environment in cells. By contrast, compound 7 changed 
significantly in lifetime when it was applied in HeLa cells. 2 reduced from 4.3 ns to 
3.1 ± 0.5 ns, FWHM of compound 7 in HeLa was 0.5 ns. However, the lifetime of 
compound 7 changed slightly to 3.8 ± 1.8 ns once it was applied to CHO cell lines. It 
again indicated there was no considerable change in fluorescence lifetime when 
compound 7 was absorbed by CHO cells.  
 
Table 5. 3. FLIM data of compound 4 and compound 7 at 100 µM in DMSO in different cell 
lines. The laser for compound 4 was excited at 810 nm, and for compound 7 was excited at 910 
nm, laser power was in between 4.3 – 7.0 mW.  
 
Compound Compound 4 Compound 7 Compound 7 
Cell line HeLa HeLa CHO 
2 1.10 1.03 1.02 
1 (ns) 0.6 0.9 0.8  
1 % 48.1 45.0 24.9 
FWHM (ns) 0.6 0.5 0.5 
2 (ns) 3.4 3.1 3.8 
2 % 51.9 55.0 75.1 
FWHM (ns) 1.2 0.5 1.8 
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Figure 5. 22. FLIM decay curves for compound 4 and 7 in HeLa and CHO cell line in 




Figure 5. 23. Fluorescence lifetime distribution curve of compound 4 and 7 in HeLa and 
CHO cells 




 Compound 4 in HeLa
 Compound 4 in HeLa fit curve
 Compound 7 in HeLa
 Compound 7 in HeLa fit curve
 Compound 7 in CHO
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Figure 5.23 shows three fluorescence lifetime distribution curves, these were 
the overall fluorescence summarised from Figure 5.21 (b), (d) and (f). From the plot, it 
can be easily observed that the fluorescence lifetime distribution of compound 4 was in 
the range between 0 and 4.0 ns, compound 7 in HeLa was within 1.0 to 3.0 ns and 
compound 7 in CHO was in between 1.25 ns and 4.75 ns. The distribution of lifetime 
in this curve was based on the corresponding components, i.e. the proportion of 
individual lifetime. For example, 75.1 % of the overall lifetime (τm) in compound 7 in 
CHO was 3.8 ns, which draws the blue lifetime distribution curve towards 3.5 ns. The 
other reason to plot the lifetime distribution curve was it could be used to estimate the 
FWHM in order to access the error of m. 
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Figure 5. 24. FLIM images of cells treated with 10 µL of 10 mM compound 7 with 1 mg/mL 
-D-glucan in 1% DMSO, 20 mM compound 7 with 1 mg/mL glucan and 1 mg/mL of SWNTs 
in water or 20 mM compound 9 with 1 mg/mL glucan and 1 mg/mL of SWNTs in water, cells 
were incubated at 37 ºC where (a) two photon fluorescence intensity diagram of compound 7 
@glucan in CHO cells, (b) the fluorescence lifetime map of m of compound 7 @glucan in 
CHO cells (c) two photon fluorescence intensity diagram of compound 7 @glucan @SWNTs 
in CHO cells, (d) the fluorescence lifetime map of m of  compound 7 @glucan @SWNTs in 
CHO cells, (e) two photon fluorescence intensity diagram of compound 9 @glucan @SWNTs 
in HeLa cells and (f) the fluorescence lifetime map of m of compound 9 @glucan @SWNTs 
in HeLa cells. 
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Another three samples were tested by FLIM, namely, Compound 7 @ glucan, 
Compound 7 @ glucan @SWNTs and Compound 9 @ glucan @SWNTs. From the 
microscopy results displayed in Figure 5.24, each compound show different behaviour 
different. In Figure 5.24 (a), CHO cells were treated with Compound 7 @ glucan, 
compared the result exhibited in 5.24 (c), similarly, the fluorescence lifetime mainly 
distributed in the cytoplasm from the fluorescence lifetime map, however, the 
brightness of the colour was significantly reduced in 5.24 (c), which indicated a longer 
lifetime, i.e. quench effect induced by SWNTs. Lifetimes were calculated from each 
pixels of the fluorescence image. As seen in Figure 5.24 (d), Compound 7 @ glucan 
@SWNTs enters cells and fluorescence lifetimes were mostly calculated from 
cytoplasm, but it seemed compound 7 suffered a quenching effect from SWNTs, hence, 
the lifetime of fluorescence was remarkably decreased. At the same time, due to the 
aggregation problems caused by SWNTs, there were an obvious accumulation of 
composition on the cell membrane and it was highly fluorescent (Figure 5.24 d), the 
fluorescence lifetime discovered in cells was close to the lifetime of Compound 7 @ 
glucan @SWNTs in solvent. It indicated the fluorescence lifetime of Compound 7 @ 
glucan @SWNTs did not change remarkably in the cellular environment. The results 
displayed in Figures 5.24 (e) and (f) showed a totally different result compared with 
previous compounds and compositions. Compound 9 was carried by glucan @SWNTs 
and entered HeLa cells, but unlike other samples, which gave an evenly distributed 
fluorescence lifetime in the cytoplasm, it spread randomly in cells instead. There were 
two hypothesis made, one was cells died during the experiment, so compositions 
located unregularly. The other one was the amount of compositions carried by glucan 
@SWNTs was not enough to distribute across the whole cytoplasm, hence, the pattern 
of distribution presented in the fluorescence mapping looked like compositions 
aggregated in specific regions of the cell. 
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Table 5. 4. Two-photon Time Correlated Single Photon Counting data of compound 7 at 100 
µM in DMSO, compound 7 @glucan @SWNTs at 10 µg/mL in water and compound 9 
@glucan @SWNTs at 10 µ g/mL in water in different cell lines. ex = 910 nm, laser power was 
in between 2.5 – 8.7 mW. 
 
Compound Compound 7 @ 
glucan 
Compound 7 @ 
glucan @SWNTs 
Compound 9 @ 
glucan @SWNTs 
Cell line CHO CHO HeLa 
2 1.01 1.10 1.25 
1 (ns) 1.8 0.9 0.8  
1 % 39.4 39.3 80.1 
FWHM (ns) 0.5 0.5 1.1 
2 (ns) 4.0 3.3 3.3 
2 % 60.6 60.7 19.9 





Figure 5. 25. FLIM decay curves for compound 7 at 100 µM in DMSO, compound 7 @glucan 
@SWNTs at 10 µg/mL in water and compound 9 @glucan @SWNTs at 10 µ g/mL in water 
in HeLa and CHO cell line. ex = 910 nm, laser power was in between 2.5 – 8.7 mW. 





 Compound 7 @glucan in CHO
 Compound 7 @glucan in CHO fit curve
 Compound 7 @glucan @SWNTs in CHO
 Compound 7 @glucan @SWNTs in CHO fit curve
 
 Compound 9 @glucan @SWNTs in HeLa
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 Figure 5.25 and Table 5.4 displayed the corresponding lifetime and lifetime 
related information to Figure 5.25. The first and most important parameter observed 
from the table was the 2 value. Each value was approximately 1, therefore all data 
listed on this table are considered statistically reliable. Then, the lifetime from these 
experiment were compared. There was an increase from 2.8 ns to 4.0 ±1.8 ns in the 2 
lifetime of compound 7 @ glucan when it had been moved from DMOS solvent system 
into CHO cells (Table 5.2). This expected results mainly due to ions, biomolecules 
(sugar, proteins etc.) existed in the cells, which could bind to compound 7 @glucan and 
caused a conformational change of the structure, which prolonged the fluorescence 
lifetime and result in an increase of the fluorescence lifetime. Likewise, the lifetime of 
compound 7 in CHO cells was 3.8 ± 1.8 ns (Table 5.3), which was not much different 
from 4.0 ± 1.8 ns. Thus it was indicated that introduction of glucan did not introduce a 
dramatic changes in the fluorescence lifetime in the same cell line and shift of solvent 
system would cause a considerable change in the fluorescence lifetime. Both 
Compound 7 @ glucan @SWNTs and Compound 9 @ glucan @SWNTs had similar 
fluorescence lifetimes in water and cells, however, the lifetime proportion in cells 
varied. Both samples have two components in cell FLIM. Compound 7 @ glucan 
@SWNTs’ lifetime changed from 3.6 ns (100%) in water to τ1=0.9 ± 0.5 ns (39.4%, 
FWHM 0.5 ns), τ2=3.3 ± 1.6 ns (60.7%, FWHM 1.6 ns) in CHO cells, whereas the 
lifetime of compound 9 @ glucan @SWNTs decreased sharply from 3.5 ns(100%) in 
water to τ1=0.8 ± 1.1 ns (80.1%, FWHM 1.1 ns), τ2=3.3 ± 1.4 ns (19.9%, FWHM 1.4 
ns) in HeLa cells.  
Figure 5.26 represented the fluorescence lifetime distribution of compound 7 @ 
glucan in CHO, compound 7 @ glucan @SWNTs in CHO and compound 9 @ glucan 
@SWNTs in HeLa cells. The range of lifetime for three samples were distinct from 
each other, compound 7 @ glucan had the most wide range from 0 to 5 ns and also had 
two peaks at 1.8 ns and 3.3 ns respectively, it might be due to binding to a protein in 
cells to give a second fluorescence lifetime peak. Compound 7 @ glucan @SWNTs 
stayed in the range of 1 to 4 ns and peaked at 2.5 ns. Whilst Compound 9 @ glucan 
@SWNTs ranged from 0 to 2.6 ns and had a rough peak at 0.7 ns. Compound 7 @ 
glucan displayed the most fluorescent signals, compound 7 @ glucan @SWNTs ranked 
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second, Compound 9 @ glucan @SWNTs had the least fluorescence signals, indicating 
that SWNTs functionalised with compound 7 @ glucan are better suited for imaging 




Figure 5. 26. Fluorescence lifetime distribution curve of compound 7 and 9 composition in 
different cell lines. ex = 910 nm, laser power was in between 2.5 – 8.7 mW. 
 
5.6. FLIM data of boronic acid-based fluorescent sensor under 
various conditions 
Figure 5.27 to 5.32 show the fluorescence lifetime images corresponded to all confocal 
images listed in chapter 5.4, which studied how fluorescence differentiated in varies 
conditions. Figure 5.27 focus on the lifetime changes of compound 7 in distinct 
circumstances. Whereas 5.31 mainly explored the lifetime alteration of compound 7 
@glucan.  
Images exhibited in Figure 5.27 showed that after incubated cells with 100 µM 
of compound 7 at 37 ºC for 60 minute, fluorescence lifetime could be clearly observed 












 Compound 7 @glucan in CHO
 Compound 7 @glucan @SWNTs in CHO
 Compound 9 @glucan @SWNTs in HeLa
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from the cell cytoplasm. Images labelled Figure 5.27 (e) and (f) similarly supported the 
results represented in Figure 5.13, lifetime of compound 7 was revealed from the cell 
membrane, diffusion and moving speed inside cells were remarkably inhibited at 4 ºC 
in 15 minutes, which lead to a brighter colour (shorter lifetime) from the cell membrane 
and darker colour (longer lifetime) was detected from inside of cells.  
 
 
Figure 5. 27. FLIM images of HeLa cells treated with 100 µM compound 7 in 1% DMSO, cells 
were incubated at 37 ºC or 4 ºC for 15 minutes or 60 minutes. where (a) two photon fluorescence 
intensity diagram of compound 7 in HeLa cells (37 ºC, 60 minutes incubation), (b) the 
fluorescence lifetime map of m of  compound 7 in HeLa cells (37 ºC, 60 minutes incubation), 
(c) two photon fluorescence intensity diagram of compound 7 in HeLa cells (4 ºC, 15 minutes 
incubation) and (d) the fluorescence lifetime map of m of compound 7 in HeLa cells (4 ºC, 15 
minutes incubation), (e) two photon fluorescence intensity diagram of compound 7 in HeLa 
cells (4 ºC, 60 minutes incubation) and (f) the fluorescence lifetime map of m of compound 7 
in HeLa cells (4 ºC, 60 minutes incubation). 
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Because of the cold environment, some precipitations were detected in the 
image. The result found in 60 minutes (Figure 5.27 f) had no much different from 15 
min (Figure 5.27d) incubation at low temperature, fluorescence lifetime remained 
concentrated at the cell membrane, but there was an increased amount of fluorescence 
detected inside cytoplasm, which indicated although the active absorption of 
compounds were inhibited, there was compound 7 across cell membrane and entered 
cells via diffusion during time period.  
 
Table 5. 5. Two-photon Time Correlated Single Photon Counting data of HeLa cells treated 
with compound 7 at 37 ºC or 4 ºC for 15 minutes or 60 minutes at 100 µM in DMSO. ex = 910 
nm, laser power was 1.8 – 7.0 mW. 
Compound Compound 7 Compound 7  Compound 7 Compound 7  
Cell line HeLa HeLa HeLa HeLa 
Temperature 
(ºC) 
37 37 4 4 
Incubation 
time (min) 
15 60 15 60 
2 0.96 1.14 1.05 1.00 
1 (ns) 0.9 0.9 1.1  1.3 
1 % 72.2 28.6 36.6 15.5 
FWHM (ns) 0.6 1.2 1.5 0.39 
2 (ns) 3.8 3.4 3.6 3.3 
2 % 27.8 71.4 63.4 84.5 
FWHM (ns) 1.2 0.8 1.7 1.4 
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Figure 5. 28. FLIM decay curves for compound 7 in HeLa in different incubation 
conditions.ex = 910 nm, laser power was 1.8 – 7.0 mW. 
 
Table 5.5 and Figure 5.28 listed all the information of fluorescence lifetime 
corresponding to Figure 5.27, all data showed in the FLIM decay curve carried an 
acceptable low 2 value, which indicated these data were reliable and usable in the 
analysis. Compound 7 cultured at all four conditions carried two components, the 
lifetime of compound 7 in cells cultured at 37 ºC for 15 minutes was τ1=0.9 ± 0.6 ns 
(72.2%, FWHM 0.6 ns), τ2=3.8 ± 1.2 ns (27.8%, FWHM 1.2 ns), compared with the 
lifetime of compounds in cells cultured at same condition in 60 minutes, which was 
τ1=0.9 ns ± 1.2 (28.6%, FWHM 1.2 ns), τ2=3.4 ± 0.8 ns (71.4%, FWHM 0.8 ns). It 
clearly showed a considerable change in the percentage of components, at 15 minutes 
τ1 was dominant, whereas with the increase of incubation time, more compound 7 
absorbed by cells, hence the percentage of τ2 was raised. Similar situation occurred at 4 
ºC, the percentage of τ2 increase from 63.4% to 84.5%.  










 Compound 7 at 4ºC for 15 minutes in HeLa
 Compound 7 at 4ºC for 15 minutes in HeLa fit curve
 Compound 7 at 4ºC for 60 minutes in HeLa
 Compound 7 at 4ºC for 60 minutes in HeLa fit curve
 Compound 7 in HeLa at 37ºC for 15 minutes
 Compound 7 in HeLa at 37ºC for 15 minutes fit curve
 Compound 7 in HeLa at 37ºC for 60 minutes
 Compound 7 in HeLa at 37ºC for 60 minutesfit curve
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In conclusion, temperature or incubation time change would influence not only the 
ratio of two lifetime components in cells, but also it had little effect on the fluorescence 




Figure 5. 29. Fluorescence lifetime distribution curve of HeLa cells treated with compound 7 
in different conditions. ex = 910 nm, laser power was 1.8 – 7.0 mW. 
 
Figure 5.29 represented the fluorescence distribution of each condition, from the 
plot, it was clearly exhibited that most conditions peaked around about 3 – 4 ns apart 
from cells treated with compound 7 at 37 ºC for 15 minutes, as was discussed previously, 
due to smaller component represented a larger proportion of the fluorescence lifetime, 
the overall fluorescence was distributed mainly in the range of 0.6 ns to 3 ns and peaked 
at 1.7 ns. There were two conditions had two peaks in its system, which happened in 
cells treated with compound 7 at 37 ºC for 60 minutes and compound 7 at 4 ºC for 60 
minutes. Because all experiments apply the same batches of compound 7, hence, the 
possible reason of this unexpected fluorescence distribution might be due to the 









 Compound 7 at 37ºC for 15 minutes in HeLa
 Compound 7 at 37ºC for 60 minutes in HeLa
 Compound 7 at 4ºC for 15 minutes in HeLa
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prolonged incubation of compounds, leads to two components with differ ent lifetime 
accumulated and stabilised during the period of incubation.  
 
 
Figure 5. 30. FLIM images of HeLa cells treated with 20 µL of 20 mM compound 7 with 
1mg/mL -D-glucan in 1% DMSO, cells were incubated at 37 ºC or 4 ºC for 15 minutes or 60 
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minutes. where (a) two photon fluorescence intensity diagram of compound 7 @glucan in HeLa 
cells (37 ºC, 15 minutes incubation), (b) the fluorescence lifetime map of m of compound 7 
@glucan in HeLa cells (37 ºC, 15 minutes incubation) (c) two photon fluorescence intensity 
diagram of compound 7 @glucan in HeLa cells (37 ºC, 60 minutes incubation), (d) the 
fluorescence lifetime map of m of  compound 7 @glucan in HeLa cells (37 ºC, 60 minutes 
incubation), (e) two photon fluorescence intensity diagram of compound 7 @glucan in HeLa 
cells (4 ºC, 15 minutes incubation) and (f) the fluorescence lifetime map of m of compound 7 
@glucan in HeLa cells (4 ºC, 15 minutes incubation), (g) two photon fluorescence intensity 
diagram of compound 7 @glucan in HeLa cells (4 ºC, 60 minutes incubation) and (h) the 
fluorescence lifetime map of m of compound 7 @glucan in HeLa cells (4 ºC, 60 minutes 
incubation). 
 
Figure 5.30 shows FLIM images of HeLa cells treated with 2% of compound 7 
@glucan in 2% DMSO, incubated at 37 ºC for 15 minutes, 37 ºC for 60 minutes, 4 ºC 
for 15 minutes and 4 ºC for 60 minutes respectively. It can be observed from all pictures 
that samples entered cells in all conditions. There were precipitations accumulated on 
top of cells and in 5.30 g & h, it looked like there was a layer of fluorescent substances 
covered the cells. These problem were mainly caused by the excess amount of glucan 
applied to cells, which carried fluorescent compounds and was difficult to wash away. 
At 37 ºC, compound 7 with glucan appeared to enter cells and mainly stayed in 
cytoplasm and the cells’ morphology was unchanged. At 37 ºC 60 minutes incubation, 
the image captured was again out of focus, Hence, it became difficult to extract useful 
information, but it could still be seen that there was fluorescence signal detected from 
cells, although it was difficult to tell whether it was due to the fluorophore located in 
the cell cytoplasm or attached to the cell membrane, and there was precipitation of 
fluorescence accumulated on cells. As for the images at 4 ºC, there were an interesting 
phenomenon, it was discovered that with the assistance of the glucan, compound 7 was 
no longer accumulated on the cell membrane, but entered the cells and even seemed to 
enter the nuclei. After a 60 minutes period of incubation, compound 7 @glucan 
appeared to accumulate inside the cell membrane, which resulted in an intensive 
fluorescence out of cells and made the washing of the cells extremely difficult.  
As seen in Figure 5.31, all the TCSPC decay curves for compound 7 @ glucan in 
different conditions carried a similar fitting curve, although the fluorescence counts for 
cells treated with compound 7 @glucan at 4 ºC for 15 minutes were significantly higher 
than cells cultured in other conditions. They would yield a similar result of the lifetime. 
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The results represented in Table 5.6 showed that the all the lifetimes calculated from 
Figure 5.31 were similar to each other and in the range of 3 ns, it also did not differ 
much from Table 5.5, which indicated there was no significant effect in lifetime when 
functionalised compound 7 onto glucan. However, combined compound 7 and glucan 
did affect proportions between components one and two, which keep the percentage of 
both components at around about 50%; there was a slight drop of lifetime in all 
components two and the change of the overall fluorescence lifetime τm distribution was 
clearly showed in Figure 5.32. 
 
Table 5. 6. Two-photon Time Correlated Single Photon Counting data of HeLa cells treated 
with compound 7 at 37 ºC or 4 ºC for 15 minutes or 60 minutes. ex = 910 nm, laser power 
was 2.5 mW. 
 
Compound Compound 7 
@glucan  
Compound 7  
@glucan 
Compound 7  
@glucan 
Compound 7  
@glucan 
Cell line HeLa HeLa HeLa HeLa 
Temperature 
(ºC) 
37 37 4 4 
Incubation 
time (min) 
15 60 15 60 
2 1.03 1.01 1.05 0.99 
1 (ns) 1.0 0.5 0.7  0.7 
1 % 50 59.8 56.2 34.5 
FWHM (ns) 1.0 0.6 1.7 1.4 
2 (ns) 3.8 3.1 3.0 3.4 
2 % 50 40.2 43.8 65.5 
FWHM (ns) 1.8 1.6 0.3 1.3 
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Figure 5. 31. FLIM decay curves for compound 7 @ glucan in HeLa in different incubation 




Figure 5. 32. Fluorescence lifetime distribution curve of HeLa cells treated with compound 7 
@glucan in different conditions.ex = 910 nm, laser power was 2.5 mW 
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 Compound 7 @glucan at 4ºC for 15 minutes in HeLa
 Compound 7 @glucan at 4ºC for 15 minutes in HeLa fit curve
 Compound 7 @glucan in HeLa at 37ºC for 15 minutes
 Compound 7 @glucan in HeLa at 37ºC for 15 minutes fit curve
 Compound 7 @glucan in HeLa at 37ºC for 60 minutes
 Compound 7 @glucan in HeLa at 37ºC for 60 minutesfit curve
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As was mentioned above, use of functionalised compound 7 onto glucan dropped 
the percentages of the second component in the system, this resulted into to a shift of 
the overall fluorescence lifetime distribution towards the shorter lifetimes. For instance, 
cells treated with compound 7 at 4 ºC for 60 minutes had a lifetime distributed in a 
range of 0 to 4 ns, peaked at 3.2 ns, when combined compound 7 and glucan and then 
incubated at the same condition, the range of the composition became 0.4 – 4 ns and 
which peaked at 2.8 ns. It can be conclude that by functionalisation of compound 7 with 
glucan, this would not affect the fluorescence lifetime of compound 7. However, after 
the introduction of -D-glucan, the morphology of cell and uptake route of composition 
appeared significantly changed, and as a result, the overall fluorescence lifetime in cells 
was changed due to the significant changes in the environment of the fluorophore.  
 
5.7. Cell imaging and FLIM data of compounds from collaborating 
projects under various conditions 
       
             
There were many fluorescent sensors in this general family, available from the research 
groups of Pascu and James and which were studied to explore the different use of 
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boronic acid and fluorophores in biological applications. For example, compound 24 
(designed and synthesised by Sabrina Wang, in Tony James’ group, University of Bath) 
was a compound simply made up of boronic acid and FITC, without a linker and a 
biotin. This compound was used as a comparison for compound 7 to see whether there 
was a difference without a diamine linker and a targeting group. Compound 25 
(designed by Prof Tony James in University of Bath) and 26 (synthesised by Dr. 
Stephen Flower, in University of Bath) were prototypes of compounds 15 and 13 
respectively. Compound 27 (designed and synthesised in Tony James’ group University 
of Bath) was another boronic acid-based compound, which was designed to have altered 
fluorescence properties upon binding metal ions.11 Whereas for compound 7, the 
boronic acid was developed to attach onto glucan wrapped SWNTs, i.e. it was attached 
onto SWNTs indirectly. Through investigations of these novel boronic acid-based 
fluorescent sensors, additional boronic acid-based fluorescent sensor derivatives would 
be designed, developed and applied in research areas, and the methods devised hereby 




Figure 5. 33. Confocal microscopy images of HeLa cells treated with 100 µM of compound 24 
in 1% DMSO, incubated at 37 ºC for 15 minutes. The sample was excited at 488 nm and long-
pass filtered at 515 nm. Image (a) was the merged image of images (b) and (c). Image (b) green 
fluorescence channel. Image (c) represented for image took from DIC. Scale bar: 20 µm. 
 
 Figure 5.33 represents HeLa cells treated with compound 24, which had a 
similar structure to compound 7 and 9. Thus it was a good candidate to test how a 
structural difference might affect function. Although the results displayed in Figure 19 
(b) clearly showed the compound 24 penetrated the cell membrane and distributed 
b. a. c. 
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mainly in cytoplasm, unlike compound 7 in Figure 5.2, little of compound 24 could 
breach the cell nuclei. Nuclei appear to be stained by compound 24. The morphology 
of the cells was unchanged, which showed a similar level of cytotoxicity of compound 
7 showed in Figure 5.2 (c) and confirmed the result of MTT assays exhibited in Figure 
4.9 and 4.11, thus indicating that the nuclear uptake was not as a result of damage.  
 
 
Figure 5. 34. Confocal microscopy images of HeLa cells treated with 20µL of 10 mM 
compound 25, incubated at 4 ºC for 15 minutes. The sample was excited at 405 nm wavelength 
and emitted at 450 nm long pass. Image (a) was the merged image of images (b) and (c). Image 
(b) green fluorescence channel. Image (c) represented for image took from DIC. Scale bar: 20 
µm. 
 
 Compound 25 possessed a coumarin group, which absorbs light at 405 nm and 
emitted at 450 nm. This enables compound 25 to emit a blue fluorescence signal. The 
result in Figure 5.34 (b) clearly revealed there was a significant fluorescence signal 
appearing in the cell cytoplasm at 4 ºC, at which temperature it should have a reduced 
uptake rate of the compounds as well as uptake exclusively due to passive methods. 
The distribution of fluorescence demonstrated that the compound does not entered the 
nuclei. The morphology of cells was damaged as expected, due to the strong laser 
energy had been introduced onto cells, photodynamic effect occurred, which elevated 
the level of oxidative stress and formed a lot of “bubbles” in the cells. The surface of 
cells also become unstable; this indicated that there was a certain level of damage 
introduced on the membrane, to disturbing the homeostasis of the cell membrane.    
 
b. a. c. 
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Figure 5. 35. Confocal microscopy images of HeLa cells treated with 100 µM of compound 25 
functionalised with 1 mg/mL -D-glucan in 1% DMSO, incubated at 4 ºC for 15 minutes. The 
sample was excited at 405 nm wavelength and emitted at 450 nm long pass. Image (a) was the 
merged image of images (b) and (c). Image (b) was taken at > 450 nm wavelength. Image (c) 
represented for image took from DIC. Scale bar: 20 µm. 
 
 In Figure 5.35, -D-glucan was applied in order to improve the survivability of 
cells. Similar to Figure 5.34, compound 25 @ glucan easily entered cells without 
breaching the cell nuclei. There was an increment in the fluorescence in Figure 5.35 (b), 
compared with Figure 5.34 (b). This phenomenon indicated that binding to glucan 
enhanced the fluorescence of compound 25 and facilitated the entrance of the 
compound 7. However, the damage caused by fluorescence to cells increased as well, 
because the morphology of cells in figure 5.35 (c) is significantly worse than that in 
figure 5.34 (c). As a result, the outcome displayed in Figure 5.35 (c) did not show any 




Figure 5. 36. Confocal microscopy images of HeLa cells treated with 100 µM of compound 26 
in 1% DMSO, incubated at 37 ºC for 15 minutes. The sample was excited at 543 nm wavelength 
b. a. c. 
b. a. c. 
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and emitted at 605 nm long pass. Image (a) was the merged image of images (b) and (c). Image 
(b) was taken at > 605 nm wavelength. Image (c) represented for image took from DIC. Scale 
bar: 20 µm. 
 
 Rhodamine was another fluorophore chosen for study, which was excited at 543 
nm and emitted at 605 nm, therefore, it emitted a red fluorescence. The reason to choose 
rhodamine was it absorbed and emitted light at a high wavelength, hence, it need low 
energy laser to activate the fluorescence. Therefore, a boronic acid attached rhodamine 
(compound 26) was delivered into HeLa cells. However, there were severe problems 
inspected in Figure 5.36 (c), in which most cells were moderately damaged, the shape 
of cells were irregular and cell nuclei were slightly affected. Fluorescent image 5.36 (b) 
indicated that most fluorescence were held in the cytoplasm and seemed concentrated 
in ER and Golgi, a further colocalisation study is require to confirm, but the size and 
frame of nuclei were unusual compared with nuclei displayed in Figure 5.36 (b). This 




Figure 5. 37. Confocal microscopy images of HeLa cells treated with 100 µM of compound 26 
in 1% DMSO, incubated at 4 ºC for 15 minutes. The sample was excited at 543 nm wavelength 
and emitted at 605 nm long pass. Image (a) was the merged image of images (b) and (c). Image 
(b) was taken at > 605 nm wavelength. Image (c) represented for image took from DIC. Scale 
bar: 20 µm. 
 
 This experiment was designed to show that the reduced uptake of compound 26 
would reduce the cytotoxicity by decreasing the uptake. As experiment was repeated at 
4 ºC, there were less compound 26 absorbed into cells, consequently, there fewer 
fluorescence signals were detected from 5.37 (b) compared that was detected in 5.36 
b. a. c. 
  Chapter 5. In vitro fluorescence imaging of 







(b). as a result, the shape for both cell membrane and nuclei looked more intact than 
that in Figure 5.36 b and c. In order to further investigate the cytotoxicity of the 




Figure 5. 38. Confocal microscopy images of HeLa cells treated with 10µL of 5 mM compound 
27 in 1% DMSO, incubated at 37 ºC for 15 minutes. The sample was excited at 408 nm 
wavelength and long-pass filtered at 515 nm. Image (a) was the merged image of images (b) 
and (c). Image (b) green fluorescence channel. Image (c) represented for image took from DIC. 
Scale bar: 20 µm. 
 
 The results in Figure 5.38 represent those resulting from the study of a different 
type of fluorescent sensor. The boronic acid group of compound 27 was used as a 
detector rather than an anchor as in compound 7. Compound 27 could bind to copper 
ions directly to form a complex, hence, it was designed to sense the level of copper 
concentration in the living organism. HeLa cells treated with compound 27 (Figure 5.38) 
were compared with HeLa cells pre-treated with copper then treated with compound 27 
(Figure 5.39), in order to examine whether elevated the copper level would cause any 
effect on the fluorescence of compound 27.11  
In the situation of compound 27 only, there was a strong fluorescence appearing 
in the cell cytoplasm, the hollow cavity surrounded by the fluorescence represented cell 
nuclei. The shape of nuclei in 5.38 (b) combined with the structure of cell membrane 
revealed in Figure 5.38 (c) altogether demonstrated that compound 27 could pass 
through cell membranes freely but would not penetrate into cell nuclei and it possessed 
limited cytotoxicity that would not cause a visible disruption of cells.  
 
b. a. c. 
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Figure 5. 39. Confocal microscopy images of HeLa cells was pre-treated with 10µL of 50 mM 
CuCl2 in 1% DMSO (37 ºC, 60 minutes incubation), subsequently 10 µL of 5 mM compound 
27 was added incubated at 37 ºC for 15 minutes. The sample was excited at 405 nm wavelength 
and long-pass filtered at 515 nm. Image (a) was the merged image of images (b) and (c). Image 
(b) green fluorescence channel. Image (c) represented for image took from DIC. Scale bar: 20 
µm. 
 
When cells were pre-treated with copper ions, as seen in Figure 5.39 b, there was 
a significant decrease in the strength of fluorescence in side cells when there were 5 eq. 
of copper ions were added. Consequently, compound 27 could still enter the cell 
membrane freely without breaching the nuclei, but caused much less fluorescence at 
the same concentration and same temperature. It showed that the copper ions present in 
excess would remarkably influence the function of compound 27, which made 
compound 27 a potential sensor for copper. On the other hand, results from the Figure 
5.39 concluded that both pre-treatment of copper and the formation of compound 27 – 
copper complexes would not damage cells. This phenomenon demonstrated that 
compound 27 and its copper complexes were biocompatible, which was one of the 
premise condition to design a sensor or detector for living organisms. 
Figure 5.40 and Table 5.7 together revealed information regarding the fluorescence 
lifetime of compound 24 and compound 24 @glucan respectively. Both samples 
contained a second lifetime, which were fitted on multi-functional exponential with two 
components and the 2 were 1.15 and 1.2 respectively. These indicated a reasonable 
fitting parameters in data analysis. The lifetime of compound 24 had a lifetime of 3.6 
ns and the lifetime dropped to 3.0 ns when compound 24 was functionalised onto glucan. 
This lifetime alteration was due to interaction between compound 24 and glucan. The 
fitting in Figure 5.40 also shows that for the values this lifetime, as seen in the diagram 
b. a. c. 
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and their gradients of both fitting were visually different, the gradient of compound 24 
was slightly higher than that of compound 24 @glucan. This indicated that the lifetime 
of compound 24 was slightly longer than compound 24 @glucan. 
 
Table 5. 7. Two-photon Time Correlated Single Photon Counting data of compound 24 and 
compound 24@glucan in 1% DMSO. ex = 910 nm. Laser power was in between 2.0 and 8.8 
mW. 
 
Compound Compound 24 Compound 24 
@glucan 
Solvent system DMSO DMSO 
2 1.15 1.2 
1 (ns) 1.4 1.1 
1 % 60.5 55.8 
2 (ns) 3.6 3.0 




Figure 5. 40. TCSPC decay curves for compound 24 and compound 24 @ -D-glucan in 1% 
DMSO.ex = 910 nm. Laser power was in between 2.0 and 8.8 mW. 
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Figure 5.40 and Table 5.7 has all the information about fluorescence lifetime of 
compound 24 and compound 24 @glucan. Both samples contained two components, 
the chi square were 1.15 and 1.2 respectively, which were a reasonably acceptable value 
for data analysis. The lifetime of compound 24 had a lifetime of 3.6 ns and the lifetime 
dropped to 3.0 ns when compound 24 was functionalised onto glucan. This lifetime 
alteration was due to a conformational change of compound 24 when bound to glucan. 
This tendency in Figure 5.40 also shows this lifetime, as seen in the diagram, the 
gradients of both tendency were visually different, the gradient of compound 24 was 
significantly higher than that of compound 24 @glucan, which indicated the lifetime of 
compound 24 was longer than compound 24 @glucan. 
 
 
Table 5. 8. Two-photon Time Correlated Single Photon Counting data of compound 25 and 
compound 25 @glucan in 1% DMSO.ex = 810 nm, laser power was 8.0 mW  
 
Compound Compound 25 Compound 25 
@glucan 
Solvent system DMSO DMSO 
2 1.47 1.43 
1 (ns) 0.2 0.1 
1 % 41.4 41.3 
2 (ns) 1.3 0.9 
2 % 40.8 38.2 
3 (ns) 4.2 3.1 
3 % 17.8 20.8 
 
Table 5.8 and Figure 5.41 were set of data represented all the solvent FLIM 
information of compound 25 and its composite with the glucan. The results showed that 
both samples carried an unusually large 2 compared with that of compound 24, which 
might be due to the noise from the back ground or the interaction of compound with 
cellular environment.as such, fitting of the data on two exponential components was 
needed. There were also three components exposed in the sample solution, 1 = 0.4 ns 
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(55.6%), 2 = 2.6 ns (44.4%) and there was a slight decrease in the lifetime from 4.2 ns 
to 3.1 ns in 2. When compound 25 was bound onto glucan, this feature of TCSPC 
indicated that binding to glucan would not cause a significant change in lifetime for 




Figure 5. 41. TCSPC decay curves for compound 25 at 10 mM and compound 25 @ -D-
glucan at 1 mg/mL in 1% DMSO.ex = 810 nm, laser power was 8.0 mW  
 
Table 5. 9.  Two-photon Time Correlated Single Photon Counting data of compound 26 and 
compound 26@glucan in 1% DMSO.ex = 910 nm. Laser power was in between 2.0 and 8.8 
mW. 
Compound Compound 26 Compound 26 
@glucan 
Solvent system DMSO DMSO 
2 1.01 1.35 
1 (ns) 0.3 0.4 
1 % 50.6 52 
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2 (ns) 2.5 2.7 
2 % 49.4 48 
 
Table 5.9 and Figure 5.42 exhibit a set of data representing all the solvent FLIM 
information of compound 26 and its composition with glucan. Both samples possessed 
reasonable chi squared values, which were 1.01 and 1.35 for compound 25 and 
compound 25@glucan respectively. The fluorescence lifetime showed the opposite 
results after binding to glucan, compared with compound 24 and 25. The lifetime of 
compound 26 was slightly increased from 2.5 ns to 2.7 ns, instead of decreasing as was 
observed with compounds 24 and 25. This result was calculated from the plot in Figure 
5.42, there were more fluorescence signals detected in the FLIM of compound 26 
@glucan, the gradients of compound 26 and compound 26 @glucan were different and 
the gradient of compound 26 was slightly smaller than compound 26 @glucan, thus the 




Figure 5. 42.TCSPC decay curves for compound 26 and compound 26 @ -D-glucan in 1% 
DMSO.ex = 910 nm. Laser power was in between 2.0 and 8.8 mW. 
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Figure 5. 43. FLIM images of HeLa cells treated with 10 µL of 10 mM compound 24 and 10 
mM compound 25 @ 1 mg/mL  glucan in 1% DMSO, cells were incubated at 37 ºC for 15 
minutes. where (a) two photon fluorescence intensity diagram of compound 24 in HeLa cells 
(37 ºC, 15 minutes incubation), (b) the fluorescence lifetime map of m of compound 24 in HeLa 
cells (37 ºC, 15 minutes incubation) (c) two photon fluorescence intensity diagram of 
compound 25 @glucan in HeLa cells (37 ºC, 15 minutes incubation), (d) the fluorescence 
lifetime map of m of  compound 25 @glucan in HeLa cells (37 ºC, 15 minutes incubation). 
 
Figure 5.43 showes FLIM images of cells cultured with compound 24 and 
compound 25 @glucan. The results displayed in Figure 5.43 (b) was compared with 
Figure 5.33 (b), fluorescence distribution was similar, compound 24 entered cells and 
spread in the cytoplasm. During the imaging there was notable presence of 
precipitations of the compound on the membrane of cells, and the morphology of cells 
remain unchanged in 5.43 (b), this appeared to be healthier than the morphology 
observed in 5.33 (b). In Figure 5.43 (d), compound 25 assisted by glucan easily entered 
HeLa cells, but, unlike the fluorescence lifetime distribution exhibited in Figure 5.35 
(b), there were fluorescence signals discovered in some of the cell nuclei too. However, 
a. b. 
c. d. 
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it seemed that the morphology of cells were severely interrupted and there was 
significant increase in the intensity of fluorescence in majority of the cells. All indicated 
that cell damage occurred and made the compound 25 @glucan with more likely to 
access to cell nuclei.  
 
 
Table 5. 10. FLIM data of HeLa cells treated with compound 24 and compound 25 @glucan 
at 37 ºC for 15 minutes. Compound 24 was excited at ex = 910 nm wavelength. Compound 
25 was excited atex = 810 nm, laser power was 8.0 mW. 
 
Compound Compound 24 
 
Compound 25  
@glucan 




Incubation time (min) 15 15 
2 1.02 1.01 
1 (ns) 0.9 0.8 
1 % 30.5 39.5 
FWHM (ns) 1.2 0.5 
2 (ns) 3.5 2.7 
2 % 69.5 60.5 
FWHM (ns) 1.0 0.6 
 
The results obtained in Table 5.10 were used to access the fluorescence lifetimes 
differences between compound 24 and compound 25 @glucan. There was no 
significant contrast between each other. As seen in Table 5.10 and 5.7 together, 
compound 24 showed little change in its fluorescence lifetime from 3.6 ns to 3.5± 1.0 
ns, but it altered significantly in its proportion: the percentage of component two was 
raised from 39.5% to 69.5%. Hence, the fluorescence of the second lifetime component 
became more significant, and the overall lifetime of fluorescence shifted towards 3.5 
ns. Similar changes were observed for to compound 25 @glucan: its fluorescence 
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lifetime reduced from 3.0 ns to 2.7 ± 0.6 ns, with a percentage change from 20.8% in 
the solvent to 60.5% in cells for this component.  
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Figure 5. 44. FLIM images of HeLa or PC-3 cells treated with 10 µL of 10 mM compound 26 
and 10 mM compound 26 @ 1 mg/mL glucan in 1% DMSO, cells were incubated at 37 ºC or 
4 ºC for 15 minutes. where (a) two photon fluorescence intensity diagram of compound 26 in 
HeLa cells (37 ºC, 15 minutes incubation), (b) the fluorescence lifetime map of m of compound 
26 in HeLa cells (37 ºC, 15 minutes incubation) (c) two photon fluorescence intensity diagram 
of compound 26 @glucan in PC-3 cells (37 ºC, 15 minutes incubation), (d) the fluorescence 
lifetime map of m of  compound 26 @glucan in PC-3 cells (37 ºC, 15 minutes incubation). (e) 
two photon fluorescence intensity diagram of compound 26 in HeLa cells (4 ºC, 15 minutes 
incubation), (f) the fluorescence lifetime map of m of compound 26 in HeLa cells (4 ºC, 15 
minutes incubation). 
 
The results exhibited in Figure 5.44 represented the two photon FLIM data of the 
rhodamine-tagged fluorescent molecule (compound 26). They are linked to Figure 5.36 
and Figure 5.37. As was revealed in Figure 5.44 (a) and (b), the fluorescence lifetime 
of compound 26 was mainly from cytoplasm. In Figure 44 (c) and (d), cells were 
cultured with compound 26 @glucan at 37 ºC in order to change the uptake route of 
compound 26. The outcome showed a significant change in the cell morphology, 
although limited change in fluorescence lifetime was detected from the cytoplasm. The 
same phenomena was observed in Figure (e) and (f), as the temperature was dropped to 
inhibit the active uptake of compound 26. Although the outcome was not as good as 
that observed for figure 5.44 (c) and (d), the fluorescence lifetime mainly comes from 
the cytoplasm, the colour combines blue and green indicate at least two components 
existed.  
 
Table 5. 11 Two-photon Time Correlated Single Photon Counting data of HeLa or PC-3 cells 
treated with compound 26 and compound 26 @glucan at 37 ºC or 4 ºC for 15 minutes. ex = 
910 nm. Laser power was in between 2.0 and 8.8 mW. 
 
Compound Compound 26 
 
Compound 26  
@glucan 
Compound 26  
 
Cell line HeLa PC-3 HeLa 
Temperature 
(ºC) 
37 37 4 
Incubation time 
(min) 
15 15 15 
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2 1.08 1. 25 1.40 
1 (ns) 0.4 0.6 0.3  
1 % 48.8 72.3 82.8 
FWHM (ns) 0.6 0.5 0.6 
2 (ns) 2.4 2.9 2.8 
2 % 51.2 27.7 17.2 




Figure 5. 45. FLIM decay curves for compound 26 and compound 26 @glucan in HeLa and 
PC-3 cell line.ex = 910 nm. Laser power was in between 2.0 and 8.8 mW. 
 
Figure 5.45 and Table 5.11 together determined the lifetime of compound 26 and 
compound 26 @glucan.  It could be observed from Table 5.11 that compound 26 was 
a compound with a short lifetime. Whereas there was a slight increase in the lifetime 
when treated cells with compound 26 at 4 ºC or compound 26 @glucan at 37 ºC. The 
lifetime was raised from 2.4 ± 2.6 ns to 2.9 ± 2.7 ns and 2.8 ± 0.9 ns respectively. At 
the same time, there were a remarkable drop in the proportion of fluorescence, which 




 Compound 26 in HeLa
 Compound 26 in HeLa fit curve
 Compound 26 @ glucan in PC-3
 Compound 26 @ glucan in PC-3 fit curve
 Compound 26 in HeLa at 4 ºC
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was from 51.2% (compound 26 alone, 37 ºC) to 27.7% (compound 26 @glucan, 37 ºC) 
and 17.2% (compound 26 alone, 4 ºC) respectively. This might because the route of 
uptake changed when combined with glucan, lead to a slow absorption, or uptake of 
compound reduced at 4 ºC. The tendency in Figure 5.45 also proved that there were less 




Figure 5. 46. Fluorescence lifetime distribution curve of HeLa cells treated with compound 26 
and compound 26 @glucan in different conditions.ex = 910 nm. Laser power was in between 
2.0 and 8.8 mW. 
 
The overall lifetime distribution of compound 26 in HeLa at 37 ºC was mainly 
distributed in between 0 and 4 ns, it had peaks at 0.8 ns and 1.3 ns respectively. When 
compound 26 was on -D-glucan, the range of fluorescence distribution shortened to 
0.6 ns to 3.2 ns and peaked at 1.9 ns. For compound 26 at 4 ºC as well, due to a reduced 
uptake rate, the fluorescence photon counts were significantly lower than at 37 ºC, and 
the lifetime distribution ranged in between 0 to 2.6 ns with a broad peak at 1.3 ns.  
 








 Compound 26 in HeLa at 37ºC
 Compound 26 @glucan in PC-3 at 37ºC
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Table 5. 12. Two-photon Time Correlated Single Photon Counting data of compound 27 and 
compound 27 with CuCl2 in 1% DMSO.ex = 910 nm, laser power was 0.25 – 0.5 mW. 
 
Compound Compound 27 Compound 27 with 
CuCl2 
Solvent system DMSO DMSO 
2 1.06 1.23 
1 (ns) 9.0 4.4 
1 % 100 100 
 
 
Figure 5. 47. TCSPC decay curves for compound 27 and compound 27 with CuCl2 in 1% 
DMSO.ex = 910 nm, laser power was 0.25 – 0.5 mw. 
 
Figure 5.47 with table 5.12 fully explained the lifetime of compound 27 and 
compound 27 with CuCl2 in 1% DMSO. It was showed clearly in both diagram and 
table that there was a significant difference in fluorescence lifetime between compound 
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27 and compound 27 bound to copper ions. The lifetime dropped from 9.0 ns to 4.4 ns 
when compound 27 was bound to copper ions. There was only one component found 
in both conditions and the chi squared values were 1.06 and 1.23 respectively, both in 




Figure 5. 48. FLIM images of HeLa cells treated with 10 µL of 10 mM compound 27 in 1% 
DMSO, cells were incubated at 37 ºC for 15 minutes. where (a) two photon fluorescence 
intensity diagram of compound 27 in HeLa cells (37 ºC, 15 minutes incubation), (b) the 
fluorescence lifetime map of m of compound 27 in HeLa cells (37 ºC, 15 minutes incubation) 
(c) two photon fluorescence intensity diagram of compound 27 in HeLa cells, which were pre-
treated with 5 eq. of CuCl2 for 60 min (37 ºC, 15 minutes incubation), (d) the fluorescence 
a. b. 
c. d. 
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lifetime map of m of  compound 27 in HeLa cells, which were pre-treated with 5 eq. of CuCl2 
for 60 min (37 ºC, 15 minutes incubation).  
 
FLIM images displayed in Figure 5.48 showed that compound 27 entered HeLa 
cells without entering the cells’ nuclei, the fluorescence signal mainly emitted from 
cytoplasm. The morphology of cells did not change significantly, which indicated that 
compound 27 was non-toxic to HeLa cells. In Figures 5.48 (c) and (d), a similar pattern 
was observed, compound 27 easily entered HeLa cells that pre-treated with CuCl2, there 
were no significant fluorescence signals visualised in nuclei. However, there was a 
considerable drop in the fluorescence intensity. At the same time, there was a slight 
increase in the size of the nuclei, which might due to a prolonged incubation of copper 
ions during the period of pre-treatment.  
 
Table 5. 13. Two-photon Time Correlated Single Photon Counting data of HeLa cells treated 
with compound 27 and compound 27 with CuCl2 at 37 ºC for 15 minutes. ex = 910 nm, laser 
power was 0.25 – 0.5 mW. 
 
Compound Compound 27 
 
Compound 27  
with CuCl2 




Incubation time (min) 15 15 
2 1.05 1.07 
1 (ns) 2.3 1.2 
1 % 51.3 40.3 
FWHM (ns) 1.9 3.3 
2 (ns) 12.0 6.8 
2 % 48.7 59.7 
FWHM (ns) 3.8 4.6 
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Figure 5. 49. FLIM decay curves for compound 27 and compound 27 with CuCl2 in HeLa. 
ex = 910 nm, laser power was 0.25 – 0.5 mW. 
 
Figure 5.49 and table 5.13 together represented all lifetime information 
corresponding to Figure 5.48, first of all, the chi square for both compound 27 and 
compound 27 with copper were 1.05 and 1.07 respectively, they were in the reliable 
range of analysis. The lifetime of compound 27 in HeLa cells was 12 ± 3.8 ns, which 
was higher than that in 1% DMSO, hence, the fluorescence cycle of compound 27 was 
processed slower in cells. Then the fluorescence lifetime was reduced remarkably to 
6.8 ± 4.6 ns when band to copper ions. The tendency of compound 27 and compound 
27 and copper complexes were similar, but the gradient of compound 27 was slightly 
more flattened than that of compound 27 –copper complexes, which resulted a longer 
lifetime for the compounds’ fluorescence emission in this environment.12  
 




 Compound 27 in HeLa at 37ºC
 Compound 27 in HeLa at 37ºC fit curve
 Compound 27 + Cu in HeLa at 37ºC
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Figure 5. 50 fluorescence lifetime distribution curve of HeLa cells treated with compound 27 
and compound 27 – copper complexes at 37 ºC for 15 minutes.ex = 910 nm, laser power was 
0.25 – 0.5 mW. 
 
As seen in Figure 5.50, the lifetime distribution of compound 27 was in 0 to 11 ns, 
the peak was appeared at 7 ns. Whereas compound 27 with copper had lifetime 
distributed in between 2 ns and 13 ns, the peak was also appeared at 7 ns. The difference 
in the fluorescence counts was due to different strength of laser power applied.  
  










 Compound 27 in HeLa at 37ºC
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5.8. Summary of chapter five 
This Chapter detail an investigation into a number of fluorophores and imaging within 
different cell lines and under distinct environmental conditions, using laser scanning 
confocal microscopy and FLIM, with single photon and two photon excitation.  
 In confocal microscopy, first of all, compound 4 was shown to have a good 
penetrability through cell membrane, but not through the nuclear membrane. 
Compound 7 was found to pass through both membrane, but most of compound 7 was 
retained in the cytoplasm. A Hoechst dye co-localisation experiment was carried out to 
confirm the presence of compound 7 in the nucleus. In addition, Lysotracker 
experiments were also performed to confirm the distribution of compounds in the 
lysosomes. Secondly, biocompatible SWNTs with fluorescent sensors were examined. 
The -D-glucan, attached to a compound 7 as a composite, was structured with two 
different cell lines. Both cell types showed a reasonable uptake of the composites and 
there was a reduction in the fluorescence signal from the nucleus. This indicated that 
there were fewer compounds (or composites), which had the ability to entered the cell 
nucleus. However, imaging of SWNTs@ glucan@ compound 7 showed a clear 
penetration of both cell membrane and nuclear membrane, which gave a significant 
fluorescent signal from cells and slight disruption of cell homeostasis. SWNTs 
@glucan @compound 9 was also studied as a comparison, because there were no 
boronic acids present in the structure to bind to the glucan surface. As such most of 
compound 9 was washed out from cells and imaging showed only a weak fluorescent 
signal. In the next step, the same concentration of fluorescent compounds were studied 
at different incubation times and temperatures. It was clear that the increase in the time 
of incubation would significantly increase the fluorescence signals and toxicity in cells 
too. Incubated cells at lower temperatures (4 ºC) could considerably reduce the uptake 
rate of fluorescent compounds and therefore inhibited the damage caused by these 
compounds. Finally, a list of fluorescent sensors with different fluorophores from 
collaborators were investigated, most of compounds showed a good uptake, sharp 
fluorescence and reasonable damage to cells, however those fluorophores could be 
potentially useful in life science imaging experiments, after some modification of their 
structures. The result of compound 27 revealed potential applications of boronic acid 
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based fluorescent sensors in ion detection, which could be very useful in the search for 
cancer diagnostics. 
 As for the FLIM, the fluorescence lifetime and components distribution varied 
under various conditions, which referred to lifetime and distribution of components. 
This could be influenced by the solvent or the cells’ nature, under different 
environmental conditions. In TCSPC measurement, the fluorescence lifetime appeared 
from multi-exponential fitting functions using single components or two components, 
which percentage or the ratio of the two components was commonly closed to 1:1. With 
cells, most of the fluorescence lifetimes were presented in the two-component form and 
the multi- exponential fitting components were distributed in a more variable ratio, 
which may be due to the complicated cellular environment and the presence of the 
biomolecules affecting the binding and conformation of the compound. As a result, 
most of the 2 values of the FLIM were reasonably acceptable. The FWHM 
corresponded to the lifetime and binding of molecules, in general, a fluorophore with a 
high fluorescence lifetime commonly had a larger FWHM. The binding of a small 
molecule to a biomolecule inside cells would lead to significant conformational changes, 
resulting in an altered FWHM. Furthermore, temperature and incubation time 
modification affected the uptake of fluorescent sensors, leading to a change in the 
distribution of the components and in different FHWM values. Most commonly, it was 
shown that higher temperatures and longer incubation times yield a broader uptake of 
compounds or composites and hence produce a wider FHWM. These observations led 
to a generalised method for studying small molecules, biocompatible polymers and 
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Chapter 6. Experimental section 
 
6.1. Chemicals and glassware  
All solvent and chemicals used in this project were reagent-grade and HPLC-
grade responsively unless stated otherwise. These were purchased from Fisher 
scientific and Sigma Aldrich Company Ltd, and were usually used without further 
purification, unless specified otherwise. The majority of life science consumables, such 
as cellular, media, labels and proteins, were obtained from Sigma Aldrich Company 
Ltd and Invitrogen Company. Carbon dioxide cylinders used in cell culture, was 
supplied by BOC. 
All glassware was bought from Fisher scientific and VWR international and 
cleaned via the standard base- and acid-bath methods. The base bath was made of 300 
g of potassium hydroxide, 10 L of isopropanol and 100 mL of toluene. Glassware was 
immersed totally in the base bath for 24 hours at room temperature and then rinsed with 
excess of MilliQ water (MilliQ water is purified via a Milli-Q Reference purification 
system), whereby the purity of water used was normally characterised in terms of 
resistivity, which was 18.2 MΩ·cm at 25 °C. The glassware used was subsequently 
placed in an acid bath, which was made of diluted hydrochloric acid, for 24 hours at 
room temperature. Afterwards, glassware was rinsed with MilliQ water to remove the 
acid and was then dried on the rack or at 60°C oven. This complex protocol was needed 
to ensure that the carbon nano materials used are not contaminated with ions.  
 
6.2. Thin Layer Chromatography (TLC)  
TLC was performed using commercially available Merck aluminium backed plates 
coated with 200 µm layer of silica gel 60 with fluorescent indicator F254 for detection 
of colourless substances. These plates were visualised by using either ultraviolet light 
of 254 nm or 365 nm wavelengths, samples which absorb at 254 nm or at 365 nm will 
be revealed due to a fluorescence quenching.  
 








6.3. Column chromatography 
Silica gel column chromatography was carried out by using silica gel (60 Ǻ, 35-70 μm 
particle size). The volume of silica gel depended on the mass of the sample available; 
normally 30 g of silica gel was needed per 1g of sample. Weighted silica was made into 
a slurry in excess of methanol and then silica precipitated in the column. Then samples 
were dissolved in a minimum volume of solvent and added carefully to the column to 
form a thin layer in between the silica gel and sand layer. Finally, sand was added on 
top of the silica as a buffer layer.  
The column was washed with a mixture of two solutions in different proportion 
in order to separate samples into different layers. Then the washout was collected into 
different fractions and each fraction would be checked with a TLC test until the desired 
spot was found. Eventually, the fraction carried the compound was dried using a freeze 
drier and further spectroscopic characterisation carried out to confirm the result. 
 
6.4. High performance liquid chromatography (HPLC) 
HPLC was carried out using a ThermoFisher HPLC systems, samples of 1 mg/mL 
concentration in DMSO were injected and passed through a Symmetry® C-18 column 
(4.6 x 260 mm) through a UltiMate 3000 Diode Array Detector with the UV/visible 
detection measured at obs = 200 nm, 300 nm, 400 nm, 450 nm, 500 nm, 600 nm, 700 
nm and 800 nm. The flow rate was 0.8 mL/minute and the eluents involved gradient 
methods of two solvents: solvent A was made of MilliQ water with 0.1% TFA and 
solvent B as MeCN in 0.1% TFA.  
 The HPLC system was switched on 60 minutes prior to the initial measurement, 
the flow was set at 0.2 mL/minute under UV/Vis detection in order to wash all residuals 
in the column. Samples were injected and examined with the following method: Start, 
95 % A reverse gradient until 5% A at 7.5 minutes, kept rinsed samples with 5% A :95% 
B solvent mixture until 15 minutes, reverse gradient until 17.5 minutes 95% A, then 
hold to 21 minutes. 







 The UltiMate 3000 pump was maintained by the solution made of 80% MilliQ 
water, 15% MeCN and 5% Isopropanol. All solvents used in HPLC measurements were 
HPLC grade and the water was deionised. 
 
6.5. Mass spectrometry 
Data was acquired on a Bruker Daltonics electrospray ionisation – time-of-flight (ESI-
TOF) mass spectrometry. Samples were dissolved in HPLC-grade methanol or distilled 
water, and under some circumstances, in methanol with one drop of DMSO. The 
concentration of the solution needs to be kept in a range of 1 µg to 10 µg, the formula 
of samples were identified or confirmed via positive or negative loop injection. The 
results were analysed using the Bruker Daltonics Data Analysis 4.0 software package. 
 
6.6. Nuclear magnetic resonance spectroscopy (NMR) 
1H NMR, 13C NMR, COSY NMR, (including solvent suppression techniques), HSQC 
and HMBC spectra were recorded on a Bruker 300 UltrashieldTM (1H: 300 MHz, 13C: 
75.5 Mhz) at the room temperature, using in the facilities of the University of Bath. All 
spectra were recorded in chloroform-d, methanol-d, dimethyl-d6 sulfoxide or 
combination of deuterated solvents, for instance, in methanol-D with a drop of 
dimethyl- d6 sulfoxide, depending on the sample solubility. Chemical shifts () of NMR 
spectra were expressed in parts per million (ppm) and relative to a reference signal, 
which is usually tetramethylsilane (TMS), as an internal standard. The multiplicity and 
general assignments of the spectroscopic data were abbreviated to: singlet (s), doublet 
(d), triplet(t), quartet (q), doublet of doublet (dd), doublet of doublet of doublet (ddd), 
doublet of triplet (dt) triplet of triplet (tt), unresolved multiplet (m), apparent (app), 












6.7. Fluorescence spectroscopy 
Fluorescence spectroscopy measurements were performed on a Perkin Elmer 
Luminescence spectrophotometer LS 55 in the Department of Chemistry at University 
of Bath, utilising 1.2 mL volume quartz cuvettes, with 10 mm path length. The 
spectrophotometer was usually turn on for 30 minutes prior to use. All solvents used in 
fluorescence measurements were HPLC grade and the water used was MilliQ quality. 
The concentration of samples could be varied between 10-5 and 10-7 M dependent on 
the strength of fluorescence; however, a pre-scan in the range of 200 – 900 nm was 
usually necessary to determine the maximum excitation and emission wavelength. Then 
the maximum excitation will be applied to acquire the precise emission peak. Data 
collected was processed via the FL WinLab v1.60 software package and origin 9.1.  
 
6.8. UV spectroscopy 
Electronic absorption spectroscopy (UV/vis) was examined by using a Perkin-Elmer 
Lambda 35 spectrometer and spectra were measured using two 1.00 cm quarz cuvettes. 
Data was collected and analysed via the UV Winlab software package. The instrument 
was usually switched on 30 minutes prior measurement for stabilisation. All solvents 
used in UV Vis measurements were HPLC grade and the water was deionised. All 
measurements started with calibration, which set solvent as standard in the same solvent 
system, recalibration was essential for switching to another solvent system. 
 
6.9. Transmission electron microscopy (TEM) 
High resolution transmission electron microscope (HR TEM) images of functionalised 
SWNTs were captured with Gatan Dualvision digital camera on a JEOL 1200EXII high 
resolution microscope (operating voltage of 120 kV) coupled with Energy-dispersive 
X-ray spectroscopy (EDS) (point resolution, 0.16 nm) in the University of Bath. 
Samples for HR TEM were dispersed in EtOH or MilliQ water environment and load 
drop wise onto a copper grid coated with holey carbon film. In circumstances, copper 
grids could be oxidised by exposure to UV light, as a result, an ozone layer was created 







on the surface of the grid to improve the hydrophilicity. Finally, samples would be left 
in a desiccated environment overnight prior the observation by TEM.  
 
6.10. Scanning electron microscopy (SEM) 
SEM images were taken using JEOL JSM6480LV scanning electron microscope and 
Oxford INCA X-ray analyser used for mapping, scanning and quantitative analysis. 
Samples of SEM were dispersed in ethanol and mounted on stubs. A convenient 
adhesive was a double-stick, electrically-conductive carbon tape. Samples were left in 
a desiccated environment overnight prior to the observation by SEM. 
 
6.11. Raman spectroscopy 
Raman spectroscopy was performed at central laser facilities in the Rutherford 
Appleton Laboratory. A Renishaw upright microscope was adopted and samples were 
excited at 830 nm wavelength. The working distance (LWD) of objective was 2 cm and 
operated at 50× magnification. The laser power pulsed at samples was 220 mW. 
    
6.12. SWNTs Purification 
The purification of SWNTs was carried out via a solvent oxidation method, which 
included the steps described below. The whole purification process was started with a 
microwave heating to expose the metal catalyst from inside of nanoparticles. Next, an 
ultrasonication was utilised to disperse aggregated SWNTs, then a hydrochloric acid 
wash followed by filtration to dissolve and rinsed metal catalyst away. Subsequently, 
an oxidative treatment using concentrated nitric acid was performed in order to oxidise 
the amorphous carbon and graphite carbon. Finally, a NaOH / aqueous washing and 
filtration step were carried out to improve the dispersibility of oxidised amorphous 
carbon and graphite carbon and wash these impurities away from the system.  
In a typical experiment, 20 mg of raw SWNTs (as made by the arc discharge 
method, supplied by Carbolex, Rice) were weighed and added to 20 mL of H2O2 in 50 







mL centrifuge tube. The mixture was ultrasonicated in an ultrasonic bath (Ultrawave 
U-500 30 Hz or Agar scientific S0080 Sonomatic 30 HZ, 80W) for five minutes. This 
step was repeated four times with one minute intervals to minimise the damage to the 
tubes. Then, the mixture was separated into four 10 mL microwave vials for the 
microwave treatment (Biotage initiator 2.0), using the microwave setting at 120 W and 
40 °C. This step lasted one minute and was repeated over five cycles per vial. 
Subsequently all the mixtures were collected into 50 mL centrifuge tube and diluted 
with excess MilliQ water and filtered through a cyclopore track etched membrane. This 
was a hydrophilic membrane with 0.2 μm pores with resistance to inorganic corrosive 
aqueous solutions. The solid left on the membrane was then collected and dispersed 
into 70 mL of MilliQ water, then heated under reflux with 70 mL 16% HCl at 120 °C 
whilst stirring at 1000 rpm overnight. After that, the mixture was diluted with excess 
MilliQ water and neutralized with NaOH and subsequently filtered through a cyclopore 
track etched membrane (0.2 µm pore from Camlab). The solid collected on the 
membrane was dispersed into 50 mL of MilliQ water and 30 mL of 9 M HNO3 were 
added dropwise. Subsequently, the mixture was heated under reflux with stirring at 
1000 rpm for 24 hours. Afterwards, the sample was diluted, filtrated and washed with 
excess MilliQ H2O and re-dispersed into 20 mL of MilliQ H2O. The mixture was 
transferred into a polytetrafluoroethylene (PTFE) container which is base resistant, then 
treated with 100 mL of 8M NaOH and heated under reflux and stirred at 1000 rpm for 
48 hours under nitrogen condition. The mixture was subsequently diluted with MilliQ 
water and filtrated though a cyclopore track etched membrane and washed with excess 
(1L) MilliQ water. The final product was washed with excess MilliQ water through the 
hydrophilic membrane and 300 mL of toluene through a hydrophobic membrane 
(polyethylene membrane). Purified SWNTs were dispersed into a MilliQ water or 
ethanol for characterisation, which was carried out via high resolution TEM / SEM 












6.13. General synthesis of compounds@ Glucan@ SWNTs 
 
 
Scheme 6. 1. Synthetic pathway of Glucan@SWNTs component and R-B (OH) 2 
(compounds) @Glucan @SWNTs, where R = fluorophore. 
 
1 mg SWNTs was weighed and dispersed into 1 mL DMSO, the mixture was sonicated 
for five minutes with one minute interval and the procedure was repeated four times. A 
stock solution of 1 mL glucan in DMSO (1 mg/mL) was added; the mixture was diluted 
to 10 mL with MilliQ water and stirred overnight at room temperature. Then the mixture 
was filtered using a cyclopore track etched membrane and washed with excess of 
MilliQ water. The solid part on the filter membrane was dispersed in 1 mL of water. 
Boronic acid-based fluorophores were added into the dispersion and stirred for 48 hours 
at room temperature.  The mixture was filtered and washed with excess of MilliQ water. 
Finally, the residue on the filter membrane was dispersed into MilliQ water, and then 
products were freeze dried and re-dispersed into 1 mL of MilliQ water. 
 
  












Scheme 6. 2. Synthetic pathway of copper filled SWNTs 
 
In a typical procedure, a sample of ca. 1 mg SWNTs was weighed and dispersed into 1 
mL MilliQ water, the mixture was sonicated for five minutes with one minute interval 
and the procedure was repeated four times. 1 mg copper acetate in 1 mL MilliQ water 
was added; the mixture was stirred overnight at room temperature for two hours. Then 
1 mL glucan (2mg /mL) in MilliQ water was added and stirred for an hour. Finally, 1 







mg C70 was added and stirred at room temperature for an hour. The mixture was filtered 
using a cyclopore track etched membrane and washed with excess of MilliQ water. The 
solid part on the filter membrane was dispersed in 1 mL of ethanol. Then the product 
was filtered again through polyethylene membrane and rinsed with toluene. The residue 
remained on the membrane, was collected and dispersed into MilliQ water. 
 
6.15. Specific synthetic details and structures  





Figure 6. 1. Sturcture of 2,5-dioxopyrrolidin-1-yl 5-((3aS,4S,6aR)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanoate 
 
488 mg (2 mmol) N-Biotin and 230 mg (2 mmol) N-Hydroxysuccinimide (NHS) were 
added into 20 mL of Dimethylformamide (DMF). The mixture was heated to 100 °C 
until all the suspensions was dissolved. 412 mg (2 mmol) of N, N-
dicyclohexylcarbodiimide (DCC) was subsequently added to the solution then the 
mixture was stirred under nitrogen at room temperature. A white suspension was 
formed at the end and then been filtered, the filtrate was evaporated to collect 669 mg 
of white solid products (98% yield).    
 
1HNMR (300 MHz, CD3OD, 298 K) δ = 6.42 (m, 2H, Ha, b), 4.29 (m, 1H, H9), 4.13 (m, 
1H, H8), 2.83 (d, 2H, H10, J= 5.43 Hz), 2.89-2.54 (m, 4H, H1, 2), 1.87-1.26 (m, 9H, H3-
7).  
 







Mass Spectrum ESI-MS calculated for C14H19N3O5S [M + H]
 + 342.1182, found 
342.1097. HPLC Rt= 5.2 minutes.  
 
IR spectrum: 1711 cm-1, 1645 cm-1, 1552 cm-1, 1061 cm-1, 861 cm-1. 
 





Figure 6. 2. Structure of N-(6-aminohexyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamide 
 
500 mg (1.46 mmol) of compound 1 was dissolved into 20 mL of DMF solution and 
0.3 mL of TEA added. The mixture was sonicated until all white solids were dissolved. 
Then 1.7 g (14.6 mol) of Hexamethylenediamine was added, dissolved into 50 mL 
MilliQ water. Subsequently the mixture was stirred overnight under room temperature. 
Finally, 100 mL of diethyl ether was added to the mixture and the formation of a white 
solid was observed. This was separated from the supernatant by filtration and dried in 
the freeze dryer overnight, 200 mg of white solid of collected (40% yield). The 
formation of the desired product (Compound 2) was confirmed by mass spectrometry 
(ESI+) and 1H NMR spectroscopy.  
 
1HNMR (300 MHz, CD3OD, 298 K) δ = 4.52 (t, 1H, H13, J=3.92), 4.34 (s, 1H, H12), 
3.07 (m, 1H, H11), 3.10 – 2.85 (m, 2H, H14), 1.83–1.34 (m, 20H, H1, 2, 3, 4, 5, 6, 7, 8, 9, 10).  
 
Mass Spectrum ESI-MS calculated for C16H31N4O2S [M + Na]
 + 365.1982, found 
365.2005. HPLC Rt= 6.7 minutes. 
 












Figure 6. 3. Structure of 5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-
N-(6-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)amino)hexyl)pentanamide 
 
200 mg (0.61 mmol) of compound 2 were dissolved in 20 mL of DMF. To this 92 mg 
(0.61 mmol) of 4-formylphenylboronic acid and 72 mg (0.61 mmol) of pinacol were 
added, as well as activated molecular sieves (3 Å). The mixture was then stirred for 16 
hours under an inert atmosphere (N2). Next, 0.61 mmol sodium triacetoxyborohydride 
was added to this, and the mixture was stirred for a further 24 hours. Finally, the 
solution was neutralised by excess ethyl acetate, filtered and evaporated under reduced 
pressure to give 58 mg of compound 3 as a white solid (11% yield). The purity was 
verified by TLC and the identity was confirmed by mass spectrometry (ESI+) and 1H 
NMR spectroscopy.  
 
1H NMR ((CD3)2OS, 300 MHz, 298K)  =  7.89 (d, 2H, H5, 8, J=8.32 Hz), 7.54 (d, 2H, 
H6, 7, J=8.32 Hz), 4.21 (m, 1H, H22), 4.04 (m, 1H, H21, J= 6.94 Hz), 3.41 (d, 2H, H9, J= 
6.93), 2.75 (dd, 1H, H23, J= 5.12 Hz), 2.48 (d, 1H, H23, J= 12.28 Hz), 1.79-1.30 (m, 
21H, H10-15, 16-20), 1.24 (s, 12H, H1-4)  
 
ESI-MS (m/z) calc. for C29H47BN4O4S [M+H]
















Figure 6. 4. Structure of tert-butyl (4-((5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamido)methyl)benzyl)carbamate 
 
250 mg (0.73 mmol) of biotin-NHS and 173 mg (0.73 mmol) boc protected p-
xylylenediamine were dissolved in 10 mL DMF, and then 4 eq. of TEA was 
subsequently added. The mixture was stirred at room temperature overnight. The 
product was evaporated and yielded 220 mg of white solid. (83% yield)  
 
1H NMR (500 MHz, (CD3)2OS) δ = 8.25 (t, 1H, Ha, J = 5.6 Hz), 7.34 (t, 1H, Hb, J= 5.8 
Hz), 7.1 (m, 4H, H8-12), 6.42 (s, 1H, Hc), 6.35 (s, 1H, H20), 4.30 (t, 1H, Hd, J= 5.3 Hz), 
4.21 (d, 2H, H13, J = 5.5 Hz), 4.11 (m, 1H, H21), 4.06 (d, 2H, H6, J = 5.5 Hz), 3.08 (m, 
1H, H19), 2.82 (dd, 1H, H22, J = 12.2 Hz, J = 5.0 Hz), 2.58 (t, 1H, H22, J=5.0 Hz), 2.13 
(t, 2H, H15, J = 7.6 Hz), 1.5 (m, 2H, H16), 1.8 – 0.98 (m, 4H, H17,18), 1.39 (s, 9H, H1-3).   
 
13C NMR ((CD3)2OS, 500MHz, 298 K) δ = 173.3 (C5), 172.4 (C14), 163.2 (C23), 139.1  
(C7), 138.5 (C10), 127.5 (C8,12), 127 (C9,11), 78.2 (C4), 61.5 (C21), 61.2 (C20), 55.9 (C19), 
43.6 (C6), 42.2 (C13), 39.5 (C22), 35.6 (C15), 33.7 (C16), 28.7 (C1-3), 28.5 (C17), 22.8 
(C18).  
 
Mass Spectrum ESI-MS calculated for C31H43BN4O4S [M + H] 
+ 485.2193, found 
485.2300. 
 







IR spectrum: 3298 cm-1, 1778 cm-1, 1695 cm-1, 1637 cm-1, 1522 cm-1, 1163 cm-1, 871 
cm-1. 
 
(e) Synthesis of 5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)-N-(4-(((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-




Figure 6. 5. Sturcture of 5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-N-
(4-(((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)amino)methyl)benzyl) 
pentanamide 
281 mg (0.5 mmol) of compound 5 was dissolved in 8 mL TFA and DCM (1:3), the 
mixture was stirred at room temperature for two hours. The solvent was evaporated and 
white solid was yielded. 220 mg (0.5 mmol) of de-protected compound 5 was mixed 
with 110 mg (0.5 mmol) 4-formal-benzoic boronic acid, 79 mg (0.5 mmol) pinacol and 
142 mg (0.5 mmol) triacetoxyborohydride were subsequently dissolved into 10 mL 
DMF, the mixture was stirred overnight at room temperature. The solvent was 
evaporated to yield 260 mg of white solid. (89% yield) 
1HNMR (300 MHz, CD3OD, 298 K) δ = 7.69 (d, 2H, H8, 12, J=7.80 Hz), 7.31 (d, 2H, 
H9, 11, J=7.72 Hz, overlapping), 7.27 (d, 2H, H17, 19, J=8.45 Hz, overlapping) and 7.15 
(d, 2H, H16, 20, J=8.33 Hz, overlapping), 4.40 (m, 1H, H30), 4.28 (d, 2H, H14, 
J=10.86Hz), 4.20 (m, 1H, H28), 3.99 (d, 2H, H13, J=6.56Hz), 3.92 (bd, 2H, H
21
, 
J=5.37Hz), 3.09 (m, 1H, H27), 2.90 (s, 2H, H26), 2.77 (s, 2H, H31), 2.17 (m, 2H, H23), 
1.60 (m, 4H, H24, 25), 1.25 (s, 12H, H1-4).  







13C NMR ((CD3)2OS, 300MHz, 298 K) δ = 186.2 (C22), 181.0 (C29), 176.4 (C18), 166.5 
(C10), 165.3 (C15), 136.6 (C7), 131.1 (C8), 130.1 (C12), 129.8 (C9), 129.7 (C11), 129.6 
(C16), 129.5 (C20), 124.6 (C17), 124.5 (C19), 85.6 (C5), 76.3 (C6), 63.7 (C30), 62.0 (C28), 
57.4 (C27), 53.0 (C21), 52.8 (C14, 13), 37.1 (C26), 41.5 (C31) 35.2 (C25), 30.5 (C24), 30.1 
(C23), 25.6, 25.4 (C1-4). 
Mass Spectrum ESI-MS calculated for C31H43BN4O4S [M + H] 
+ 579.3171, found 
579.3316. HPLC: Rt = 7.5 min. 
 
IR spectrum: 2973 cm-1, 1704 cm-1, 1610 cm-1, 1566 cm-1, 1510 cm-1, 1357 cm-1, 1164 
cm-1, 1141 cm-1, 1084 cm-1, 857 cm-1, 658 cm-1. 
 











231 mg (0.44 mmol) compound 6 was deprotected in 1 mL TFA to remove the boc 
group, mixed with 172 mg (0.44 mmol) FITC in 10 mL of DMF, 4 eq. of TEA was 
added consequently. The mixture was stirred overnight at room temperature covered 







with aluminium foil. The mixture was separated via extraction with DCM and water, 
products were isolated in organic phase, the DCM was evaporated and 41 mg scarlet 
solid was yielded. (4.4% yield)  
 
1HNMR (300 MHz, CD3OD, 298 K) δ = 7.65 (d, 2H, H25, 27 , J=7.83 Hz), 7.28 (m, 5H, 
H1, 3, 4, 24, 28), 6.53 (m, 10H, H8, 9, 11, 15, 17, 18, 37, 38, 40, 41), 4.95 (s, 2H, H22), 4.37 (m, 1H, 
H51), 4.25 (d, 2H, H35, J=8.21Hz), 4.14 (m, 1H, H49), 3.98 (s, 2H, H42), 3.07 (m, 1H, 
H48), 2.79 (d, 2H, H52, J=4.93Hz), 2.14 (m, 8H, H
44-47), 1.27(m, 12H, H30-33).  
 
13C NMR ((CD3)2OS, 300MHz, 298 K) δ = 172.4 (C21), 169.3 (C43), 169.0 (C20), 163.1 
(C50), 162.6 (C10), 157.5 (C12), 156.1 (C13), 152.7 (C2), 146.4 (C43), 142.9 (C16), 141.6 
(C14), 141.0 (C39), 139.0 (C26), 138.5 (C23), 134.9 (C18), 134.6 (C36), 129.5 (C8), 128.8 
(C4), 128.4 (C17), 127.4 (C24, 28), 127.2 (C19), 126.6 (C38), 126.4 (C40), 126.0 (C25), 
125.9(C27), 125.2 (C15), 83.6 (C29, 34), 35.5(C49, 51), 33.7 (C22, 35), 28.5 (C42), 28.4 (C52), 
25.7 (C44), 25.3 (C47), 25.0 (C46), 24.8(C45), 24.4 (C30-33),  
 
Mass Spectrum ESI-MS calculated for C39H37N5O7S2 [M - H] 
– 966.3383, found 
966.3471. HPLC Rt= 8.9 minutes 
 
IR spectrum: 3390 cm-1, 1735 cm-1, 1659 cm-1, 1500 cm-1, 1450 cm-1, 1357 cm-1, 1250 
cm-1, 1206 cm-1, 1174 cm-1, 1164 cm-1, 845 cm-1, 657 cm-1. 
 
  







(g) Synthesis of 4-[({[4-({[(tert-butoxy) carbonyl] amino} methyl) phenyl] methyl} 




Figure 6. 7. Strcture of 4-[({[4-({[(tert-butoxy) carbonyl] amino} methyl) phenyl] methyl} 
carbamothioyl) amino]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid 
 
196 mg (0.5 mmol) FITC and 118 mg (0.5 mmol) boc protected p-xylylenediamine 
were dissolved in 10 mL of DMF, 4 eq. of TEA (146.83 µL) was added consequently. 
The mixture was stirred overnight at room temperature and covered with aluminium 
foil. The product was evaporated and 200 mg of yellow solid yielded. (63% yield)  
 
1HNMR (300 MHz, (CD3)2OS, 298 K) δ =  8.29 (s, 1H, H1), 7.79 (d, 1H, H3, J=8.90 
Hz), 7.30 (d, 2H, H25, 27, J=8.22 Hz,), 7.21 (d, 2H, H24, 28, J=7.95 Hz), 7.18 (d, 1H, H4, 
J=7.95 Hz), 6.70 (m, 4H, H8, 9, 11, 18), 6.60 (m, 2H, H15, 17), 4.75 (s, 2H, H29), 4.12 (s, 
2H, H22), 1.34 (s, 9H, H32, 33, 34).  
 
13C NMR ((CD3)2OS, 300MHz, 298 K) δ =181.1 (C21), 169.1 (C20), 160.0 (C2), 156.3 
(C30), 152.3 (C13), 141.6 (C16), 139.4 (C26), 137.4 (C23), 130.0 (C4, 8), 129.6(C4, 8), 127.7 
(C25, 27), 127.3 (C25, 27), 127.2 (C24, 28), 127.0 (C17), 117.2 (C15), 113.0 (C3, 9), 102.7 (C1, 
11), 48.1 (C22), 43.5 (C29), 36.6 (C31), 28.7 (C32, 33, 34). 
 
Mass Spectrum ESI-MS calculated for C39H37N5O7S2 [M - H] 
– 624.1882, found 
624.1861. HPLC Rt= 9.0 minutes 
 
IR spectrum: 3256 cm-1, 1751 cm-1, 1696 cm-1, 1608 cm-1, 1535 cm-1, 1247 cm-1, 1164 
cm-1. 
 







(h) Synthesis of 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-4-(3-(4-((5-((3aS,4S,6aR)-
2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)methyl)benzyl) 




Figure 6. 8. Structure of 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-4-(3-(4-((5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)methyl)benzyl)thioureido) 
benzoic acid 
376 mg (0.5 mmol) of compound 8 was added to a solution of 2 mmol TFA and 6 mL 
DCM, the mixture was stirred at room temperature for two hours. Then solvent was 
evaporated and 263 mg yellow solid was yielded. Subsequently, 263 mg (0.5 mmol) 
de-protected compound 8 was mixed with 171 mg (0.5 mmol) biotin-NHS were 
dissolved into 6 mL DMF, the mixture was stirred overnight at room temperature. 
Evaporate solvent to yield 117 mg scarlet solid (compound 9). (31% yield)  
 
1H NMR (300 MHz, CD3OD, 298 K) δ = 10.70 (s, 1H, H20), 9.03 (s, 1H, Hc), 8.84 (s, 
1H, Hb), 8.03 (s, 1H, H15), 7.75 (d, 1H, H17, J = 8.64 Hz), 7.40 – 7.07 (m, 4H, H24, 25, 
27, 28), 6.93 (d, 1H, H18, J = 8.40 Hz), 6.63 (bd, 2H, H4, 8, J
orth = 9.34 Hz), 6.47 (s, 1H, 
Hd), 6.41 (s, 1H, He), 6.02 (dd, 2H, H3,9, Jorth = 9.34 Hz, Jmeta = 1.66 Hz), 5.92 (s, 2H, 
H1,11), 4.70 (m, 2H, H22), 4.27 (m, 1H, H38), 4.21 (d, 2H, H29, J = 5.36 Hz), 4.10 (m, 
1H, H36), 3.07 (m, 1H, H35), 2.80-2.55 (dd, 2H, H39, J = 5.02 Hz), 2.12 (t, 2H, H34), 
1.71 (m, 6H, H31,32,33). H4 and H8 are chemically inequivalent. However, due to the 
frequency of the spectrometer and a possible dynamic tautomeric equilibrium involving 
FITC unit and affecting its protons in the NMR time scale. These resonances appear as 
magnetic equivalent leading to a broad doublet peak. 
 







13C NMR ((CD3)2OS, 300MHz, 298 K) δ = 181.2 (C20), 172.6 (C21), 170.2 (C30), 163.8 
(C37), 162.9 (C2, 10) 158.8 (C19), 141.4 (C16), 139.2 (C26), 138.7(C23), 130.0 (C4, 8), 129.4 
(C18), 127.5 (C24, 25), 124.3 (C15), 123.2 (C17), 123.1 (C3,9), 122.7 (C27, 28), 102.9 (C1,11), 
61.4 (C38), 59.6 (C36), 55.8 (C35), 46.8 (C22), 42.5 (C39), 42.2 (C29), 35.4 (C34), 29.5 
(C31), 28.6 (C32), 23.4 (C33). 
 
Mass Spectrum ESI-MS calculated for C39H37N5O7S2 [M - H] 
- 750.2062, found 
750.2128. HPLC Rt= 8.7 minutes. 
 
IR spectrum: 3244 cm-1, 1751 cm-1, 1632 cm-1, 1608 cm-1, 1535 cm-1, 1247 cm-1, 1166 
cm-1, 849 cm-1. 




Figure 6. 9. Structure of 4-(tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde 
 
149 mg (1 mmol) 1, 4-formyl-phenyl-Boronic acid and 118 mg (1 mmol) pinacol were 
added to 10 mL of THF and 10 mL Toluene. The mixture was concentrated to dryness 
under reduced pressure and this procedure (solvents addition/evaporation) was repeated 
three times. (81.9% yield).  
 
1HNMR (300 MHz, CDCl3, 298 K) δ = 10.05 (s, 1H, H1), 7.98 - 7.79 (m, 4H, H3, 4, 6, 7, 
J= 8.2 Hz), 1.35(s, 12H, H10, 11, 12, 13).  
 
13C NMR (300 MHz, (CD3)2OS, 298K) = 194.8 (C1), 136.6 (C3, 7), 130.1 (C4, 6), 127.0 
(C2), 86.0 (C8, 9), 25.6 (C10-13). The peak of C5 is broadened by the quadrupole relaxation 
effect caused by the boron group attached, hence no peak has been detected in this NMR 
time scale by using a 300MHz spectrometer at 298 K.  








Mass Spectrum ESI-MS calculated for C13H17BO3 [M + H] 
+ 255.1116, found 255.1164. 
HPLC Rt= 6.6 minutes. 
 
IR spectrum: 1662 cm-1, 1564 cm-1, 1505 cm-1, 1339 cm-1, 1200 cm-1, 1184 cm-1, 1167 
cm-1, 600 cm-1. 
 
(j) Synthesis of tert-butyl N-({4-[({[4-(tetramethyl-1, 3, 2-dioxaborolan-2-yl) 




Figure 6. 10. Structure of tert-butyl N-({4-[({[4-(tetramethyl-1, 3, 2-dioxaborolan-2-yl) 
phenyl] methyl} amino) methyl] phenyl} methyl) carbamate 
 
142 mg (0.6 mmol) Boc protected p-xylylenediamine and 139 mg (0.6 mmol) pinacol 
protected boronic acid were added into 18 mL DCM, 178 mg (0.6 mmol) Sodium 
triacetoxyborohydride was subsequently added. The mixture was stirred overnight at 
room temperature under nitrogen conditions. Then MilliQ water was added to eliminate 
Sodium triacetoxyborohydride and compound 11 was washed by water. DCM was 
evaporated to yield 202 mg of white solid (73% yield).  
 
1H NMR (300 MHz, CDCl3, 298K)  =  7.69 (d, 2H, H8, 12, J=8.17 Hz), 7.33 (d, 2H, 
H9, 11, J=8.17 Hz, overlapping with H8 and H12), 7.28 (d, 2H, H17, 19, J=8.17 Hz, 
overlapping with H16 and H20) and 7.15 (d, 2H, H16, 20, J=8.17 Hz, overlapping with H17 
and H19), 4.85 (s, 1H, Hb), 4.32 (d, 2H, H21, J=6.52Hz), 3.75 (bs, 2H, H14), 3.46 (bs, 
2H, H13), 1.39 (s, 9H, H24, 25, 26), 1.27 (s, 12H, H1-4).  
 







13C NMR (300 MHz, (CD3)2OS, 298K)  = 193.9 (C22), 143.0 (C18), 135.3 (C10), 132.8 
(C15), 131.9 (C8, 12), 129.0(C9), 128.9 (C11),128.4 (C16, 20), 127.3(C17), 127.2 (C 19), 84.0 
(C5, 6), 78.4 (C23) 58.0 (C13, 14), 28.4 (C1-4, 24-26),  
 
Mass Spectrum ESI-MS calculated for C26H37BN2O4 [M + Na] 
+ 453.2920, found 
453.2966. HPLC Rt= 5.1 minutes. 
 
IR spectrum: 2980 cm-1, 1695 cm-1, 1564 cm-1, 1508 cm-1, 1357 cm-1, 1140 cm-1, 1086 
cm-1, 1200 cm-1, 600 cm-1. 
 
 (k) Synthesis of 4-{[({4-[(tert-butylamino)methyl]phenyl}methyl)({[4-
(tetramethyl-1,3,2 - dioxaborolan-2-yl)phenyl]methyl})carbamothioyl]amino}-




Figure 6. 11. Structure of 4-{[({4-[(tert-butylamino)methyl]phenyl}methyl)({[4-(tetramethyl-
1,3,2 - dioxaborolan-2-yl) phenyl]methyl})carbamothioyl]amino}-2-(6-hydroxy-3-oxo-3H-
xanthen-9-yl)benzoic acid 
 
196 mg (0.26 mmol) FITC and 118 mg (0.26 mmol) boc protected p-xylylenediamine 
were dissolved in 10 mL of DMF, 4 eq. of TEA (146.8 µL) was added consequently. 
The mixture was stirred overnight at room temperature and covered with aluminium 
foil. The product was evaporated and yielded 102 mg yellow solid. (46.7% yield)  
 
1HNMR (300 MHz, CD3OD, 298K)  = 7.89 (d, 1H, H1 , J=1.61 Hz), 7.79-7.10 (m, 
6H, H2, 3, 11, 12, 13, 14), 6.69-6.50 (m, 10H, H4, 5 , 6, 7, 8, 9, 20, 21, 22, 23), 5.11 (s, 2H, H15), 4.23 
(s, 2H, H10), 3.87 (s, 2H, H19), 1.43 (s, 9H, H16-18), 1.27(s, 12H, H24-27).  








Mass Spectrum ESI-MS calculated for C47H48BN3O9S [M - H] 
- 840.3132, found 
840.3195. HPLC Rt= 9.2 minutes. 
 












57 mg (0.16 mmol) bodipy and 68 mg (0.16 mmol) compound 6 were dissolved in 6 
mL of DMF, 4 eq. of TEA was added subsequently. The mixture was stirred overnight 
at room temperature and covered with aluminium foil. Subsequently, the mixture was 
separated via extraction with DCM and water, products were isolated in organic phase, 
the DCM was evaporated and yielded a red solid.  
 
1H NMR (300 MHz, (CD3)2OS, 298K) δ = 8.18-7.01 (m, 12H, H15,16,18, 19, 23, 24, 26, 27, 
35,36, 38, 39), 6.82 (s. 1H, H11), 5.98 (s. 1H, H3), 4.31 (m, 1H, H48), 4.24 (d, 2H, H41, J = 
3.3 Hz), 4.12 (m, 1H, H49), 4.10 (m, 2H, H34),3.41 (m, 2H, H21) 3.17-0.70 (m, 11H, 
H43-47, 50), 1.32 (s, 6H, H1, 13), 1.23 (s, 12H, H29-32), 1.10 (s, 6H, H5, 10).  
 







13C NMR (300 MHz, DMSO-d6, 298K) = 211.8 (C42), 211.1 (C20), 210.5 (C51), 144.7 
(C14), 140.1 (C4), 136.6 (C22), 136.2 (C37), 130.6 (C23, 24, 25, 27), 129.7 (C35, 36, 38, 39), 129.1 
(C15, 16, 18, 19), 126.5 (C12), 85.0 (C28, 33), 63.7 (C48), 59.3 (49), 57.4(C47), 45.3 (C34), 44.4 
(C21), 41.5 (C41), 37.1(C50), 35.8(C43), 29.8 (C45), 27.2 (C44), 26.5 (C46), 25.4 (C29-32), 
15.2 (C5, 10), 11.9 (C1, 13).  
 
Mass Spectrum ESI-MS calculated for C51H60B2F2N6O5S [M - 2H] 
2- 463.2177, found 
463.2174. HPLC Rt= 10.1 minutes. 
 
IR spectrum: 3244 cm-1, 1698 cm-1, 1632 cm-1, 1557 cm-1, 1545 cm-1, 1359 cm-1, 1260 
cm-1, 1166 cm-1, 1087 cm-1, 1017 cm-1, 849 cm-1, 796 cm-1. 
 











42 mg (0.22 mmol) Coumarin-3-carboxylic acid and 127 mg (0.22 mmol) compound 6 
were dissolved in 6 mL of DMF, with 4 eq. (123.3 µL) of TEA subsequently added. 
The mixture was stirred overnight at room temperature and covered with aluminium 
foil. Consequently, the mixture was separated via extraction with DCM and water, 
products were isolated in the organic phase, the DCM was evaporated and 52 mg of 
yellowish solid was yielded (31% yield).  








1H NMR (300 MHz, (CD3)2OS, 298K) δ = 8.07-6.99 (m, 13H, H1, 2, 3, 7, 9, 13, 14, 16, 17, 26, 
27, 29, 30), 4.31 (m, 1H, H38), 4.23(m, 4H, H24, 31), 4.15 (m, 1H, H39), 3.46 (s, 2H, H11), 
1.96-0.63 (m, 23H, H19-22, 33-37, 40)  
 
13C NMR (DMSO-d6, 500MHz, 298 K): δ = 206.2 (C32), 172.0 (C41), 141.8 (C5), 137.7 
(C4), 136.0 (C28), 134.3 (C25), 134.0, 133.7 (C14, 16), 133.6 (C13, 17), 128.0 (C26, 30), 127.9 
(C27, 29), 127.2 (C2), 126.8 (C9), 126.6 (C1), 83.9 (C23), 83.1 (C18), 82.7, 33.0 (C35), 24.6 
(C34), 23.9 (C36), 23.8 (C19-22).  
 
Mass Spectrum ESI-MS calculated for C41H47BN4O7S [M + H]
 + 750.3331, found 
750.3338. HPLC Rt= 12.0 minutes. 
 
IR spectrum: 1699 cm-1, 1611 cm-1, 1565 cm-1, 1515 cm-1, 1355 cm-1, 1164 cm-1, 1143 
cm-1, 1086 cm-1, 1020 cm-1, 857 cm-1, 658 cm-1. 
 
6.16. Fluorescence spectroscopy test 
Fluorescence spectroscopy titration:  
1×10-6 mol of compound 7 was dissolved into 50 mL methanol (HPLC) solvent to give 
2×10-5 M compound 7 stock solution. From this stock, 1 mL was taken and dissolved 
into 49 mL of MilliQ water solution to make 4×10-7 M solution. 1 mg of -D-glucan 
was weighed and dissolved into 1 mL DMSO at 50 ºC.  
The fluorimeter was switched on and warmed for 30 min before use. The spectra 
were recorded with a 488 nm excitation wavelength. A blank reading for the pure 
solvent mixture used was taken, then for the stock solution and the glucan solution was 
added cumulatively, one aliquot per every 10 minutes, as it is shown in the following 
table. Because -D-glucan is a polysaccharide, the number of glucose repeating units is 
known to vary in different glucan chains. Therefore, average molecule weight of glucan 
used in this project is 2 kDa, which was the molecular weight provided by the supplier. 
  







Table 6. 1. Volume of -D-glucan (1 mg/mL in DMSO) titrated 
 Volume (µL) Total conc. (M)  Volume (µL) Total conc. (M) 
1 10 1×10-7 6 100 2.5×10-6 
2 20 3×10-7 7 100 3.5×10-6 
3 30 6×10-7 8 150 5×10-6 
4 40 1×10-6 9 250 7.5×10-6 
5 50 1.5×10-6 10 250 1×10-5 
 
All the results are fitted by the equation: 
I = 





I stands for overall intensity, I0 and If is initial and final intensity respectively, [C] means 
concentration of compound and KD
−1 is the binding constant.  
 
Kinetic stability of fluorescence compound: 
4 mg of compound 7 was dissolved in 1 mL of methanol (4 mM), 0.1 mL of the 
compound 7 solution was diluted into 3.9 mL of water (0.1 mM). The fluorescence of 
solution was measured every 30 minutes in 4.5 hours.  
 
Kinetic stability of fluorescence compound in different medium: 
4 mg of compound 7 was dissolved in 1 mL of methanol (4 mM), 0.1 mL of the 
compound 7 solution was diluted into 9.9 mL of methanol (0.04 mM), then mix solution 
one to one with water, serum medium or serum free medium respectively.  
 
Qualitative avidin binding tests for the fluorescence sensors: 
1 mg avidin was dissolved into 1 mL of water, which made avidin solution to react with 
10 µg of biotin. 4.0 mg of compound 7 was dissolved into 1 mL of methanol (4 mM), 
and then diluted 1 in 100 into water. 3.0 mg of compound 9 was dissolved into 1 mL of 
methanol (4 mM), and then diluted 1 in 100 into water. 0.5 mL of compound 7  or 
compound 9 was mixed with 0.5 mL of water to give samples 1 and sample 2, 0.5 mL 







of compound 7   or compound 9 was mixed with 0.5 mL of avidin solution (1 mg/ml in 
water) to give samples 3 and 4. 
 
Direct interaction between fluorescent sensors with purified SWNTs: 
4 mg (4 mM) of compound 7 was dissolved into 1 mL of methanol (4 mM stock solution) 
and then solution was diluted 500 µL in 1500 µl water (Compound 7 solution). 500 µL 
compound 7 stock solution was dissolved into 1 mL of water, and then add 500 µL of 
1mg/mL SWNTs dispersion (Compound 7 @SWNTs dispersion). 
 
6.17. Cellular culturing methods 
Cell lines involved in this project include cervical cancer cells (HeLa) and epithelial 
fibroblast cells (FEK-4), breast cancer cells (MCF-7) and prostate cancer cells (PC-3). 
All cells lines were inherited from Rex Tyrrell group or provided in Rutherford 
Appleton Laboratory (RAL). Cells were normally frozen at -196 °C under liquid 
nitrogen condition until required, then cells would be thrown quickly and incubated at 
37 °C under 5% carbon dioxide environment. Different cells required different solvent 
system to grow, for example, HeLa and FEK-4 cells were usually incubated in an 
Eagle’s Minimum Essential Medium (EMEM), whilst Dulbecco’s Modified Eagle’s 
Medium (DMEM) were suitable for MCF-7 cells growing and PC-3 cells could be 
cultured in Roswell Park Memorial Institute (RPMI) medium. All media contained 
activated foetal calf serum (FCS) (10% for HeLa, PC-3 and MCF-7 and 15% for FEK-
4), 0.5% penicillin/streptomycin (10,000 IU mL-1/10,000 mg mL-1) and 2.5% L-
Glutamine. 
 
6.18. Cells thawing 
A vial of frozen cells were taken from the liquid nitrogen storage and placed in a 37 °C 
water bath. Immediately after all the ice had thawed, the cells were transferred into a 
centrifuge tube with 10 mL of serum media. Unless otherwise stated, serum media 
contained 10% foetal calf serum (FCS) for cancer cell lines and 15% FCS for healthy 







cell lines. The centrifuge tube was then spun at 1000 rotations per minute (rpm) for 5 
minutes to precipitate the cells. The supernatant would subsequently be aspirated and 
refilled with 10 mL serum media. Finally, all cells with fresh media were transferred 
into a T75 cell culture flask and incubated at 37 °C.  
 
6.19. Cells splitting 
Cell splitting was the fundamental part of the cell growing experiment, as it was 
essential to split cells once or twice per week depending on the confluence of the cells 
in the flask, in order to harvest cells for the research and to leave space for more cells 
to grow.  
 The surplus supernatant contained dead cell matter and excess proteins were 
aspirated. All attached cells were washed by 10 mL phosphate buffer saline (PBS) twice, 
(all solvents, buffer solutions and media were warmed to 37 °C in the water bath prior 
to addition) 3 mL of trypsin - PBS solution (0.25% trypsin) was subsequently loaded 
and incubated at 37 °C for 5 minutes. After trypsinisation, 5 mL serum medium was 
added to neutralise the excess trypsin and solution was centrifuged at 1000 rpm for 5 
minutes. Afterwards, the supernatant was aspirated and re-suspended with 5 mL serum 
medium. Cells were counted in a haemocytometer and seeded appropriately for 
different applications.                             
 
6.20. Cell freezing 
After cell splitting, the excess cells could be frozen for future use. 0.5 million – 1 
million cells were kept in a vial with 2 mL mixture solution of 50% serum medium, 40% 
foetal calf serum and 10% DMSO. There were two ways to freeze cells; A Thermo 
Scientific™ Mr. Frosty™ Freezing Container was used in the direct method, vials were 
placed in the container and left container at -80 °C freezer overnight, cells would be 
cooling at rate of -1 °C / minute and be ready to stay in a liquid nitrogen environment. 
If there was no freezing container, an indirect method was applied instead; vials were 
placed in the 4°C fridge for 20 min. Then vials were transferred into -20°C freezer for 







30 min. Subsequently, vials were moved into -80°C freezer for 24 hours. Finally, vials 
would be sent to liquid nitrogen for long term storage. 
 
6.21. MTT assays 
After cell splitting, cells (3×103 cells per well) were seeded on a sterile 96 well plate 
and incubated for 48 hours to adhere. Varieties of compound were subsequently loaded 
at different concentration into wells and cultured for another 48 hours. The 
Concentration used ranged between 250 μM (1% DMSO, 99% Eagle’s Modified 
Essential Medium (10% FCS, or 15 % FCS as per cell line) and 100 nM as they were 
shown in Table 6.1. Subsequently, cells were washed three times with PBS and 3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) was added (0.5 mg/ 
mL, 10% serum free medium (SFM)) followed by a two hour incubation. After 
aspiration, 100 μl of DMSO was added and 96 well plates were read by an ELISA plate 
reader, Molecular Devices Versa Max (BN02877). The absorption wavelength was at 
570 nm and 630 nm wavelength was used as a reference. For establishing the correct 
protocols, a library of known compounds with solubility similarities and which also 





Figure 6. 14. Compounds 16a-c, 17a-b were antihypoxia reagent tested in MTT assays 
(samples were provided by Professor Golzar Hossain, from University of Dhaka in Bangladesh) 










Figure 6. 15. Complexes 18a-c, 19a-c were thiosemicarbazonato antihypoxia reagents 
examined by MTT assays (samples were provided by Rory Arrowsmith, from University of 
Bath). 
 
Standard conditions of the MTT assays was established based on several classes of 
anticancer reagent provided by Prof. Golzar Hossain, from University of Dhaka in 
Bangladesh and Rory Arrowsmith (Pascu group, University of Bath). As it was shown 
in figure 6.14 and 6.15, both compound 16 -17(organic compounds) and compound 18-
19 (bisthiosemicarbazonato complexes) series are known to have potential to target 
hypoxic regions, a trait commonly associated with later stages of cancer. The reason 
compound 16-17 was chosen was because these compounds all carried –NC=SN– 
groups, which was similar to compound 7. In addition, the qualities of compounds were 
enough for sufficient repeats of the experiment. Compound 18-19 was chosen as a 
comparison of compound 16-17, in order to investigate whether the protocol established 
was suitable for the general use of the MTT assays. As a result, the following conditions 
were subsequently established, and for all new compounds developed in this project.











Sample 1  Sample 2  Smaple 3  Sample 4  Sample 5  
  250µm 1µm 250µm 1µm 250µm 1µm 250µm 1µm 250µm 1µm 
  250µm 1µm 250µm 1µm 250µm 1µm 250µm 1µm 250µm 1µm 
  100µm 0.5µm 100µm 0.5µm 100µm 0.5µm 100µm 0.5µm 100µm 0.5µm 
  100µm 0.5µm 100µm 0.5µm 100µm 0.5µm 100µm 0.5µm 100µm 0.5µm 
  50µm 100nm 50µm 100nm 50µm 100nm 50µm 100nm 50µm 100nm 
  50µm 100nm 50µm 100nm 50µm 100nm 50µm 100nm 50µm 100nm 
  10µm 1nm 10µm 1nm 10µm 1nm 10µm 1nm 10µm 1nm 
  10µm 1nm 10µm 1nm 10µm 1nm 10µm 1nm 10µm 1nm 
  











Sample 1  Sample 2  Smaple 3  Sample 4  Sample 5  
  1µg/mL 10ng/mL 1µg/mL 10ng/mL 1µg/mL 10ng/mL 1µg/mL 10ng/mL 1µg/mL 10ng/mL 
  1µg/mL 10ng/mL 1µg/mL 10ng/mL 1µg/mL 10ng/mL 1µg/mL 10ng/mL 1µg/mL 10ng/mL 
  0.5µg/mL 5ng/mL 0.5µg/mL 5ng/mL 0.5µg/mL 5ng/mL 0.5µg/mL 5ng/mL 0.5µg/mL 5ng/mL 
  0.5µg/mL 5ng/mL 0.5µg/mL 5ng/mL 0.5µg/mL 5ng/mL 0.5µg/mL 5ng/mL 0.5µg/mL 5ng/mL 
  0.1µg/mL 1ng/mL 0.1µg/mL 1ng/mL 0.1µg/mL 1ng/mL 0.1µg/mL 1ng/mL 0.1µg/mL 1ng/mL 
  0.1µg/mL 1ng/mL 0.1µg/mL 1ng/mL 0.1µg/mL 1ng/mL 0.1µg/mL 1ng/mL 0.1µg/mL 1ng/mL 
  50ng/mL 0.5ng/mL 50ng/mL 0.5ng/mL 50ng/mL 0.5ng/mL 50ng/mL 0.5ng/mL 50ng/mL 0.5ng/mL 
  50g/mL 0.5ng/mL 50g/mL 0.5ng/mL 50g/mL 0.5ng/mL 50g/mL 0.5ng/mL 50g/mL 0.5ng/mL 
  







In the next stage, several compounds and composites were tested in the 
previously established procedure, including individual boronic acid attached 
fluorophores (Figure 6.16), SWNTs in different stages (raw, purified and -D-glucan 
coated) (Figure 6.17) and fluorophore @glucan @SWNTs. All compounds and 
composites were dissolved or dispersed into DMSO to make a stock solution 





Figure 6. 16. Sturcture of biotin-boronic acid fluorecent probes with different fluorophores 
 
  









Figure 6. 17. Strcuture of SWNTs at different stages: (a) Raw SWNTs, (b) Purified SWNTs, 
(c) -d-glucan coated SWNTs and (d) Fluorescent probe attached -d-glucan SWNTs 
nanohybrids. 
 
6.22. Confocal microscopy 
Fluorescence microscopy images were captured on a Nikon eclipse TE2000 epi-
fluorescence or a Zeiss LSM510META microscope at University of Bath, whereas at 
the Rutherford Appleton Laboratory a modified Nikon TE2000-U was utilised. HeLa, 
PC-3 or MCF-7 cells were cultured as above and plated in a glass bottomed petri dish 
(35 mm diameter and 1.5 mm thickness) at 1.5×105 -2.5×105 cells per dish depending 
on the cell line and culture time. In general, HeLa cells required 12 hours to attach onto 
the dish, whereas MCF-7 and PC-3 needed 48 hours to adhere. Prior to the microscopy 
observation, cultured cells were washed with Hank’s solution (HBSS) five times and 
refilled with 990 µL of serum free medium. Subsequently, a small volume of compound 
(10 µL) in DMSO was loaded to make the final volume 1 mL at the appropriate 
concentration. The final concentration on the plate were usually at 100 nM with 1% - 
5% DMSO depending on the compound solubility. After 15 min or 1 hour incubation 
at 37 °C, cells were washed with HBSS three times and refilled with fresh SFM (1 mL). 
Confocal images were captured immediately afterwards. 
  
Concentration dependent confocal imaging protocols 
HeLa cells were cultured as above and plated in a glass bottomed petri dish at 1.5×105 
cells per dish. Prior to the microscopy observation, cultured cells were washed with 
HBSS five times and refilled with 990 µL of serum free medium (room temperature). 







Subsequently, a small volume of compound (10 µL) in DMSO was loaded to make the 
final concentration 1 nM, 10 nM, 50 nM or 100 nM with 1% DMSO. After 15 min or 
1 hour at 37 °C, cells were washed with HBSS three times and refilled with fresh SFM 
(1 mL). Confocal images were captured immediately afterwards.  
 
Temperature dependent confocal imaging methods 
HeLa cells were cultured as above and plated in a glass bottomed petri dish at 1.5×105 
cells per dish. Prior to the microscopy observation, cultured cells were washed with 
HBSS five times and refilled with 990 µL of cold serum free medium (4°C). 
Subsequently, a small volume of compound (10 µL) in DMSO was loaded to make the 
final concentration at 100 nM with 1% DMSO. After 15 min or 1 hour incubation at 
4 °C in the fridge, cells were washed with HBSS three times and refilled with fresh cold 
SFM (1 mL). Confocal images were captured immediately afterwards.  
 
Time dependent confocal imaging methods 
HeLa cells were cultured as above and plated in a glass bottomed petri dish at 1.5×105 
cells per dish. Prior the microscopy observation, cultured cells were washed with HBSS 
five times and refilled with 990 µL of serum free medium (room temperature). 
Subsequently, a small volume of compound (10 µL) in DMSO was loaded to make the 
final concentration 100 nM with 1% DMSO. After 15 min, 30 min, 1 hour, 3 hour or 
overnight incubation at 37 °C, cells were washed with HBSS three times and refilled 
with fresh SFM (1 mL). Confocal images were captured immediately afterwards.  
 
Alternative method to wash cells 
HeLa cells were cultured as above and plated in a glass bottomed petri dish at 1.5×105 
cells per dish. Prior to the microscopy observation, cultured cells were washed with 
phosphate buffered saline (PBS) five times and refilled with 990 µL of serum free 
medium. Subsequently, a small volume of compound (10 µL) in DMSO was loaded to 
make the final concentration 100 nM with 1% DMSO. After 15 min incubation at 37 °C, 
cells were washed with PBS three times and refilled with PBS (1 mL). Confocal images 
were captured immediately afterward.  







Cell fixation with methanol 
The cell plate was washed by PBS two times, then 1 mL of 10% methanol / 90% water 
was added and left for five minutes, afterward, supernatant was removed. 1 mL of 30% 
methanol / 70% water mixture was subsequently loaded. Cells were incubated for five 
minutes and the supernatant was removed. The plate was refilled with 1 mL of 50% 
methanol / 50% water mixture and after five minutes the supernatant was removed. 
Next, 1 mL of 80% methanol / 20% water mixture was added to the plate, left for five 
minutes and the supernatant was removed. Finally, the sample was left on the beach to 
dry in air. 
 
6.23. Fluorescence lifetime imaging microscopy (FLIM) 
Lifetime measurements were recorded using time-correlated single photon counting 
with an excitation wavelength of 910 nm and the emission measured at 360-580 nm. 
The measurement of compounds were carried out in DMSO/ water solvent with 
concentration of 10 mM. Emission spectral detection was carried out using an acton 
Research Component 275 spectrograph and an Andor iDus 740-BU CCD camera.  
Cell uptake studies were performed using HeLa, PC-3 and CHO cells. Cells 
were plated on a glass petri dishes and left cells to attach for 12-24 hours depend on the 
growth rate. Control FLIM were recorded before the addition of compound. Plates were 
then mounted on the microscope stage and kept at 37ºC.  
Compounds were dissolved in DMSO and added to cells to achieve final 
concentration of 100µM in EMEM/RPMI medium containing 1% of DMSO. Cells were 
incubated for 15 minutes prior to confocal imaging, FLIM was carried out immediately 
after the confocal imaging with the same area as the confocal imaging.   
















6.24. Co-localisation studies 
There were varieties of tracking dyes used to localise distribution of samples via 
confocal microscopy; all dyes in the following studies were purchased from Invitrogen. 
Cells were cultured in Eagle’s Minimum Essential Medium (EMEM) or Roswell Park 
Memorial Institute (RPMI)-1640 medium using standard protocols described above. 
Prior to addition of any commercial co-localisation dye, cells were washed five times 
with HBSS. Protocols were adapted from Invitrogen.1-4 
 




Figure 6. 18. Structure for Hoechst® nucleus stain from Invitrogen 
 
The 10 mg/mL Hoechst original solution was prepared by dissolving 10mg Hoechst 
33342 (Invitrogen) in 1 mL of sterile MilliQ water, 10 μL of the original solution was 
dissolved into 990 μL sterile water to make a 100 μg/mL stock solution. Cells were then 
washed five times with HBSS, and then refilled with 990 μL SFM. 10 μL of stock 
solution was then added to the 990 μL SFM. Cells were then incubated for 20 to 30 
minutes. Subsequently, cells were washed three times with HBSS and refilled with 1 
mL SFM to take control images. Then, cells were washed and the compounds of interest 
for co-localisation studies were loaded.  After 15 min incubation with the compound, 
cells were washed three times with HBSS and refilled with fresh SFM (1 mL). Confocal 
images were recorded immediately afterwards. 
 
Mitotracker (mitochondrial dye) 







There were two mitotracker dyes used (Invitrogen) in this group’s research, one was 
mitotracker Red (Figure 6.19 20) and the other one was mitotracker Green (Figure 6.19 
21), both dyes could label mitochondria with the former excited by red light at 543 nm 
and the later excited at 488 nm, which was a green light. In each case, to prepare stock 
solutions, to the as-bought 50 μg of mitotrackers, 69 μL DMSO was added to 




Figure 6. 19. Structure of mitotracker dyes used 
 
Subsequently, 20 μL of the 1 mM stock solution was diluted into 980 μL of DMSO to 
make 20 µM solution. Prior to the test, cells were washed five times with HBSS, then 
the cell plate was refilled with 990 μL SFM. To this, 10 μL of 20 µM solution was 
added. Cells were incubated for 15 to 45 minutes and subsequently washed three times 
with HBSS. The dishes were then refilled to 1 mL fresh SFM to take control images of 
the cells with dye-stained mitochondria. Then, cells were washed and the imaging probe 
of interest for the co-localisation studies was loaded. After 15 min incubation with the 
compound, cells were washed three times with HBSS and refilled with fresh SFM (1 
mL). Confocal images were recorded immediately afterwards. 
 
 











Figure 6. 20. Structure of Lysotracker dyes used 
 
As was for the lysotracker dye, the group also uses two different dyes: Lysotracker red 
(Figure 6.20 22-a) and Lysotracker green (Figure 6.20 22-b). The excitation wavelength 
for each Lysotracker was 577 nm and 488 nm respectively. The stock solution available 
from the supplier (Invitrogen) is 1 mM. For co-localisation experiments, 20 μL of this 
stock was dissolved into 980 μL DMSO to obtain 20 μM diluted solutions ready for use. 
Cells were washed five times with HBSS, and then plates were refilled with 990 μL 
SFM. 10 μL of the diluted stock solution was prepared as above and were added to the 
990 μL SFM to make a 200 nM final concentration on the cell plate. Cells were 
incubated for 30 to 120 minutes then washed three times with HBSS. Plates were 
refilled with 1 mL SFM to take control images of lysosomes stained cells. Then, cells 
were washed with HBSS and refilled with fresh SFM and the desired compound for co-
localisation images were loaded. After 15 min incubation with the compound, cells 
were washed three times with HBSS and refilled with fresh SFM (1 mL). Confocal 
images were recorded immediately afterwards. 
 
ER tracker (stains the endoplasmic reticulum): 
The original solution provided by the supplier (Invitrogen) was 1 mM. From this 10 μL 
was diluted with 90 μL DMSO to obtain 100 μM stock solutions. Then, cells were 
washed five times with HBSS and plates were refilled with 990 μL SFM. Subsequently, 
10 μL of the diluted stock solution (prepared as above) was added to make 1 μM 







solutions on the cell plate. Cells were incubated for 15 to 30 minutes and subsequently 
cells were washed three times with HBSS. The plates were refilled with 1 mL SFM to 
take control images of ER (endoplasmic reticulum) -stained cells. Finally, cells were 
washed and the compound of interest for co-localisation studies was loaded. After 15 
min incubation with the compound, cells were washed three times with HBSS and 





Figure 6. 21. Structure of ER tracker dyes used 
 
6.25. Epifluorescence microscopy 
Epifluorescence imaging was performed on a Nikon Eclipse TE2000-E epifluorescence 
microscopy. This was equipped with a mercury lamp (Nikon HG-100W, Tokyo, Japan) 
as the excitation source, and a high-definition cooled colour digital camera (DXM 
1200C, with 12.6-mega output pixels). Fluorescence images were captured at four 
different channels, including, DAPI (blue) channel: ex = 340-380 nm, em = 435-485 
nm. GFP-L (green) channel: ex = 460-500 nm, em = 510 nm long pass. CY3 HYQ 
(orange) channel: ex = 530-560 nm, em = 573-648 nm. CY5 HYQ (red) channel: ex 
= 590-650 nm, em = 663-738 nm. Pictures were collected and analysed via NIS-
elements software package. 
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Chapter 7. Conclusions and proposals for 
future work 
 
In this research project, a novel synthetic pathway for boronic acid-based fluorescence 
sensors was designed and several new fluorophores were synthesised. A biotin-
xylylenediamine-boronic acid linker was established as the most promising scaffold. 
Three fluorophores: FITC, Bodipy and coumarin were functionalised onto this linker 
respectively. These fluorescent molecules were synthesised and characterised 
successfully by spectroscopic techniques, but due to the presence of the boronic acid, 
all of the final products were difficult to purify through column chromatography. Hence, 
a low yield was one of the major challenges encountered in these synthesis. These 
fluorescent sensors were examined via fluorescence and UV-Vis spectroscopies, which 
allowed kinetic stability tests and binding studies to be performed. SWNTs-based 
hybrids incorporating these fluorophores were synthesised, characterised by 
microscopies such as TEM and SEM, and investigated in vitro via MTT assays, 
confocal microscopy and fluorescence-lifetime imaging microscopy (FLIM).  
At the start, the purification of arc-made SWNTs through well-established 
solvent oxidation methods was performed and it was found that the literature published 
methods are not ideal to generate entirely defectless SWNTs strands, as it was 
previously predicted, and as is necessary, for any biomedical application. Although the 
methods available are sufficiently proficient at removing the metal particles present as 
contaminants (e.g. Fe, Ni, Y catalysts), it remains challenging to eliminate the 
carbonaceous structures, attached to the surface of these SWNTs strands, such as 
amorphous carbon and carbon nanoparticles, without damaging the structure of SWNTs. 
Further improvements were introduced here, but the remains scope for improvement 
for the mass production of such defect-free species in high yield needed for commercial 
applications. Commercially available, already pre-modified, CVD-made SWNTs 
became available instead as a part of an on-going collaboration involving the Oxford 
Nanotube Group and Thomas Swann & Co. Ltd. Those samples were readily purified 
by a steam-based gas phase oxidation methods and have been proven hereby that they 
are appropriate to be used in vitro on basic of investigation research purposes through 








TEM, Raman spectra and MTT assays. There were two methods applied in this work 
to functionalise the purified SWNTs in H2O, the non-covalent functionalisation of 
SWNTs with -D-glucan or interior cavity filling of SWNTs with metal ions as models 
for metal radioisotopes incorporation. Both methods were successfully established and 
resulting nano-hybrid characterised via TEM, EDX analysis and Raman spectroscopy. 
However, the resolution of TEM micrograph obtained so far with available 
instrumentation was not high enough for imaging the soft material wrapped around the 
SWNTs strands and -D-glucan was deteriorated under the electron beam, forming an 
aggregation in the dry state. Under TEM, it was difficult to find an individual SWNT 
or several SWNT bundles from the film resulting from -D-glucan aggregation. Higher 
resolution TEM imaging of metal salt filled SWNTs still needed to clearly demonstrate 
the expected filling and estimate the filling yield in the presence of glucan. Nevertheless, 
despite difficulty with TEM imaging, both EDX analysis and Raman showed that the 
wrapping and filling of SWNTs was successfully achieved.  
Several MTT assays have been carried out to determine the cytotoxicity of 
varieties of compounds as well as nano-composites of relevance to this work. The 
library tested included SWNTs, functionalised SWNTs and the fluorescent sensor 
synthesised. In fact, SWNTs were found to be toxic materials via the biological assays, 
but after purification and functionalisation with -D-glucan, the cytotoxicity dropped 
significantly and thus the viability of these systems as nanomedicines increased 
considerably. As for the fluorescent sensors used in this research, the cytotoxicity 
varied across these series and the majority of these sensors were only cytotoxic at high 
concentration (5×10-6 mg/mL). Most of the fluorescent compounds synthesised were 
non-toxic at the concentration used in the confocal microscopy and could be tolerated 
in the living cell experiments under the dilution of the experiments. The results were 
extremely promising indicating that most of the fluorescent sensors in assays are 
suitable for imaging experiments in cells, and matched expectations with errors within 
acceptable ranges (< 0.05).  
Confocal images the fluorescent sensors synthesised were recorded, but only 
fluorescein- (FITC), coumarin- and bodipy-based boronic acid fluorescent sensors 
showed interesting results in terms of cellular uptake and cell stability, since these three 








systems covered a wide range of the fluorescence emission spectrum. Hence, these 
three fluorophore were selected to incorporate with design of the new fluorescent 
sensors. There were a variety of fluorescent sensors imaged in different cell lines, under 
different ambient conditions, under laser scanning confocal microscopy and FLIM 
(single photon and two photon excitation. In confocal microscopy, FITC based 
fluorescent sensors were shown to have a good penetrability through the cell membrane 
and nuclear membrane, but most of FITC-based fluorescent sensors stayed in the 
cytoplasm. Both Hoechst and lysotracker co-localisation experiments were performed 
to confirm the presence of FITC-based fluorescent molecules in the nucleus and 
cytoplasm respectively. Biocompatible SWNTs functionalised with fluorescent sensors 
were subsequently examined. As a result, -D-glucan with a FITC fluorescent sensor 
tag was added to two different cell lines. Both cells types showed a reasonable uptake 
of these composites and fluorescence imaging showed that there were fewer composites 
absorbed by the cell nucleus than by the cytoplasm. However, SWNTs@ glucan@ 
FITC fluorescent sensor images showed a clear penetration of both the cell membrane 
and nuclear membrane, strong fluorescent signals were detected from the entirety of the 
cells, with slight disruption of the cell homeostasis. Subsequently, it found that 
incubation time and temperature are also important factors affecting the results of 
confocal imaging experiments. The increment of incubation time significantly 
augmented both the fluorescent signals and toxicity in cells. Conversely, cells cultured 
at lower temperatures could considerably reduce the uptake rate of fluorescent 
compounds and inhibited the damage caused by these compounds. As for the FLIM 
experiments, the fluorescence lifetime and component distributions were performed for 
different fluorescent sensors, with a variety of solvents or cells under different 
conditions. In TCSPC, the fluorescence lifetime were appreciated on single components 
or two components exponential fitting functions and the two lifetime components were 
close to evenly separated in solutions (DMSO).  In FLIM, the majority of the 
fluorescence lifetimes were presented only two-component functions, with the 
components distributions being rather variable. The chi-squared values were, however, 
within the acceptable range (basically, 2<1.5).  







In conclusion, novel boronic acid-based fluorescent sensors incorporating biotin 
as the targeting biomolecule were designed, synthesised and characterised. Robust 
MTT assay and confocal imaging protocols were established successfully based on a 
large number of iterative experiments on a number varieties of anticancer drugs and 
fluorescent sensors which were incorporated to verify the robustness of the method. As 
made fluorescent sensors have been proven to be useful and biocompatible in the in 
vitro experiment based on confocal imaging via established MTT assays and the 
confocal imaging processes designed. In the same way, commercial steam-purified 
SWNTs were functionalised by 𝛽-D-glucan through a non-covalent wrapping method 
in aqueous media. After characterisation via TEM, SEM and Raman spectroscopy, 
these glucan@ SWNTs and fluorescent sensor @ glucan @ SWNTs nanohybrid have 
been delivered to HeLa cells to investigate cytotoxicity effect and obtain confocal 
images of their bio-localisation. On the other hand, purified SWNTs have been used to 
encapsulate small ions in water, such as Zr4+, Na+ and Cu2+, of relevance to 
radiochemistry with unusual metallic radioisotopes and a protocol of filling, followed 
by wrapping for SWNTs was subsequently established for SWNTs.  
In future work, more fluorophores could be tagged onto the biotin-
xylylenediamine-boronic acid linkers designed to form new fluorescent sensors, giving 
a broader selection of fluorescent sensors. SWNTs can be filled with radiolabelled 
metal ions, which could be used in applications such as positron emission tomography 
(PET), to investigate the distribution of radiolabelled SWNTs in living animal 
experiments. As for MTT assays, time-dependent assays or assays in additional cell 
lines, including in healthy cells (e.g. a FEK-4 cell line), could be carried to make all 
data more comparable. Synthesised and characterised fluorescent sensors could also be 
radiolabelled in order to be traceable in tissue via PET, compared with optical 
multimodality imaging techniques, which could make the fluorescent sensors usable in 
both in vivo and in vitro imaging.








Appendix A: control confocal image of different cell lines 
 
Appendix A. 1. Confocal microscopy images of CHO cells treated with 10 µL DMSO (1% 
DMSO), incubated at 37 ºC for 15 minutes. The sample was excited at 488 nm wavelength and 
long-pass filtered at 450 nm, 515 nm and 605 nm. Image (a) was merged image of images (b), 
(c), (d) and (e). Image (b) was blue fluorescence channel Image, (c) was green fluorescence 
channel. Image (d) was red fluorescence channel, Image (e) represented for image took from 
DIC. Scale bar: 50 µm.  









Appendix A. 2. Confocal microscopy images of HeLa cells treated with 10 µL DMSO (1% 
DMSO), incubated at 37 ºC for 15 minutes. The sample was excited at 488 nm wavelength and 
long-pass filtered at 450 nm, 515 nm and 605 nm. Image (a) was merged image of images (b), 
(c), (d) and (e). Image (b) was blue fluorescence channel Image, (c) was green fluorescence 
channel. Image (d) was red fluorescence channel, Image (e) represented for image took from 













Appendix A. 3. Confocal microscopy images of PC-3 cells treated with 10 µL DMSO (1% 
DMSO), incubated at 37 ºC for 15 minutes. The sample was excited at 488 nm wavelength and 
long-pass filtered at 450 nm, 515 nm and 605 nm. Image (a) was merged image of images (b), 
(c), (d) and (e). Image (b) was blue fluorescence channel Image, (c) was green fluorescence 
channel. Image (d) was red fluorescence channel, Image (e) represented for image took from 













Appendix B: colocalisation investigation in confocal image of 
different cell lines 
 
 
Appendix B. 1. Confocal microscopy images of CHO cells treated with 1 µg/mL Hoechst 
33342 (Compound 19) (1% water), incubated at 37 ºC for 15 minutes. The sample was excited 
at 405 nm wavelength and long-pass filtered at 450 nm, 515 nm and 605 nm. Image (a) was 
merged image of images (b), (c), (d) and (e). Image (b) was blue fluorescence channel Image, 
(c) was green fluorescence channel. Image (d) was red fluorescence channel, Image (e) 
represented for image took from DIC. Scale bar: 20 µm. 
 









Appendix B. 2. Confocal microscopy images of HeLa cells treated with 1 µg/mL Hoechst 
33342 (Compound 19) (1% water), incubated at 37 ºC for 15 minutes. The sample was excited 
at 405 nm wavelength and long-pass filtered at 450 nm, 515 nm and 605 nm. Image (a) was 
merged image of images (b), (c), (d) and (e). Image (b) was blue fluorescence channel Image, 
(c) was green fluorescence channel. Image (d) was red fluorescence channel, Image (e) 















Appendix B. 3. Confocal microscopy images of HeLa cells treated with 0.2 µM lysosome red 
tracker (Compound 22-a) (1% DMSO), incubated at 37 ºC for 60 minutes. The sample was 
excited at 543 nm wavelength and long-pass filtered at 450 nm, 515 nm and 605 nm. Image (a) 
was merged image of images (b), (c), (d) and (e). Image (b) was blue fluorescence channel 
Image, (c) was green fluorescence channel. Image (d) was red fluorescence channel, Image (e) 















Appendix B. 4. Confocal microscopy images of HeLa cells treated with 0.2 µM Mitochondria 
red tracker (Compound 21-a) (1% DMSO), incubated at 37 ºC for 30 minutes. The sample was 
excited at 543 nm wavelength and long-pass filtered at 450 nm, 515 nm and 605 nm. Image (a) 
was merged image of images (b), (c), (d) and (e). Image (b) was blue fluorescence channel 
Image, (c) was green fluorescence channel. Image (d) was red fluorescence channel, Image (e) 















Appendix B. 5. Confocal microscopy images of HeLa cells treated with 0.2 µM Mitochondria 
green tracker (Compound 21-b) (1% DMSO), incubated at 37 ºC for 30 minutes. The sample 
was excited at 488 nm wavelength and long-pass filtered at 450 nm, 515 nm and 605 nm. Image 
(a) was merged image of images (b), (c), (d) and (e). Image (b) was blue fluorescence channel 
Image, (c) was green fluorescence channel. Image (d) was red fluorescence channel, Image (e) 























Appendix C. 2. Dose response curve of HeLa cells treated with compound 16b over 48 
hours, EC50 = 1.63 × 10-6 M. 







Dose response curve of HeLa cells treated 























Appendix C. 3. Dose response curve of HeLa cells treated with compound 16c over 48 hours, 




Appendix C. 4. Dose response curve of HeLa cells treated with compound 17a over 48 
hours, EC50 = 2.23 × 10-7 M. 
 









Appendix C. 5. Dose response curve of HeLa cells treated with compound 17b over 48 hours, 
EC50 = 1.02 × 10-6 M. 
 
 
Appendix D: NMR spectra of synthesised compounds 
 
 
Appendix D. 1. 1H COSY spectrum of compound 7 in deuterated methanol 













Appendix D. 3. 13C NMR spectrum of compound 8 in d6-DMSO 













Appendix D. 5. 1H COSY spectrum of compound 9 in deuterated methanol 













Appendix D. 7. 1H, 13C HMBC spectrum of compound 9 in d6-DMSO 
 













Appendix D. 9. 13C NMR spectrum of compound 11 in d6-DMSO 









Appendix D. 10. 1H, 13C HMBC spectrum of compound 11 in d6-DMSO 
 
 




Appendix E. 1. The ESI/MS spectrum of compound 2, showing peak at m/z 365.2005 and 




Appendix E. 2. The ESI/MS spectrum of compound 3, showing peak at m/z 559.3679 and 
corresponding to [M + H] +. 









Appendix E. 3. The ESI/MS spectrum of compound 4, showing peak at m/z 969.4586 and 




Appendix E. 4. The ESI/MS spectrum of compound 5, showing peak at m/z 485.2193 and 




Appendix E. 5. The ESI/MS spectrum of compound 6, showing peak at m/z 579.3316 and 














Appendix E. 6. The ESI/MS spectrum of compound 7, showing peak at (a) m/z 966.3471 and 
corresponding to [M - H] -, data acquired at University of Bath (b) m/z 968.90 and corresponding 




Appendix E. 7. The ESI/MS spectrum of compound 8, showing peak at m/z 624.1861 and 




Appendix E. 8. The ESI/MS spectrum of compound 9, showing peak at m/z 750.2128 and 
corresponding to [M - H] -. 
03-Jul-2013 07:38:26MALDIMSS 12867 [C52 H54 B N5 O9 S2]
m/z



















































Appendix E. 9. The ESI/MS spectrum of compound 10, showing peak at m/z 255.1164 and 




Appendix E. 10. The ESI/MS spectrum of compound 11, showing peak at m/z 453.2966 and 




Appendix E. 11. The ESI/MS spectrum of compound 12, showing peak at m/z 840.3195 and 





Appendix E. 12. The ESI/MS spectrum of compound 13, showing peak at m/z 463.2174 and 
corresponding to [M - 2H] 2-. 










Appendix E. 13. The ESI/MS spectrum of compound 15, showing peak at m/z 751.3338 and 
corresponding to [M + H] +. 
 
Appendix F: Inferred spectrum of synthesised compounds 
 
 
Assignment Range (cm-1) 
biotin ureido C=O 1711 
-NH-C=O 1645 
N-H bend with C-N stretch 1552 
cycloalkane 1061 
Alkane chain 861 








































Assignment Range (cm-1) 
Ar C-H 3298 
biotin ureido C=O 1778 
-NH-C=O 1695 
Ar C-C 1522;1637 
C-N 1163 
Alkane chain 871 
 
Appendix F. 2. Infrared spectra of compound 5 
 











































Assignment Range (cm-1) 
Ar C-H 2973 
biotin ureido C=O 1704 
 -NH-C=O 1610 




Alkane chain 857 
B-C 658 
 
Appendix F. 3. Infrared spectra of compound 6 
 
 







































Assignment Range (cm-1) 
COO-H 3390 
biotin ureido C=O 1735 
 -NH-C=O 1659 





Alkane chain 845 
B-C 657 
 
Appendix F. 4. Infrared spectra of compound 7 
 
 






































Assignment Range (cm-1) 
COO-H 3256 
Ar C=O 1751 
-NH-C=O 1696 














































Assignment Range (cm-1) 
COO-H 3244 
Ar C=O 1751 
-NH-C=O  1632 
Ar C-C 1608;1535 
C=S 1247 
C-N 1166 
Alkane chain 849 
 
Appendix F. 6. Infrared spectra of compound 9 
 
 







































Assignment Range (cm-1) 
C=O 1662 





Appendix F. 7. Infrared spectra of compound 10 
  








































Assignment Range (cm-1) 
C-H comb 2980 
C=O 1695 





Appendix F. 8. Infrared spectra of compound 11 
 
 








































Assignment Range (cm-1) 
COO-H 3244 
biotin ureido C=O 1698 
-NH-C=O 1632 





Alkane chain 849 
B-O 796 
 
Appendix F. 9. Infrared spectra of compound 13 







































Assignment Range (cm-1) 
biotin ureido C=O 1699 
-NH-C=O 1611 





Alkane chain 857 
B-C 658 
 
Appendix F. 10. Infrared spectra of compound 15 
 
  





































Appendix G: UV-Vis spectra of as-made compounds 
 
 





Appendix G. 2. UV-Vis spectrum of compound 9 in methanol at 4×10-7 M. 


























































Appendix G. 4. UV-Vis spectrum of compound 15 in methanol at 4×10-3 M. 
 
  

















































Appendix H: Fluorescent spectra of synthesised compounds 
 
 




Appendix H. 2. Fluorescence spectrum of compound 9 in methanol at 4×10-7 M. 

















































Appendix H. 4. Fluorescence spectrum of compound 15 in methanol at 4×10-3 M. 
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